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The obstructive sleep apnoea hypopnoea syndrome (OSAHS) is a common disorder,
affecting 1-4 % of the middle-aged population. The consequences ofOSAHS include
an impact on sleepiness, health status, cognitive function and driving. There has been
conflicting data in the literature concerning the impact of sleep apnoea on arterial
blood pressure (BP). Apnoeas and hypopnoeas are associated with acute swings in
nocturnal BP of up to 100 mmHg. However whether sleep apnoea leads to sustained
daytime hypertension was unresolved. Early uncontrolled studies by Guilleminault in
the 1970's showed BP in severe OSAHS returning to normal levels after
tracheostomy, and this was later echoed by Sullivan using CPAP to treat the disorder.
Later studies however suggested that the association between these two disorders was
as a result of common confounding factors in OSAHS rather than the disorder having
a true causal role in hypertension. Young et al in the early 1990's, looked at a subset
of their large epidemiological group, the Wisconsin Sleep cohort, and showed the
prevalence of hypertension was higher in patients with sleep disordered breathing
compared to matched controls. More recently Brooks using chronically instrumented
dogs as a model of OSAHS, showed systemic BP was elevated in the daytime when
they simulated sleep apnoea, and this resolved back to normal levels over a period of
several days to weeks when the apnoeas were stopped. This study provided
convincing evidence that sleep apnoea caused elevated BP, which persisted during
waking hours, at least in dogs.
The purpose of this thesis was to demonstrate in a randomised controlled trial whether
BP was higher in untreated OSAHS. The study was crossover in design with the
patients acting as their own controls so increasing the power of the study. Sixty-eight
patients were studied with at least two major symptoms of OSAHS, and a mean AHI
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of >15 events/hour slept and a mean age of 49 years (27-72). During the study,
mechanisms for the elevated BP were looked for, with a sub-set of patients taking part
in a further study looking at baroreceptor sensitivity. Urinary microalbumin was also
studied in a smaller cohort looking to see if this simple test could be used as an easy
marker to predict the patient group who were most at risk of renal and cardiovascular
disease. Health status and cognitive function were also measured, to confirm the
health benefits of treating this patient group with CPAP compared to an oral placebo.
Diastolic Blood Pressure (DBP) was reduced by CPAP in patients with OSAHS. The
data were analysed on an intention to treat basis, including all 68 patients including
poorly compliant patients. This showed a 1.5 mmHg drop in DBP (p = 0.04) with
CPAP. In an a priori compliant subset (CPAP use > 3.5 hours/night) DBP remained
significantly lower by a magnitude of 1.9 mmHg (p = 0.03). In the other a priori
subset of severely hypoxaemic patients (4% desaturation index > 20/hour) there were
also falls in Systolic BP (4.0 mmHg, p = 0.009), DBP (5.0 mmHg, p = 0.002) and
mean arterial pressure (3.4 mmHg, p = 0.012). Although all the reductions in
pressures were small, data from population studies suggest such reductions may be
associated with significant health benefits. In addition the effects may have been
underestimated as the equipment used to measure BP may cause an arousal from sleep
there by artificially elevating the night-time BP recorded. The baroreceptor function
was not different between the two treatments. The urinary microalbumin was
abnormal in 35% of the patient group, the reasons for this needs further investigation.
The benefits found in quality of life confirmed previous studies although this is the
first randomised controlled trail to show benefits in the Functional Outcomes of Sleep
Questionnaire. The lack of improvement in the neuropsychological testing may
reflect the tests used. The CPAP compliance on this study was less than ideal, but
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similar to those in other prospective studies.
This thesis reports the first randomised controlled trial in OSAHS patients to show a
reduction in BP with CPAP therapy. The mechanisms require further study.
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'It is a good thing for an uneducated man to read books of quotations. The
quotations, when engraved upon the memory, give you good thoughts. They also
make you anxious to read the authors and look for more.'
Sir Winston Churchill
'Thoroughness is the most difficult habit to acquire, but it is the pearl of great price,
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Chapter 1.
Obstructive Sieep Apnoea/Hypopnoea Syndrome and its
Treatment.
1.1 Introduction.
Obstructive sleep apnoea/hypopnoea syndrome (OSAHS) was only recognised
relatively recently but has been extensively researched in the last 30 years. It has an
estimated prevalence of 1-2% ofmiddle aged women and 2-4% ofmiddle aged men1.
The disorder is characterised by recurrent upper airway collapse during sleep2,
causing arousal from sleep with associated hypoxaemia and sleep fragmentation.
The consequences of this disorder are multiple and include excessive daytime
sleepiness 3, cognitive dysfunction 4, and a reduction in psychological well being 5.
The physiological consequences are complex, including cardio-respiratory
disturbances, with night-time hypertension being well documented 6"15, however
whether OSAHS itself leads to daytime hypertension remains unclear and is the main
focus of this thesis.
1.2 History.
In 1837 in 'The Posthumous Papers of the Pickwick Club' Charles Dickens described
a very obese boy called Joe with hypersomnolence. There are earlier references in
the literature referring to particularly sleepy people who probably had OSAHS or
Narcolepsy. Caton in 1889 and Lamacq in 1897 both observed that some
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'narcoleptics' suffered obstructed airways during sleep. However it was Sir William
Osier in 1918 that first used the term 'Pickwickian' to refer to his obese
hypersomnolent patients. Kerr and Lagen first reported the significant cardiovascular
sequelae of the disorder in 1936. In the 1950's Burwell classically described the
disorder, with a combination of obesity, hypersomnolence, periodic breathing,
hypoventilation and cor pulmonale. Sleep medicine was brought to the fore by
Gastaut et al in 1965 when they observed sleeping patterns with renewed interest,
and noted multiple pauses 16 in 'Pickwickian' patients. Jung et al followed this up
later that year with a case report describing the physiology further '7. The term Sleep
Apnoea Syndrome (SAS) was coined in 1972 after the first symposium on sleep and
related respiratory problems led by Sadoul and Lugaresi '8. Hypopnoeas were first
described by Block et al in 1979, and it was recognised that the hypopnoeas noted
were also of clinical significance therefore the term sleep apnoea/hypopnoea
syndrome (SAHS) was used. To clarify the obstructive nature of the disorder, this
term has been added to the name to become obstructive sleep apnoea/hypopnoea
syndrome (OSAHS).
1.3 Definitions.
The definitions in OSAHS remain a subject of debate, it is generally accepted that
apnoea is a cessation of breathing at both nose and mouth for >10 seconds; and
hypopnoea is a reduction in tidal volume by > 50% or a reduction in flow rate of >
50% 20 21 plus or minus at least a 4% arterial oxygen desaturation (in the recent
classifications the desaturation has been removed from the definition of hypopnoea
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20). Arousal is defined by a return of alpha or theta rhythm in the EEG of >1.5
seconds and a rise in EMG activity during this period. The definition of sleep apnoea
syndrome itself is difficult as many normal people have 10-second apnoeas with
normal oxygen saturation as shown by Block et al22.
In 1966 Gastaut et al distinguished three types of sleep apnoea 23:
□ Central: defined by cessation of airflow past nasal and buccal thermistors
and cessation of respiratory movements from both thoracic and abdominal
strain gauges.
□ Obstructive: airflow past the nasal and buccal thermistors is absent in
spite of respiratory effort noted with the abdominal and thoracic strain
gauges.
□ Mixed: cessation of airflow throughout and absence of any respiratory
effort in the early part followed by resumption of the respiratory effort.
Guilleminault et al suggested that the criterion of 5 or more events per hour, apnoea
index (Al), was used to define obstructive sleep apnoea syndrome (OSAS) in 1976
24'25. The use of an event frequency of > 5 per hour slept as a diagnostic criterion was
affirmed with epidemiological studies by Young et al, suggesting that the
consequences of OSAHS were evident at this level of disturbance. The combined
number of apnoeas and hypopnoeas divided by the total sleep time in hours
calculates the apnoea hypopnoea index (AHI).
With further research it has been realised that many people have disturbed breathing
during sleep. The significance of this so-called sleep disordered breathing (SDB) is
still unclear in many populations.
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Respiratory disturbance index (RDI) is a term that has been used more recently to
report the number of respiratory events per hour slept. It may be that the alleged
'gold standard' investigation (polysomnography) that is used in the study of sleepy
patients may not be measuring all the pathophysiologically important variables.
Research continues to look at different methods for investigating this disorder.
1.4 Physiology of Normal Sleep.
With the onset of sleep the heart rate drops, cardiac output falls, respiration slows,
and muscle tone is reduced. Sleep is a reversible physiological and behavioural state,
which has two main divisions: rapid eye movement (REM) and non rapid eye
movement (NREM) sleep.
REM sleep is characterised by brief phasic bursts of eye movement present on a
background of tonic changes, and is associated with a state of cerebral activation.
Blood pressure, heart rate and respiratory rate all vary markedly during REM sleep.
Afferent sensory and efferent motor activities are both markedly inhibited in REM
sleep. REM is the sleep state associated with dreaming.
NREM sleep encompasses all other sleep stages outside REM. It is categorised into
4 stages, identified using the electroencephalogram (EEG), electromyogram and
electro-oculogram. In NREM Stage 2 sleep the EEG shows characteristic sleep
spindles and K complexes. Slow waves increasingly dominate the EEG as Stage 3
progresses to Stage 4, often referred to as slow wave sleep (SWS), Stage 0 is
wakefulness.
There are usually 5-6 sleep cycles a night with decreasing cycle length as the night
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progresses. The sleep cycle comprises wake to stage 1 all the way through to stage 4,
then an episode of REM sleep occurring approximately 90 minutes after sleep onset.
This pattern cycles through the night with the periods of REM sleep gradually getting
• 96
longer, so that SWS predominates early and REM sleep later in the night . After the
sleep study is scored the sleep stages are charted on a hypnogram, an example of this
is included in figure 1.1 below.





Stage 1 sleep -
Stage 2 sleep -
Stage 3 sleep -








OSAHS is due to obstruction of the upper airway during sleep. The upper airway of
patients with OSAHS is already narrow before sleep. Obesity is a contributing factor
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to this airway narrowing in about half of patients . Other predisposing factors
include male gender, middle age, genetic predisposition and anatomic susceptibility
due to retrognathia or anatomical obstruction of the pharynx.
When the patient goes to sleep the activity of the upper airway dilating muscles
decrease and so the airway narrows then closes, resulting in hypopnoeas and apnoeas
5
respectively. This results in arousal from sleep, often only for fractions of a second
but sufficient to allow the airway to open once more and then the patient drifts back
to sleep once more, and the cycle begins again. This results in sleep fragmentation
and poor sleep quality.
Figure 1.2: Cycle ofEvents in OSAHS.
OSAHS arises from a sequence of events, which form a recurring cycle.
Onset of sleep
l£ K
Apnoea Resumption of airflow
* *




Strohl presented a family who all had OSAHS, surmising that there may be a genetic
component to this disorder, which sparked further research in this area 28. Familial
studies, including twin data suggest that there is a genetic predisposition for the
disorder 29"30. Lavie studied 45 patients' relatives and showed a higher prevalence of
OSAHS and snoring compared to the normal population 3I. He concluded that there
may be an element of inheritance in the disorder, however his study lacked a matched
control population. Around the same time from our own centre Mathur et al studied
first degree relatives of non obese patients with OSAHS, showing that 25% of them
had an AHI > 15 events per hour slept. No control group was included in this pilot
study; they utilised the data published by the Oxford group looking at the prevalence
in 893 middle-aged men for comparison 32. The authors concluded that there was a
strong familial component in this disorder and that further work needed to be done in
this area ". Mathur went on to perform a further study with 51 first-degree relatives
of non-obese patients with OSAHS with a carefully matched control population.
This study showed a significantly higher prevalence of SDB in the relatives than in
the control population. There were differences in the facial structure with OSAHS
relatives having retroposition of the maxillae and mandibles detected using
cephalometry. The authors concluded that there was a strong familial component to
OSAHS and this may be in part due to the facial structure 34. This work was
paralleled by work from Guilleminault who also concluded that there was a strong
familial element to the disorder and that the craniofacial features must have a part to
play in the aetiology of the disorder 35. There has been as yet no specific gene




It is not understood why 85% of diagnosed cases are male. Initial studies suggested
that there was a large difference between the sexes in prevalence of the disorder
The more recent epidemiological studies suggest that the prevalence in women is half
that seen in men, outpatient clinics are as yet to reflect this ',36'37. It may be a
reflection of the different presentations, referral patterns and expectations of the
different sexes. However very little is known about the sex differences in relation to
the pathogenesis of the disorder. Several studies have demonstrated the gender
differences in the anatomy and physiology of the upper airway suggesting
pathological differences between the sexes 38~40. Why these gender differences exist is
not clear, however it has been postulated that the female hormones may in part be
responsible 38,41, and the differences inherent between the sexes may be in part related
to the upper airway size 40,42. The distribution of body fat also has been suggested to
play an important role, with the male tending to have upper body obesity and the
female predominantly lower body 43,44.
O'Connor et al 45 retrospectively reviewed over 800 patient records looking at the
differences in sleep study results, concluding that OSAHS was less severe in women.
Reflecting that this was because they tended to have their events mainly in REM
sleep, and because of this they may therefore present at a lower AHI as the REM
events have more of an impact clinically. These findings were independent of body
weight or age, and interestingly they also did not find any significant differences in
pre and postmenopausal women.
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More recent work has looked at the prevalence of OSAHS in women, it had been
previously reported that OSAHS was uncommon in premenopausal women, and
increased post menopause 46. However the data supporting this has been mixed 3M7-48.
Because the relationship with the menopause it has been postulated that hormones
have a role in the pathogenesis of this disorder. A recent large study reported a
prevalence of 3.3 to 1 male to female ratio; this was in keeping with previous data
reported 49. This study also suggested that HRT was protective in the
postmenopausal group. There have also been reports that testosterone is associated
with upper airway collapsibility and if given to women it can induce OSAHS, which
resolves after the removal of the hormone 48'50. There is literature suggesting this may
in fact be in relation to the effect of progesterone on the upper airway musculature.
Other data published has shown differences between the sexes of upper airway fat
distribution 42.
Recent work from Sydney has suggested that the prevalence of the disorder is greater
than previously thought in the premenopausal group and that the cardiovascular risk
for this population is higher that previously reported 51. It has been postulated that
the hormonal changes associated with the menstrual cycle affect ventilatory control,
which in turn affects the upper airway dynamics and predisposes to OSAHS.
There is no doubt there are differences in the prevalence of this disorder between the




The classical Pickwickian patient was described as obese, and there is no doubt that
obesity is an aetiological factor for OSAHS in many patients, however not all
OSAHS patients are obese. Central obesity, waist-hip ratio and neck circumference
are better correlated with indices ofOSAHS than BMI per se 52"54, and these tend to be
more prominent in men and may in part explain some of the gender differences in
prevalence.
Upper airway narrowing is thought in part to be due to fat deposition especially
lateral to the upper airway 42'55, along with external compression of walls by the obese
neck and heavy jowls. Magnetic resonance imaging (MRI) has been used to show
the fatty infdtration into the pharyngeal tissue 55. Palatal enlargement is also seen
with increased fat deposition and increased muscle bulk 56. The impact of obesity in
this patient group cannot be underestimated but there is no doubt that the aetiology is
complex, and it has to be remembered that this disorder does not only affect the
obese.
1.9 Anatomic Factors.
Retrognathia, micrognathia (congenital or acquired), and retroposition of the
mandible all contribute to a reduction in upper airway size. The pharyngeal cross-
sectional area also varies with lung volume, increasing as lung volume rises ".
Tonsillar, uvular or adenoidal hypertrophy can all contribute to obstruction,
especially in children. The soft palate when exposed to recurrent vibratory trauma
(snoring) and high negative intra-lumenal pressure, this can result in lengthening of
the soft palate secondary to stretching, thickening and oedema. Patients with this
condition tended to have a narrower than average retropharynx even when awake
although a large overlap exists with normal58. The site of narrowing is usually at the
level of the tongue and soft palate with two probable contributing factors: fat
deposition as previously discussed and a familial tendency for retro-position of the
maxilla and mandible 59.
Some medical conditions can also predispose to OSAHS including myxoedema and
acromegaly. Congenital disorders such as Pierre-Robin Syndrome, or Treacher-
Collins syndrome provide an anatomical predisposition to the syndrome. More
subtle craniofacial abnormalities may be evident on cephalometric radiographic
studies.
1.9.1 The Upper Airway.
1.9.1.1 The Normal Upper Airway.









The upper airway consists of the nasal airway, the oral airway, the pharynx, the
larynx and the trachea. The soft tissues and skeletal components comprising these
structures determine the upper airway size. The narrowest point of the normal upper
airway in the awake horizontal patient, is behind the soft palate, however during
sleep the biggest increase in resistance was at the level of the palate in half of
patients and the hypopharynx in the remaining half. During normal breathing the
nasal airway is responsible for 50% of the respiratory resistance, which is dependent
on many other factors including posture. The oral airway can produce significant
resistance unless the mouth is wide open. Resistance can be generated in the
supraglottic and glottic regions.
Patency is critically dependant on the action of the dilator muscles, stylopharyngeus,
salpingopharyngeus, palatopharyngeus and palatoglossus, there may be more
muscles involved which contract during each inspiration to prevent upper airway
collapse. The muscles of the tongue are critically involved in this process with
genioglossus, hypoglossus, styloglossus, chondroglossus all contributing. These
upper airway muscles balance with the intra-lumenal pressure to keep the upper
airway patent. During inspiration the negative intra-lumenal pressure tends to
narrow the upper airway and this is opposed by the action of the upper airway
dilating muscles tensing with each inspiration thus resisting collapse of the upper
airway. Several mechanisms are involved both functionally and anatomically; the
relative importance of each factor varies from one patient to another.
□ MRI reproduced from the virtual hospital (www.vh.org).
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1.9.1.2 The Upper Airway in OSAHS.
Whether anatomical or physiological factors are the main determinants of upper
airway narrowing remains unclear. The level of occlusion varies within individuals,
several factors contribute to this; collapse of lateral oropharyngeal walls, relapse of
the tongue against the soft palate and the posterior pharyngeal wall and concentric
collapse of the hypopharynx. Since OSAHS only occurs during sleep, central
nervous system activity has a role in the pathogenesis of upper airway collapse.
Narrowing of the pharyngeal airway leads to vibration of the flaccid tissues and
generates the noise of snoring.
Patients with OSAHS have a narrower than average airway when awake, but there is
a large overlap with the normal population as previously noted 58,6°. Obstruction in
the oropharyngeal region is secondary to variable combinations of:
□ inward closure of the lateral pharyngeal walls just below the nasopharynx,
□ posterior motion of the tongue, downward and posterior movement of the soft
palate, closing the velopharyngeal sphincter,
□ downward motion of the pharynx secondary to hypotonia and negative
pressure,
□ with or without an active component of the pharyngeal constrictor muscles.
Upper airway collapse occurs when sub-atmospheric pharyngeal pressure generates
during inspiration exceeds the stabilising forces generated by contraction of the
dilator and abductor muscles of the upper airway. These muscles are typically
activated during inspiration just before diaphragmatic contraction so that by the time
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intra airway pressure is negative; the upper airway had been splinted by the muscles
to prevent collapse. Mezzanotte and Suratt 61,62 showed increased activation in the
tongue muscles during wakefulness, which may reflect the need to keep the upper
airway patent.
Some patients with OSAHS generate progressively more vigorous inspiratory events
during the apnoeas with oesophageal pressure reading minus 80 to minus 100
cmH,0. It is this negative intrathoracic pressure, which appears to lead to the arousal
from sleep which allows breathing to resume as the upper airway dilator muscle tone
returns, but also results in the sleep disturbance and blood pressure changes that lead
to the clinical entity of OSAHS. The degree of oxygen desaturation varies from
patient to patient, it is not simply related to the number and duration of each
obstructive event, it involves other physiological variables, the most important of
which seems to be wake oxygen tension and lung volume.
Secondary to hypopnoea or apnoea the patient would be progressively asphyxiated
until arousal from sleep occurs. Arousal restores muscle tone in the dilating muscles,
the patient gasps or snorts, takes a few breaths and the cycle starts again. These
arousals lead to brief awakenings from sleep, secondary to the increased respiratory
effort 63. This can occur hundred's of times per night, resulting in sleep
fragmentation, and poor sleep quality.
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1.10 Epidemiology.
OSAHS is at one end of a continuum of disorders starting with normal through
snoring to OSAHS. Snoring has been reported in up to 60% of adults 64"71, but only a
small minority of snorers develop OSAHS.
The prevalence ofOSAHS is 1-4% of middle-aged adults l 72"76, and only a fraction of
these patients are as yet diagnosed.
The Wisconsin sleep cohort is a large longitudinal study which is following the
natural history of the cardiopulmonary consequences of SDB; from which the
estimates of 1-4% of the population having OSAHS have been derived '. Partinen
and Telakivi 75 quoted the prevalence of OSAHS in adult males to be about 1%,
quantifying this further that in the 40-65 year old group it may be as much as 8.5% or
more. With ageing populations, looking at SDB in the > 65 year old age group is
important. It is generally accepted that in this age group sleep patterns alter. Snoring
and SDB are seen with increasing frequency as you increase in age 73,77. It is not clear
why snoring and SBD increase with age, it may reflect a reduction in muscle tone in
the upper airways or an increase in body weight. It may also reflect the changes in
facial anatomy that occur with age, thinning of the facial bones, loss of teeth and gum
tissue. Also there may be an increase in periodic breathing associated with
cerebrovascular disease, heart failure and a reduction in the depth of sleep.
1.11 Mortality and Morbidity.
Mortality rates from all causes are increased by 30% during sleep. Morbidity and
mortality studies have shown an increased prevalence of disease in patients with
OSAHS. Retrospective studies have shown that OSAHS is associated with an
increase in mortality in excess of 30% in some studies 78"81, and an increase in
morbidity.
OSAHS may be associated with many medical conditions, for example systemic
hypertension 82, pulmonary hypertension 83, cardiac arrhythmia's 84, ischaemic heart
disease 78 79 and stroke 85. Other investigators have compared treated SDB patients
and untreated groups with SDB, showing higher mortality in the untreated groups
78'80'86, however one major pitfall of these studies is that they failed to include a
randomly selected control sample.
Partinen et al80 found a significant increase in mortality in their cohort (n = 198) of
OSAHS patients and reported that 14 patients died over a five year period. The
reported deaths were in the conservatively treated group (n = 127), giving a mortality
of 11%, compared to zero in the tracheostomised patients (n = 71). On reviewing the
cause of death > 50% were cardiovascular in origin and the majority occurred during
sleep. This study was retrospective in design and therefore has to be interpreted with
caution. Retrospective studies have also shown the association of OSAHS with
increased mortality and morbidity is generally secondary to cerebrovascular and
cardiovascular events 78'80. OSAHS and probably snoring are associated with a poorly
understood increase in cardiovascular mortality 87.
The increased risk of road traffic accidents and accidents in the work place have also
been reported leading to an increase in mortality and morbidity 88"93, from the sequelae
of accidents. The road accidents tended to be of higher impact and have higher
mortality and morbidity than with the normal population.
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It is clear however that OSAHS needs to be recognised as a significant public health
problem, with appropriate education of the medical community and the public as a
whole in the recognition of the disorder, taking an appropriate history and ensuring
adequate investigation and treatment94,9S.
1.12 Consequences of OSAHS.
1.12.1 Blood Pressure.
Acute rises in pulmonary and systemic arterial pressure occur in association with
apnoeic episodes secondary to a complex series of physiological events and this is
discussed at length in the next chapter.
1.12.2 Cardiovascular.
In normal subjects heart rate drops during sleep and a marked sinus arrhythmia can
be seen in NREM sleep, however in REM sleep the heart rate is more erratic.
OSAHS and snoring have been associated with a poorly understood increase in
cardiovascular mortality compared with the normal population 79'87'96. The effects of
OSAHS on systemic blood pressure during sleep alone can possibly contribute to
this.
The prevalence of conduction abnormalities and arrhythmias in the OSAHS patient is
up to 48% 84, with sinus arrest being the commonest recorded, and in some cases it
has been suggested that the arrhythmia could be fatal 97. This study also shows no
significant arrhythmia recorded in their patient group after tracheotomy. Bradycardia
can occur with a marked sinus arrhythmia, however conduction defects,
tachyarrhythmias including supraventricular and ventricular tachycardias, asystole,
premature ventricular ectopics are all reported 98"101. The tachyarrhythmias usually
occur at apnoea termination, possibly as a result of the withdrawal of vagal tone,
increasing sympathetic tone, hypoxia or acidosis. The clinical significance of these
arrhythmias - other than as a marker for apnoeic events - remains to be proven.
Many cardiac deaths tend to occur in the early morning just before and after waking
from sleep, there is some evidence to suggest a relationship between OSAHS and
these deaths. A higher prevalence ofmyocardial infarction (MI) has been reported in
OSAHS patients compared to the normal population 102106 but there are many possible
confounders inadequately excluded in these studies including obesity, smoking,
gender and hypertension. A case controlled study looking at 50 patients with recent
MI showed that snoring was an independent risk factor with an odds ratio of 4.4,
however no PSG was performed and it was self reported snoring l07, however it
provides an interesting area for further research.
1.12.3 Cerebrovascular.
Studies have been done, to determine whether OSAHS is a risk factor for stroke 85
and if stroke predisposes to OSAHS 64 l08 "l> Partinen reported a case controlled study
I09, which looked at men with strokes comparing them with age-matched controls. He
reported the risk ratio (RR) of stroke at 10.3 in patients who snored compared to non-
snorers. Koskenuo 54 also reported data from a large prospective epidemiological
study, of the 42 patients who had strokes; the odds ratio (OR) of snorers against non-
18
snorers was 1.4. Spriggs 110 concluded that snoring was a risk factor for stroke in
both sexes and all age groups, also the greater the snoring the greater the risk.
Large population studies carried out in the 1980's have shown that diastolic blood
pressure (DBP) is partially related to stroke, not just in the 'hypertensive' but in the
'normotensive' subjects l12'"3. Significant relationships between DBP and stroke risk
continue with no lower 'threshold' for a reduction in DBP that is not associated with
a reduction in stroke risk.
Impairment of the cerebral blood flow autoregulation has been postulated as a
possible mechanism for the genesis of stroke ll4'"5, this is thought to be affected by
the cyclical swings in blood pressure. Palomaki reported that snoring may be a risk
factor for ischaemic stroke as there is a higher prevalence of stroke in snorers than
non snorers 85. The OR of snoring for ischaemic stroke was calculated to be 2.13, and
in patients with OSAHS this increased to an OR ratio of 8.0. Dyken et al 111 reported
that patients with recent stroke have an increased incidence of irregular breathing
during sleep compared to matched controls. However this was a small group of
patients (n = 24), reporting a 21% mortality at 4 years, and all the patients who died
had co-existing irregular breathing. The likeliest time for the occurrence of
ischaemic stroke is during sleep and in the first hour of wakefulness "6. This could
be related to the surges in the blood pressure associated with arousal, or associated
with the arrhythmias described. Palomaki 105,117,118 also concluded that there was an
increased vascular morbidity in OSAHS although the mechanisms were poorly
understood however sympathetic activation, platelet aggregation and catecholamine
release have all been postulated "9.
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These studies suggest there is an increased cerebrovascular risk from snoring itself
and OSAHS, but whether this is independent of confounders is unclear and the
possible mechanisms require further consideration.
1.12.4 Renal Function.
The effect ofOSAHS on the kidney is unclear, it is exposed to the cardiovascular and
arterial blood gas tension changes occurring as a consequence of the apnoeas and
hypopnoeas. There have been case reports of the effect of OSAHS on the kidney
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and studies performed in an attempt to clarify this relationship further 122'126.
Bailey 120 reported a morbidly obese man with OSAHS who developed a
glomerulomegaly and focal glomerulosclerosis, the authors attributed this to his
obesity, however the diagnosis of OSAHS was not considered and perhaps played a
role in the aetiology of the renal disease. A further case report121 of amorbidly obese
man with associated OSAHS who developed a focal segmental glomerulosclerosis;
the patient went on to have a tracheostomy to treat his OSAHS. The authors
postulated that the OSAHS had an aetiological role in the development of the renal
disease.
Sklar et al 122 studied 9 healthy controls, 12 obese patients (with normal PSG) and 14
OSAHS patients. The authors studied nocturnal urinary protein excretion in these
groups, reporting that levels were commonly elevated in OSAHS patients. The
authors tried to control for confounders and attempted to match the control group,
however this group was younger, lighter and had slightly lower BP, the authors did
not comment whether these differences were significant.
Fletcher reported a study of patients attending a renal dialysis centre recruiting
patients who complained of symptoms of OSAHS l23. He reported a prevalence of
OSAHS of 73% in patients he studied. However a control group was not included
and patients with renal disease can have many of the same symptoms of OSAHS, it
was not clear how and when these patients were studied.
Chaudhary 126 reported the results of dipstick urinalysis in 34 patients attending for
sleep study matching them to a control population, and showed that 18% of the
OSAHS had > 3+ proteinuria on stix testing, defined as high grade proteinuria (3 g/1),
compared to none in the control group. Interestingly the proteinuria was shown to
improve after treatment for OSAHS was commenced. A further study was
performed by Chaudhary et al 124 who analysed urine from 407 patients attending a
sleep centre with known OSAHS (AHI > 15), performing dipstick testing. They
concluded that severe proteinuria in OSAHS occurs in patients with a higher AHI,
the lesser degree ofproteinuria cannot be explained by AHI alone.
Iliescu et al recently reported that clinically significant proteinuria was uncommon in
OSAHS 127. They recruited 224 patients who were referred to their sleep centre,
performing overnight PSG and measuring their urinary protein to creatinine ratio.
OSAHS was diagnosed (AHI > 5 hour/slept) in 63.8% of this cohort. They reported
that AHI and urinary protein were weakly correlated, which was related more to the
degree of hypoxaemia than to the frequency of apnoeic events. They did not include
a normal population using the patients who had normal sleep studies as their controls,
however these patients were not matched and must have been symptomatic as they
were attending the sleep centre.
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Thus there is evidence that patients with OSAHS have co-existing renal functional
abnormality, however what the aetiology and significance of this is unclear and
requires further investigation.
1.12.5 Excessive Daytime Sleepiness.
Excessive daytime sleepiness (EDS) is the feeling of being abnormally sleepy in
wake time. EDS is not specific for OSAHS and occurs in a variety of conditions. It
may also be underreported as many patients lose their frame of reference for what
constitutes normal sleepiness. Sleep restriction or sleep fragmentation from any
cause produces daytime somnolence 128'129.
Improvements in the Epworth sleepiness score (ESS) in patients with OSAHS after
treatment have been shown l30'131, and is further discussed in section 3.2.1. The ESS is
a useful subjective method of following up patients on treatment and has been shown
to correlate with the frequency of apnoea in OSAHS 132. Objective improvements in
sleepiness have been proven after treatment with CPAP in this patient group 133.
More objective evidence has been provided using the multiple sleep latency test
(MSLT) and the maintenance of wakefulness test (MWT), showing improved times
after treatment with CPAP 13\
1.12.6 Cognitive Function.
OSAHS can also cause cognitive impairment with deficits in thinking, perception,
memory and communication. There are neuropsychological deficits in OSAHS,
which improve with nasal CPAP treatment 4'I33,I3S"140. There are randomised controlled
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trials 133135136 ,39140 included in this group of studies giving a good evidence base for the
data, both using an oral placebo and 'sham CPAP'. Function is assessed using tests
of vigilance, mental flexibility and attention. Some of the data suggests that the
degree ofhypoxia is a better correlate of the dysfunction rather than AHI4J4U42.
More sophisticated neuropsychological studies have been done l43, showing impaired
ability to initiate new mental processes, reduced memory spans, and a tendency for
perseverative errors. These studies have tried to focus cognitive tests in an attempt to
try and pinpoint the disabilities more clearly. There has been some concern that
some of the effects of OSAHS are irreversible possibly secondary to anoxic damage
within the central nervous system 144.
1.12.7 Quality of Life.
Quality of life (QoL), is frequently assessed in patients with a variety of disorders. It
is a measure of total well-being, which includes both physical and psychosocial
factors. Functional status is an important component of QoL, and is defined as a
'multifaceted concept that characterises the ability to meet needs, fulfil roles, and
maintain health and well-being'94. Changes in functional status can be secondary to
many different factors including mood, motivation and a variety of medical
conditions.
Sleepiness is a difficult symptom to quantify and its complex effects on day to day
living can be difficult to realise. Scales of sleepiness have been used for many years,
but they only give insight into how sleepy individuals are in specified situations but
do not reflect the impact of sleepiness on their normal life. Sleep specific sleep
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questionnaires have been employed to look at the impact of sleepiness in day-to-day
life. Several questionnaires have been developed, including the functional outcome
of sleep questionnaire (FOSQ) 145, Calgary sleep apnoea quality of life index
(SAQLI) l46, Sleep and Heath Questionnaire 147 and the Berlin Questionnaire 148.
These questionnaires compliment the general quality of life questionnaires frequently
used e.g. Medical Outcomes Short Form-36 (SF-36) 149150 and the Nottingham health
questionnaire l51'152. These questionnaires have been used to show that the outcome
measures improve in OSAHS patients with treatment in both randomised controlled
, • , 133,136,140,153 i a II J ± A' 137,141,154-159trials and non-controlled studies
OSAHS not only affects the patient, their partner also suffers from the snoring, which
disrupts and fragments their sleep, and from the patient's restlessness with limb
movements, especially at the time of arousal. One study tried to quantify this effect
formally. In the setting of a randomised controlled trial, patients and their partners
were studied in their own home at the end of a month treatment limb, comparing
CPAP with an oral placebo. They reported that partners had poor sleep quality and
self reported health status, however only subjective sleep quality benefited from
treatment of the patient with CPAP l60.
1.12.8 Accidents.
In patients with OSAHS there is an increased risk of road traffic accidents, and
probably also accidents in the home and industrial incidents. There is considerable
evidence that sleepiness is a major contributing factor to road traffic accidents, and
accidents are more frequent in OSAHS than the general population 8S"91'93'161"167. Recent
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data has suggested that to identify the patients more at risk of accidents it is better to
identify the patient by direct questioning who is a sleepy driver rather than just
generally sleepy. This in turn is a better predictor of identifying the group of patients
with SDB, and hopefully allows early intervention to prevent accidents 167.
Studies using driving simulators, in an attempt to assess a patients fitness to drive
and as a method of assessing vigilance have shown that patients with OSAHS
perform poorly on these tasks 168173 and worse than matched normal subjects made
legally drunk 17°.
There is data in OSAHS patients suggesting a 2-7 fold increased risk of road traffic
accidents, according to Findlay et al90'174. There were more single vehicle accidents
with increased fatalities compared to the normal population, the accidents tended to
be of higher impact and therefore more serious l75. One in three patients with
untreated OSAHS will have an accident in a 5-year period l76. It had been shown by
Engleman et al that self reported accidents reduce significantly with CPAP treatment
in patients with OSAHS, compared to an untreated group, this was reinforced with
objective data92'177.
Suratt et al in an editorial178 stressed the need for increased awareness of this disorder
by the population as a whole and its impact on driving and accidents in general.
McNicholas echoed Suratt's concerns on behalf of a working party looking at the
impact of sleep disorders on driving l79. The cost implications of accidents is huge
both financially and in terms ofmortality and morbidity 180"183.
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1.13 Upper Airways Resistance Syndrome.
Upper airway resistance syndrome (UARS), refers to a group of patients who are
generally non obese who have increased respiratory efforts terminated by transient
alpha EEG arousals, but who do not have the associated upper airway collapse,
hypoventilation or reduction in oxygen tension. If oesophageal manometry is
performed it shows the increased respiratory efforts made that precede the arousal.
These transient arousals would normally be ignored in sleep study analysis, but it is
enough to fragment sleep, their impact was evident with increased sleepiness in the
daytime shown objectively on the MSLT l84.
In UARS there seems to be a lower arousal threshold compared to the OSAHS
patient. UARS may also cause the same clinical picture as OSAHS. There remains
much debate about whether UARS is a separate clinical entity or just forms part of
the spectrum of OSAHS and snoring. A recent editorial debate on UARS between
Douglas and Guilleminault has discussed this further 185. Guilleminault postulated
that UARS patients have intact mechanoreceptor function whilst in OSAHS this was
blunted. This in turn affects the central nervous system response to the insult, as the
receptor reflexes are so different. Douglas comments on the evidence that UARS has
no signs on examination and the symptoms are the same as for OSAHS.
Furthermore that the diagnostic criteria do not fulfil the original description, and
there remains debate over the scoring of sleep studies especially with hypopnoeas. It
may just reflect the use of inadequate sensors in sleep studies rather than a different
disease entity. The diagnostic criteria set out fall within normal limits, and
oesophageal manometry is not often performed as it is unpleasant for many patients
and falls in pressure may reflect increased ventilation rather than increased resistance
per se. A major concern is that patients may be labelled with this 'diagnosis' and an
underlying problem missed. Clearly more work needs to be done in this area to
clarify this difficult diagnostic group ofpatients.
1.14 Clinical Presentation.
OSAHS is a chronic disorder, which develops with an insidious onset, with
alterations in airway patency, modifications in ventilation, quantity and quality of
sleep, and frequency of sleep disruption. OSAHS is a prevalent disorder and it is
important to keep a high index of suspicion and ensure pertinent questions are asked
in the appropriate clinical setting. Many patients present with vague symptoms,
including general fatigue and impaired concentration. There is a very wide spectrum
of symptoms from the minimally affected to the classical Pickwickian subject, it is
not clear why some patients who have mild disease have many symptoms and some
with severe disease have relatively few.
Loud snoring is present and associated with snorting and silences during which the
apnoeas occur. These may be witnessed by the bed partner and family, and can be
alarming. Abnormal behaviour during sleep is occasionally seen with abnormal
movements ranging from mild twitching to more generalised motor activity.
Enuresis is relatively common. Morning headache can occur, and is usually frontal
but can be diffuse, tending to resolve 1-2 hours following rising. The
pathophysiology of the headache is unclear, however it is thought to be linked to
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cerebral vasodilatation overnight, and possibly C02 has a role. A reduction in sexual
drive is often reported secondary to fatigue with occasional impotence.
Daytime somnolence is frequently the reason for referral to a sleep specialist, with
extreme drowsiness in inappropriate situations, and an undeniable urge to sleep,
which is especially hazardous whilst driving. Patients commonly complain of
nocturnal choking, frequent awakenings overnight, and unrefreshing sleep. They
often feel like they have not slept well, and suffer from poor concentration during the
daytime.
Clinical examination often reveals very little, obesity is common, facial
abnormalities can be obvious however more subtle abnormalities can be more
evident with the use of cephalometric studies 186,187. Blood pressure should be
checked, as it is reported that in 60% of adults with this disorder there may be
associated elevations in systolic and diastolic blood pressure 82 188"191. Chest wall
abnormalities are usually evident.
Neck circumference should be recorded, in men it is often recorded as collar size, as
there is a correlation with neck size and severity of disease 44-53 192193_ Examination of
the nose can reveal blocked nasal passages, which could contribute to the problem.
Examination of the mouth reveals any crowding of the oropharynx due to tonsillar
hypertrophy, oedema or a narrow retropharyngeal space. Evidence of cor pulmonale
should also be sought, suggesting either underlying pulmonary disease or perhaps
decompensated pulmonary hypertension.
The differential diagnosis includes other sleep disorders such as UARS, narcolepsy,
periodic limb movement's (PLM's), and a variety of medical conditions including
depression and diabetes. This disorder is generally under recognised 194,195 because of
its vague symptoms, the lack of pertinent history taking and the lack of any specific
clinical signs.
1.15 Diagnosis and Investigation.
The diagnosis is made from investigation, focused history taking can be suggestive,
however sleep studies require to be performed to establish a formal diagnosis. Using
arterial oximetry alone misses about one third of cases l96, the 'gold standard'
investigation being polysomnography (PSG). However PSG has not been
particularly well validated, although many studies and other mechanisms of sleep
study are referenced to it.
With a suggestive history the next step is to perform a sleep study either using a
limited system in the home or hospital setting, or using full in laboratory PSG. PSG
consists of a multi-channel recording of electroencephalogram (EEG), electro-
oculogram (EOG), electromyogram (EMG), electrocardiogram (ECG), airflow,
respiratory effort, body position and motion sensor, and arterial oxygenation
saturation, the data is stored via a computer system (System S, Compumedics,
Melbourne, Australia). There is a continuum from normal through snoring to
disease, and somewhere along this line the patient become symptomatic. The point
at which this occurs appears to vary markedly between individuals.
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1.16 Treatment of OSAHS.
1.16.1 Behavioural.
In some patients OSAHS is related to the supine position, therefore it was hoped that
by preventing the subject from being in this position the problem would be cured.
However this has rarely been successful. Ensuring adequate sleep time is important
in this group of patients, so called 'sleep hygiene', as insufficient time in bed will
add to daytime somnolence. Avoidance of any aggravating factors is also helpful but
rarely cures, such as the avoidance of sedative medication and alcohol especially
before bedtime. Weight loss is recommended for the obese but adequate weight loss
to cure OSAHS is rarely achieved l97. Exercise is recommended which can aid
weight loss but also may have effects on sleep architecture.
A Cochrane review has been done looking at lifestyle modifications in the treatment
of OSAHS 19R, at the time of review no published randomised controlled trials were
identified. Concluding that there is a need for lifestyle studies to be done allowing
identification of the subgroups ofpatients would benefit from these interventions.
1.16.2 Medical Therapy.
1.16.2.1 Drugs.
A pharmacological solution to OSAHS would be very useful, it would be much more
acceptable to patients than CPAP, easier to transport and less obtrusive in the
bedroom. Different agents have been tried in the past
Oxygen therapy can increase the duration of the apnoeas and is therefore not
i i 200-202
recommended
Progesterone has been used in the past as a respiratory stimulant but there is no RCT
evidence of clinical efficacy in OSAHS 38'203. It is a respiratory stimulant, and it was
postulated that it would increase respiratory drive and in doing so it would increase
pharayngeal tone. However no improvements were seen in the small studies
r i 199,203performed
Acetazolamide causes a metabolic acidosis and it was postulated that this would
improve SDB. A randomised double-blind placebo controlled crossover study by
Whyte et al showed a reduction in the frequency of apnoeas, however the apnoeas
were predominately central in origin 20\ with little work being done looking at
OSAHS as such, however there is no evidence of efficacy in OSAHS 205.
Protryptyline has been shown to reduce apnoea index and desaturation by reducing
the amount ofREM sleep, as the OSAHS tends to be more severe during REM sleep,
daytime hypersomnolence was also improved in these studies 206"209. It was though it
could be useful in up to 50% of patients however its use was limited by side effects,
and has no place in the modern treatment of this disorder63.
Sabeluzole is a putative glutamate antagonist and has been used in a small double-
blind crossover study (n = 13). Results suggested that Sabeluzole reduced the
desaturation index in OSAHS patients 21°. Further research needs to be done with this
drug.
Modafinil is a new wake-promoting agent used in the treatment ofNarcolepsy, some
trials have been done in patients with OSAHS to see if it is of benefit. A
randomised-controlled trial has been performed looking to see ifmodafinil is a useful
adjunct for the OSAHS patient who continued to be sleepy despite adequate CPAP
use. It demonstrated that modafinil did improve alertness significantly; interestingly
it also reduced CPAP use2"'212. More work is being done in this area.
Serotonin has been more recently suggested as a possible pharmacologic agent in the
treatment of OSAHS 2'3. Serotonin is a neurotransmitter; it has been implicated as a
contributor to the disorder but more recently suggested as a possible therapy.
Selective serotonin reuptake inhibitors (e.g. Fluoxetine) have shown moderate
decreases in AHI in NREM sleep but the clinical efficacy is unproven and likely to
be low.
1.16.2.2 Intra Oral Devices.
Intra oral devices (IOD) are often used as an alternative to CPAP therapy in patients
with mild disease and those intolerant of CPAP. There are more than 40 different
designs available. The devices are also referred to as mandibular advancement
devices (MAD) or mandibular repositioning splint (MRS). Common side effects
include excess salivation, mucosal dryness, tooth discomfort and temporo¬
mandibular joint discomfort2'4.
These devices have been developed as an aid for snoring and for the treatment of
OSAHS. CPAP therapy although a good treatment, has major drawbacks (which are
discussed further in Chapter 10), this has fuelled the search for other methods of
treatment which would be more acceptable to the patient.
Many different devices are available and they vary in size, cost, ease of manufacture,
and 'shelf life'. Most require custom fitting and adjustment ideally by a well-trained
individual. They generally have a 'shelf life' of approximately 6 months, then
require to be replaced. Recent evidence suggests that although for some they work
well, with around 50 % of patients' breathing normalised, this however leaves 50%
of patients who are not or only partially treated 2I5. It has been shown in a RCT that
IOD's are effective in the management of snoring 2I6. Several studies have suggested
MRS as a first line choice for mild to moderate OSAHS patients 215-217"221 but this has
been challenged 222. Comparisons between MRS and CPAP report that MRS is an
effective treatment in some mild to moderate OSAHS patients, and was associated
with fewer side effects and has greater patient satisfaction that CPAP 220 although
others have found CPAP to be associated with better outcomes across all OSAHS
severity's 222.
Further data has been produced comparing 2 different types of MRS, a one-piece
device against a two piece device. Patients were recruited who had been unable to
tolerate CPAP for a variety of reasons, introducing bias. Patients tried both devices
and had no treatment, in a random order for a period of a week each, with satisfaction
questionnaires and sleep studies performed at the end of each treatment period. The
results show that one device is preferred (the simpler one), over the other producing
better relief of symptoms, however both devices were effective treatments for
OSAHS 223.
A recent randomised controlled trial compared a MRS with a placebo MRS plate by
performing PSG to document the effects on sleep quality. Data showed that the
MRS was better than placebo in terms of sleep quality221'224. Therefore it is important
to chose a device to suit a patients needs, and to select the patients for this treatment.
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More work needs to be done on patient selection, and on the importance of the
differences between the devices available.
Tongue retaining devices are seldom used, as they may be uncomfortable to wear 225.
They comprise a custom made device which fits over both dental arches with an
attachment between designed to hold the tongue in a forward position.
1.16.2.3 Continuous Positive Airway Pressure.
Continuous positive airway pressure (CPAP) is the standard proven treatment for
OSAHS 226'227. CPAP is delivered by a small portable flow generator. There are
several different makes available, varying in design, size and cost. The principle is
that they will deliver a positive pressure to the upper airway providing a pneumatic
splint, stopping the airway collapsing and therefore preventing apnoeas and the
subsequent arousal. The pressure is applied via a close fitting nasal or oro-nasal
mask. Sullivan et al were the first group to use CPAP in this group of patients and
published their results in 1981 228. They demonstrated virtual abolition of apnoeas
and oxygen desaturations with resultant improvement in daytime symptoms, and
abolition of snoring.
The side effects of CPAP are usually minor and include discomfort from the mask,
nasal congestion or dryness and occasionally rhinorrhoea. The concept of wearing
such a device every night is not attractive, however most patients feel so much better
using it, they put up with the inconvenience of wearing the mask. The use of CPAP
in the first 3 months is a good predictor for long-term use 229. It has also been shown
that intensive initial support with education for the patient and partner improves
230 232
CPAP use " . CPAP can undoubtedly stop the arousal from sleep caused by the
obstruction in the upper airway 228,233"236. Treatment with CPAP allows normal sleep
architecture to return and the phenomenon of REM rebound is frequently seen,
however it is short lived 237.
Less subjective sleepiness is reported in patients treated with CPAP 131'236, and patients
are also less sleepy on objective testing l35 136'238. Improvements in quality of life are
also shown using subjective questionnaires 145'159'239'240. The question whether this is all
a placebo effect has been posed, however prudent use of randomised controlled trials
have shown that CPAP is better than placebo in these patients.
Wright and colleagues 241 questioned the efficacy of CPAP in 1997, when they
concluded that there was little evidence to suggest that CPAP was beneficial in these
patients. However the argument was unbalanced; examining mainly the effects on
cardiovascular disease, not on the cognitive effects, improvements in quality of life,
and improvements in driving performance, which had been documented, albeit at that
time only in one adequately controlled study 242.
A consensus statement was published from the American Sleep Disorders
Association listing the indications for CPAP therapy 243. They concluded that CPAP
was indicated for all patients with OSAHS with an RDI > 30 events per hour slept,
irrespective of symptoms because of the cardiovascular risk evident from the
Wisconsin Sleep cohort. However that statement is not based on any adequate
therapeutic trials, it is derived from population studies. For Patients with an RDI
between 5 and 30 events per hour slept CPAP is indicated on the grounds of clinical
symptoms and patient co-morbidity. It is not recommended for asymptomatic
patients with no cardiovascular disease 243. These guidelines have not been accepted
practice in most UK centres, partly because it would be difficult to convince an
asymptomatic patient to comply with therapy, but much more importantly the
evidence is lacking 244.
A Cochrane review has also been performed looking at CPAP treatment for OSAHS
245. The conclusions were that CPAP appeared to be more effective than placebo in
improving health status, that it was better at reducing the respiratory disturbances
than MRS devices. Patients preferred MRS over CPAP, but chose CPAP over
placebo.
There is no doubt the CPAP is an effective treatment for OSAHS and the level of
evidence is high, the effectiveness of intervention on cardiovascular and
cerebrovascular events is still emerging. At present CPAP remains the treatment of
choice for the majority ofpatients with OSAHS.
1.16.3 Surgical Treatments.
It would seem simple that if the problem in OSAHS is due to an unfavourable
configuration of the pharyngeal airway, that there should be a simple surgical
solution. However although several operative procedures have been tried 246 none are
panaceas. Options of removing soft tissues and modification of the underlying
craniofacial skeleton have been explored. There is no doubt that surgical procedures
can be useful in the minority of patients who have major craniofacial abnormalities.
The difficulty in performing any form of randomised controlled trial with irreversible
surgical treatments to provide good evidence remains a problem.
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Cochrane has once again published a document on the role of surgery in OSAHS 247,
they found no published randomised-controlled trials in this area.
1.16.3.1 Tracheostomy.
Tracheostomy bypasses all the sites of obstruction, and is a very effective treatment
as shown by Guilleminault et al 248, it is however a very drastic measure, and is rarely
used as a treatment for OSAHS now. It brings with it all the associated problems of
a tracheostomy, with the requirements of continued care and major psychosocial
problems for the patients.
1.16.3.2 Maxillofacial Surgery.
Micrognathia and retrognathia may require mandibular osteotomy and reconstruction
249-25'. Maxillo-mandibular osteotomy (MMO) comprises a combined Lefat 1
osteotomy and advancement of the maxilla and mandible 252,25\ Other complex
maxillofacial surgery could be considered in a small number of specialised cases
with procedures such as genioglossal advancement with or without resuspension of
the hyoid bone, with or without uvulopalatopharyngoplasty (U3P). It is impossible
to perform a large scale randomised-controlled trial in this group of patients, as the
surgery is major and would only be considered in a minority of patients. However
MMO seems to be as effective as CPAP 253, and at 2 year follow up in a small group
of patients (n = 15) who had maxillo-mandibular advancement, treatment has been
shown to remain effective 253.
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1.16.3.3 ENT Surgery.
If nasal obstruction is present it should be corrected. This may reduce the noise of
snoring by reducing turbulence of airflow, however it does not however cure OSAHS
254. There is no good evidence that it will make therapy with CPAP easier. Removal
of enlarged tonsils or adenoids can be effective in children, and occasionally in
adults.
1.16.3.4 Uvulopalatopharyngoplasty.
The uvulopalatopharyngoplasty (U3P) procedure widens the pharynx by a
combination of tonsillectomy, removal of the redundant mucosa and soft tissue of the
uvula, soft palate, posterior pharyngeal walls and posterior pillars 2M. Initial studies
reported a 50% reduction in apnoea frequency but not a cure. The surgery is painful,
often unsuccessful and it makes treating the underlying OSAHS a little more difficult
with conventional means. The surgery is associated with complications including
velopharyngeal insufficiency, voice change, post-operative bleeding, nasopharyngeal
stenosis and a foreign body sensation.
Meta analyses of short-term (< 6 months) outcomes of this procedure have shown a
50% reduction in AHI, however this procedure did not cure OSAHS 78'207-255'256, a
further study reported that the U3P is not effective in patients with severe OSAHS 257.
A major concern with this operation is that it may well reduce the noise of snoring
but it does not treat the apnoeas and so patients continue to have these events
associated with all the physiological changes and sequelae. Patients who have had a
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U3P also poorly tolerate nasal CPAP 258 and tend to require full facemask if
commenced on CPAP.
1.16.3.5 Laser Assisted Pharyingoplasty.
The laser assisted pharyingoplasty (LAUP) operation may be of benefit in snoring
but there is little convincing evidence that it is useful in patients with OSAHS with
little pre and postoperative sleep data being available. It enlarges the retro-palatal
airway by ablation of the uvula and the posterior margin of the soft palate using a
carbon dioxide laser. It can be performed under local anaesthetic 257,259,260.
1.16.3.6 Laser Midline Glossectomy.
Laser midline glossectomy (LMG) or lingaplasty involves the central portion of the
tongue being excised with a laser reducing the muscle mass, enlarging the
retrolingual airway 251. There are no randomised-controlled trials available in the
treatment ofOSAHS with this procedure.
1.16.3.7 Somnopiasty.
This procedure consists of radio-frequency ablation of the palate and tongue base
250,261. An animal model has been developed which shows the reduction in tongue
volume with this technique, inferring that it might be a useful technique for OSAHS.
This needs to be followed up with a randomised-controlled study looking at its use in
OSAHS.
1.16.3.8 Diaphragmatic Pacing.
Diaphragmatic pacing was used very occasionally for pure central sleep apnoea; it
was however limited by the development of pacing induced upper airway collapse
262'263. It is used very occasionally in the treatment of children with congenital central
sleep apnoea (Ondine's curse). There are also case reports of using pacing in the
upper airway to offset the upper airway collapse in OSAHS with variable results.
There is no RCT evidence in this area 262'264'265.
1.17 Discussion.
OSAHS is a complex multi-factorial disorder that has wide reaching implications
many of which are as yet not fully understood. Although CPAP is the treatment of
choice not all patients are able to tolerate it, IOD's may be useful in many 'milder'
patients, but have their own associated problems. The surgical options are varied but
only MMO has a real evidence base supporting it. It is also evident that the current
treatments available are not ideal, and further research needs to be done to find a




Blood Pressure and Sleep.
2.1 Introduction.
Blood pressure (BP) is a biological characteristic of an individual, with wide inter-
individual and intra-individual variability. The distribution curve of BP is slightly
skewed to the right. The spread of values reflects the influence of genetic, racial,
social and environmental factors, which are inter-dependent factors. BP tends to be
higher in social class 4 and 5, with diet, alcohol, exercise, ethnic origin, and possibly
stress all differing between social classes. In western societies a gradual rise in the
systolic blood pressure is seen until the seventh decade in men and the sixth decade
in women. However diastolic blood pressure rises in both sexes until the sixth
decade after which it begins to fall 266.
BP changes over the twenty-four hour period, reaching its nadir in the early hours of
the morning and its maximum on rising 266 269. This is not an endogenous circadian
rhythm and is clearly dependent on environmental factors, as diurnal rhythm is not
observed in an immobilised patient, or one with autonomic dysfunction (e.g.
diabetic), or after cardiac transplantation. Rapid changes in BP can be observed with
exposure to pain, mental stress, and exercise. With the onset of sleep, BP gradually
falls with the deepening stages of sleep, and remains relatively stable. However in
REM sleep the BP is more erratic and is higher than in the other stages but does not
usually reach the levels of wakefulness 267.
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The nocturnal drop in BP is often called "dipping", it is defined as a nocturnal drop
in blood pressure of > 10% of daytime values. The lack of this nocturnal drop in BP
(non-dipping) is thought to be a marker for hypertensive disease and in some patients
it seems to be associated with a poorer prognosis, acting as an independent predictor
of hypertensive end organ damage 270 272.
Several humoral mechanisms influence BP, including the kallokreinin-kinin system,
prostaglandins, atrial natriuretic peptide and the reno-medullary lipids. The renin-
angiotensin-aldosterone system has an important role to play with salt and water
homeostasis, which in turn can influence BP.
2.1.1 Pulmonary Artery Pressure.
The pulmonary vascular bed has its own homeostatic regulations keeping the
pressure within its area at necessary levels, and can be affected by a variety of
cardiac and pulmonary diseases. Pulmonary arterial hypertension is not uncommon
in OSAHS, and may be related to the severity of the obesity and its resultant effects
on the respiratory system 273. These mechanisms are out with the remit of this thesis
and will not be discussed further in detail.
2.1.2 Systemic Blood Pressure and Hypertension.
The World Heath Organisation defines hypertension as a BP of > 140/90 mmHg and
suggests a threshold for drug treatment at 160/95 mmHg. The target treated BP is <
140/90 mmHg, with lower limits set in the diabetic population. It is important not to
take a single reading as diagnostic of hypertension, remembering the effect of the
'white coat'. Recent advances in technology have allowed the development of
ambulatory devices to provide BP recordings over a 24-hour period, giving an
average reading for the period, and providing more accurate and reliable results.
Systemic hypertension is common and is one of the strongest predictors of
cardiovascular morbidity and mortality, including myocardial infarction, heart failure
and cerebrovascular disease. Hypertensive disease represents a significant public
health problem, and in 95% of cases no obvious cause can be found. It represents a
spectrum of disease from mild to severe cases.
The genesis of hypertension is complex, involving physiological dysfunction in the
nervous system including the autonomic nervous system, affecting the endocrine
system and alterations in cardiovascular function. These interrelated mechanisms
augment, stimulate and oppose each other producing a multi-factorial disease.
Increasing vascular resistance is the basic abnormality in chronic stable hypertension.
Underlying this seems to be two basic mechanisms; a vascular defect leading to
enhancement of vasoconstriction and an increase in sympathetic tone. Either of these
parameters can be genetically driven or acquired 274. There is conjecture that
initiation of hypertension by one mechanism may trigger off a cascade of events,
which may not all be fully reversible if you remove the initial stimulus.
In normal subjects the BP falls during sleep by up to 20%, increasing once more on
wakening. During NREM sleep in normal subjects SBP is reduced although this is
not a constant drop nor smooth, it contains small oscillations occurring in 20-30
second cycles. The BP is elevated in REM compared to NREM periods, however it
does not normally reach the waking levels 275. This pattern has been shown to be
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absent in some patients with OSAHS i.e. non-dipping as previously discussed 276 in
section 2.1.
2.2 Genetics.
Hypertension studies suggest genetic mechanisms are one of several factors
influencing blood pressure and that they are diluted by various environmental factors.
There are some phenotypic associations with hypertension that may provide a clue
about some of the underlying genetics. Family studies have shown the importance of
some relatively rare single gene defects in familial hypertension. At least four or five
genes may be involved in blood pressure control and probably this is an
underestimate. Most of the relevant genes have still to be identified 277 279.
2.3 Environmental Influences.
There are many and varied environmental influences on BP, some of which are
anecdotal and others have been proven with studies. Nutritionally several
components alter BP, suggesting a role for dietary manipulation of BP. However in
practice this is not very effective. A reduction in sodium, alcohol and protein intake
are associated with a lower SBP 28°. Potassium intake is associated with lower SBP
and DBP levels, alcohol (in moderation) is also associated with a lower DBP 28°. The
age changes in SBP are attenuated by increased calcium and protein intakes 28°. A
reduction in calcium and magnesium intake has also been studied with conflicting
280.281results
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Central obesity correlates better with BP than body mass per se 282, and this is most
commonly recorded by looking at the waist to hip ratio 282. Obesity alone does not
increase sympathetic activity 283, however there was a suggestion that dietary weight
reduction may be associated with a reduction in sympathetic activity 284, which in
itself can reduce BP. Further studies are needed.
Ingestion ofmore than 6 units of alcohol a day has been shown to be associated with
an increase in blood pressure. The lowest BP being associated with 1-2 units of
alcohol per day 280 and anecdotally red wine might be more protective.
Vegetarians tend to have a lower BP 266 however the reason for this is unknown,
although much postulation has been done. Stress acutely increases BP; whether
chronic stress itself leads to sustained BP elevation is still unclear.
2.4 Endothelium and Endothelin.
2.4.1 Endothelium.
The vascular endothelium is a cardiovascular endocrine organ with an approximate
surface area of 400m2, which provides the strategic interface between the blood and
the body. It has many regulatory roles, including the modulation of
immunoresponses, regulation of vascular cell growth, vasomotor control, pro and
anti thrombotic mechanisms, metabolic and immunological functions. It modulates
vascular tone with the release of vasoactive substances e.g. prostanoids, endothelin
and nitric oxide. It is sensitive to specific growth factors e.g. vascular endothelin
growth factor (VEGF), these growth factors are secreted by cells in response to
ischaemia and hypoxia and act via receptors expressed on the endothelial cells 285'286.
This increases vascular permeability, endothelial cell growth, cell proliferation, cell
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mobility, angiogenesis and vasodilatation " " .
2.4.2 Endothelins.
Endothelins are a family of potent vasoconstrictor peptides containing 21 amino
acids that are closely related to snake venom toxin. There are three isoforms named
1,2 and 3, and at least two receptors had been identified in human blood vessels,
named A and B. They are produced by a wide variety of cells.
Endothelin-1 (ET-1) is synthesised from 'big endothelin' within human vascular
endothelial cells. It had a potent and lasting vasoconstriction action on human blood
vessels, with an associated increase in blood pressure. However it can also produce
transient vasodilatation. In addition to its pressor and vasoconstrictor effects it has
been shown to be positively inotropic, mitogenic and to have an anti-natriuretic
action. ET-1 also increases central and peripheral sympathetic activity. Stimuli for
its release seems to be under the influence of chemical or physical stimuli including
hypoxia and thrombosis and by means of various receptor operated mechanisms e.g.
tissue growth factor (3 (TGF(3).
Levels have been shown to be increased in hypertensives, and in patient's with
pulmonary hypertension, and it has been postulated they might be elevated in
patient's with OSAHS perhaps contributing to elevation of BP seen in this patient
group 2,1, however the relationship remains poorly understood. There is some early
data providing conflicting evidence showing no increase in the ET-1 levels in
patients with OSAHS 292, and elevated levels in other studies 291'293. These studies
were small and may have been underpowered. A matched control group is included
in some 291'293, but others did not 292. The studies included hypertensive patients in
their study groups, which may have confounded their data.
2.5 Atheroqenesis.
Atherogenesis is the formation of atheroma within vessel walls. In the earliest stages
of atherogenesis, damaged endothelial cells become dysfunctional, resulting in the
formation of plaques. These plaques could then produce growth factors, cytokines,
chemo-attractants, clotting factors and adhesion molecules. Monocytes transform
into macrophages, recruitment and proliferation of smooth muscle cells occur, which
in turn activates the thrombotic process, altering vascular resistance. Within
resistance vessels, the wall to lumen ratio increases, and an increased reactivity to
pressor agonists occurs. Sloughing of the endothelium occurs at a later stage in the
disease process, where plaques become complicated, split or fissure.
Medial thickening in the aorta and the large arteries is associated with disruption and
uncoiling of elastic fibres and an increase in the collagen, with calcium deposition
resulting in stiff vessel walls. This decrease in the arterial compliance allows the
pressure wave generated during systole to be transmitted through the arterial tree
with an increased pulse pressure. The shape of the arterial waveform is also altered
by early return of the reflective wave in late systole from the periphery, boosting the
arterial pressure wave in late systole and so increasing the stress on the arterial wall.
Reduced compliance of the large arteries also affects the carotid and aortic
baroreceptors that would normally buffer the rapid changes in BP. This complex
process reflects the interaction of genetic and environmental factors previously
mentioned, and attempting to unravel these experimentally is very complex.
Whatever the mechanism the final pathway is common with an increase in peripheral
resistance in vessels, secondary to a reduction in lumenal diameter associated with an
increase in wall thickness.
There is also an association between the development of atheroma and BP, the higher
the arterial pressure the greater degree of atheroma. This may be secondary to the
local mechanical consequences of increased pressure and turbulence of blood flow,
almost as a self-perpetuating mechanism. Abrupt increases in BP may accelerate
atherosclerosis by causing premature plaque rupture in pre-disposed individuals.
2.5.1 Atheroma and The Cardiovascular System.
Angina and myocardial infarction usually occur secondary to atheroma. Left
ventricular (LV) hypertrophy occurs as a result of the increase in size of
cardiomyocytes, with increases in intercellular matrix that increases LV mass. These
changes are associated with a poor prognosis, as a result of worsening ischaemia,
more arrhythmias and reduced ventricular compliance, all predisposing to LV failure.
2.5.2 Atheroma and The Central Nervous System.
Cerebral atheroma may eventually lead to cerebral infarction. Haemorrhage occurs
normally as the result of rupture of small intracerebral degenerative aneurysms,
which develop in small perforating arteries in the region of the basal ganglia,
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thalamus and internal capsule. There is hyaline degeneration in the aneurysmal wall
and a defect in the media at its neck making it weak and prone to rupture.
Cerebral resistance vessels usually constrict in the face of increased pressure and
dilate in the face of reduced pressure to maintain a constant flow (autoregulation).
Resistance vessel hypertrophy seems to have a protective function in this respect so
that the autoregulation range is increased in longstanding hypertension, and
hypertensive encephalopathy may be seen and retinopathy is the commonest
manifestation noted in the eye.
2.5.3 Atheroma and The Renal Tract.
Atheroma can affect the general blood supply to the kidney resulting in renal artery
stenosis, or affect the microcirculation within the kidney itself. Renal
microcirculation can be affected with arteriolar wall thickening and a resultant
reduction in the diameter of the lumen. Hyaline degeneration is partially observed in
afferent arterioles of the kidney, thickening the whole vessel wall, beginning in the
subendothelial region and extending to the media. Progressive hyalinisation of the
nephrons accounts for the progressive slow decline in glomerular filtration rate with
age, which is accelerated by hypertension.
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2.6 Biochemical Markers.
2.6.1 Atrial Natriuretic Peptide.
Atrial natriuretic peptide (ANP) is a hormone released from the atria in response to
atrial distension, e.g. during large swings in pleural pressure. It is involved in
cardiovascular and renal homeostasis, and has been shown to induce natriuresis,
diuresis, to inhibit vascular smooth muscle contraction, and stimulate aldosterone and
renin release.
In patients with OSAHS nocturnal polyuria is common 29\ and when treated with
CPAP this resolves. The mechanism for this is not clear, however ANP has been
implicated. Conflicting data has been produced showing that ANP levels were high
in OSAHS patients and resolve with CPAP treatment 295'296, and in other studies no
difference in ANP levels before and after treatment were found 297.
2.6.2 Catecholamines.
Adrenaline (ADR) and noradrenaline (NA) are neurotransmitters excreted by the
adrenal medulla, and NA is also excreted by sympathetic nerve endings, into the
synaptic cleft. The nerve cell re-uptakes much of this NA but a proportion enters the
systemic circulation and can be measured in the plasma, where levels reflect activity,
however the circulating NA only reflects 5-10% of the total concentration. The
measurement of plasma or urinary NA is used as an indirect marker for sympathetic
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function but has been superseded by more sophisticated techniques of muscle nerve
sympathetic activity (MNSA) and power spectral analysis of heart rate variability.
2.6.3 Nitric Oxide.
Nitric oxide (NO) is a very lipophilic gaseous molecule produced by a variety of
tissues in the body and involved in the regulation of many different processes,
including pain regulation, memory function, and as a transmitter within the
genitourinary, gastrointestinal and respiratory tracts. NO also contributes to platelet
aggregation, cardiac contractility and host defence with immunological functions.
NO in the endothelium is partially responsible for the vasodilator tone that has an
integral role in BP regulation. Theoretically there could be chronic alteration of
vascular tone as a result of disordered nitric oxide production and signalling, leading
to changes in vascular resistance.
2.7 The Autonomic Nervous System.
The autonomic nervous system (ANS) is a complex regulatory system within the
body comprising two main parts, the sympathetic and the parasympathetic, these
work antagonistically to control a variety ofmechanisms.
2.7.1 Sympathetic Nervous System.















The Sympathetic Nervous System (SNS) has an integral role in the control of BP
with varied actions. It comprises both an afferent and an efferent system sensing
regulatory changes, and altering responses appropriately. Systemic arterial
baroreceptors in large arteries form an efferent feedback loop via integrating centres
in the medulla oblongata to influence areas in the hypothalamus and the reticular
activating system, and are discussed further below. These nervous circulatory
reflexes work to achieve sustained cardiac output and BP by complex mechanisms
including mobilisation of blood from the vascular bed. In normotensive subjects the
sympathetic stimulation of the heart and blood pressure is influenced by posture,
activity, emotional state, fitness, and cardiovascular state. The peripheral vascular
resistance is derived mainly from the arterioles, which are supplied by the SNS.
Sustained increase in the vascular resistance may be mediated by a variety of
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mechanisms led by the increase in sympathetic drive including; increased vascular
resistance, increased cardiac output, sodium retention and renin release, vascular
muscle defects either a membrane defect and or a problem with the synthesis of
contractile protein.
Previous studies have suggested that the sympathetic nervous system has an integral
role in the development of hypertension 298. Early hypertension was characterised by
increased cardiac sympathetic activity 299. Genetically preconditioned autonomic over
activity and stress probably play important roles in hypertension 27<U0°.
2.7.2 Baroreceptor Reflex.
Several reflexes within the cardiovascular system help control BP and heart rate, the
main one being the baroreceptor reflex. Baroreceptors are stretch receptors located in
the walls of major arteries including the aorta and carotid arteries. As the intra
lumenal pressure increases these receptors are stretched and signal the brain to inhibit
sympathetic discharge to the heart and blood vessels, altering cardiac output and
peripheral resistance to allow the pressure to fall by means of negative feedback.
The baroreceptors feed from the carotid sinus via Herring's nerve, the
glossopharyngeal nerve, the tractus solarius to the medulla and those from the aortic
baroreceptors feedback via the vagus nerve. In essential hypertension cardiovascular
homeostasis is altered, but the causes are not fully understood, however early
alteration in baroreceptor control suggests that the sympathetic system is integrally
involved. Decreased sensory input from the carotid sinus and aortic depressor nerves
cause labile or sustained hypertension. However it is not clear whether impaired
input from baroreceptors are a causative factor 301"305. Arterial baroreceptors are reset
in hypertension with a higher pressure threshold and reduced sensitivity to increases
in pressure 274, as a result of the altered vessel wall dynamics.
Generally baroreceptors are not stimulated when MAP drops below 60 mmHg in the
carotid sinus and 30 mmHg in the aortic arch 266. Even a slight increase in BP can
result in a large change in sympathetic outflow to correct the BP back to the 'normal'
level. The baroreceptor feedback mechanisms function most effectively over the
normal operating pressure range 266, therefore it is variable and can be reset. The role
of baroreceptor resetting in the long-term regulation of BP is controversial, as it
seems that it is reset within a short time. For example if the MAP was high there
should be negative feedback to allow vasodilatation to encourage a drop in BP.
However the baroreceptor impulses are marked when the BP is first increased but
during the next few hours the level of activity decays and after 1-2 days it is back to a
background level despite a high MAP, the converse is also true if the BP is low 266.
2.7.3 Chemoreceptor Reflex.
The chemoreceptor reflex is similar to the baroreceptor reflex however it is
stimulated by changes in arterial p02, pCO, and pH. These receptors are located in
the carotid and aortic bodies, and their nerves travel back along the same paths as the
baroreceptor nerves. They signal back to the vasomotor centre and help regulate BP,
and are especially important when the arterial p02 is low 306. The carotid chemoreflex
has two efferent outflows; via the phrenic motor output, and via the sympathetic
outflow to both the heart and key vascular beds. The chemoreceptor responsiveness
can vary and has been shown to be altered in 32 patients with OSAHS 307 although
these patients had co-existing obesity (mean BMI 34.2 Kg/m2).
2.7.4 Muscle Nerve Sympathetic Activity.
Muscle nerve sympathetic activity (MNSA), is a measure of sympathetic nerve
traffic to muscles used as a marker of sympathetic tone, and is usually measured in
the peroneal nerve in humans. In healthy humans MNSA fluctuates about every 10
seconds, resulting in a rapid response in vascular smooth muscle and sino-atrial node
activity, which in turn results in changes in heart rate and arterial pressure 308. MNSA
reflects approximately 50-69% of the variance in sympathetic activity it is also
affected by breathing pattern and pleural pressures. Hornyak performed an
experiment looking a the MNSA in normal subjects during the different stages of
sleep 309 showing a reduction in activity during non-REM sleep and increased activity
during REM sleep, which agreed with the previous animal studies 309. Yamada
studied MNSA in a hypertensive population and showed an increase in patients with
hypertension at all ages and concluded that the SNS played an integral role in the
maintenance of raised blood pressure 202. In the absence of pulmonary stretch
receptor induced inhibitory influence on sympathetic activity the MNSA response to
hypoxia-induced chemoreceptor activation is greatly enhanced 31°.
2.7.5 Heart Rate Variability.
Cyclical changes in heart rate and haemodynamic perameters has been recognised for
more than 100 years. However it is only more recently that importance of
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spontaneous fluctuations in heart rate has been recognised as a surrogate marker of
autonomic function 31',312. Heart rate has two main influences, intrinsic firing of the
automatic pacemaker cells in the sino-atrial node, and the modulating influences of
the ANS. The sino-atrial node is affected both by the SNS, which enhances the rate,
and by the PNS, which suppresses heart rate. It is the balance between both these
components, which results in the heart rate. This oscillation in the interval between
consecutive heartbeats, the so-called heart rate variability (HRV), is used as a non¬
invasive marker reflecting sympathovagal balance. HRV can be analysed in a variety
of ways, the two main ones being time domain analysis and frequency domain
analysis (power spectrum) 311,3!2. The R-R interval is mediated by fluctuations in
sympathetic nerve activity, the higher R-R intervals rhythms are mediated by
fluctuations in the vagal-cardiac nerve activity, and reflect events that provoke
reciprocal changes of sympathetic and vagal neural outflows 31'. The R-R spectral
power is calculated from a series of ECG recordings after a steady state is achieved
using an autoregressive algorithm, taking 5-minute intervals. This produces centre
frequencies and absolute power of component fluctuations.
2.7.6 Power Spectral Analysis.
Power spectral analysis uses the HR signal and converts it into its frequency
components and quantifies them in terms of their relative intensity, called 'power'
(msec2/Hz), resulting in a power spectrum density ofHR, which allows the separation
of the components the autonomic nervous system. This is also affected by a variety
of other factors including respiration, baroreceptor reflexes, vasomotor control and
thermoregulation. The analysis can be performed in two ways either by fast Fourier
transformation (FFT) or autoregressive model estimation 312,313. FFT gives discrete
peaks for the several frequency components, the autoregressive method results in a
continuous smooth spectrum of activity. Both methods yield similar results. The
power spectrum consists of three major bands, which vary in definition between
different authors 31'"3'5. However usually the high frequency (HF) band is 0.15 - 0.40
Hz, low frequency (LF) 0.04 - 0.15 Hz and very low frequency (VLF) 0 - 0.04 Hz.
The HF band is associated with parasympathetic activity 3", the LF band is
occasionally called the baroreceptor band because of its association with baroreceptor
activity 311,312 and it has also been linked to thermoregulatory processes, peripheral
vasomotor activity and the renin-angiotensin system. The VLF band had been
identified as a marker for sympathetic activity311, however it is poorly understood.
Sympathovagal balance is taken as the ratio between LF and HF power. Therefore a
reduction in the ratio suggests a shift towards vagal predominance and an increase in
the ratio with a shift towards sympathetic predominance. A number of power
calculations can be done. The total area under the power spectral curve represents
total power of HR. The power of the individual components can be calculated by
measuring the area under their peak on the curve. The absolute power can then be
calculated from this. The HF component is the best understood 3", it must however
be remembered that it is influenced by the degree of coupling between respiration
and HR. The respiratory pattern could therefore influence the HF power, and in
testing controlled breathing patterns can improve the reproducibility of the results.
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2.8 Epidemiology.
Large studies have looked at the natural history of hypertension, most famously the
Framingham series 3I6"318. This large study found that borderline hypertensives -
defined as SBP 140-159 mmHg and DBP < 90 mmHg - went on to develop
hypertension and had a higher incidence of cardiovascular disease. The prevalence
of this disorder in the United States is 20% of the population, with a new diagnosis
rate of 3% per annum. The figures in the UK are similar. There are also large
epidemiological cohorts showing that DBP is a good predictor for developing both
cardiovascular and cerebrovascular disease, and not just within the 'hypertensive'
confines but also in the normotensive population 112113 319 324
2.9 Morbidity and Mortality.
The most famous of epidemiological studies is the from the US, where the town of
Framingham continues to be followed more than 50 years since the start of the
project, with the investigators providing a wealth of data. In recent papers by one of
the major investigators Kannel, he reports that BP elevation is a powerful contributor
to all major cardiovascular sequelae 325"327. The influence of SBP is well described
showing a graded influence even at levels that are considered normotensive.
Furthermore he reports that hypertension occurs in conjunction with other
metabolically linked risk factors. Coronary disease is a major contributor to
morbidity in hypertensives with 40% of events in men and 68% in women being
associated with the presence of two or more risk factors. In isolation hypertensives;
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14% of events in men and 5% in women occur in isolation without any concurrent
risk factors 325,328. This view has been confirmed by other studies 3I7,322'324.
Data from the Framingham study has suggested that SBP is a more important
predictor of cardiovascular sequelae than DBP. Even mild to moderate elevations
with normal DBP levels are associated with increases in morbidity and mortality
3i8.323.329.33o jjjgj.gfQj.g by looking at DBP alone can be misleading and possibly lead to
a false sense of security. It has also been reported from this cohort that persons with
high-normal SBP (130-9 mmHg) and DBP (85-9 mmHg) have an increased risk of
cardiovascular events, which is higher in men than women 322. This reinforces that
there is no lower threshold for improvements seen with reductions in BP 317. This
viewpoint has been challenged by Port et al, who reports an age and sex-dependent
threshold for hypertension using a linear logistic regression model with the
Framingham data suggesting that a proportion of the population who would be
thought to be at risk are not.
With an ageing population there is increasing interest in the older age group, the
Framingham investigators analysed a cohort from their study looking at 6539
subjects who were free of cardiovascular disease and anti-hypertensive medication at
baseline. They report a gradual shift from DBP to SBP and then to PP as predictors
of cardiovascular risk. In the under 50 years DBP is the strongest predictor, then in
the 60's all three indices are comparable, and from 70 years on DBP is negatively
related to the risk so that PP becomes a better index than SBP 321. Heart rate (HR),
has been looked at to see if it is a useful predictor of cardiovascular mortality. A
5070 patient cohort from the Framingham group who were free from cardiovascular
disease at study entry were analysed 332. An association between a high resting HR
and cardiovascular morbidity and mortality was seen; this has also been reported in a
number ofprospective studies 332.
Night-time BP is an independent predictor of vascular disease in essential
hypertension 27''272'333. Perloff et al found that 24-hour BP was a better predictor of
cardiovascular mortality and morbidity compared with isolated measurements, i.e.
reduced white coat hypertension 334. Systolic hypertension continues to be an
important risk factor for death in the elderly where cardiac deaths were increased two
to three fold. Systolic and diastolic pressures are independent risk factors and
standard mortality ratios exist 335. In more recent years there has been interest in the
PP as an indicator for morbidity, with data suggesting the higher the PP the greater
the associated cardiovascular risk 336"340.
Numerous studies have shown that with effective SBP control, the risk of
cerebrovascular and cardiovascular events are reduced 201'317'319'341'342. The evidence for
DBP is also present but SBP is more closely linked with stroke, congestive cardiac
j- , , • , , 201,317,319,342,343disease, coronary artery disease, and renal disease
Arterial stiffness increases with age, rising markedly after the 5th decade, resulting in
a progressive rise in SBP and a fall in DBP as the vessel walls lose their elasticity 337.
The difference between SBP and DBP is the PP, and is a marker for large vessel
stiffness. PP has been shown to correlate with the development of congestive heart
failure in an elderly cohort 344, and is associated with an increased risk of myocardial
infarction (MI), and cardiovascular mortality 337'338'340'345,346.
Mild disease is a common problem and even alone it is associated with a reduction in
life expectancy. In severe disease the individual risk is increased and life expectancy
is reduced further. The presence of malignant hypertension greatly worsens the
prognosis, as you would expect. The predominant cause of death is cerebrovascular
and cardiovascular disease.
2.10 Symptoms.
Hypertension is usually asymptomatic. Headaches, although rare, are classically
seen in the morning on wakening, occipital to frontal in position, and throbbing in
nature. Epistaxis is uncommon although reported in the literature. Nocturia can
occur as a result of a reduction in urine concentrating capacity within the kidney.
2.11 Clinical Examination.
The clinical examination in the hypertensive patient is often unremarkable, but
should include auscultation of the heart and lungs, palpation of the abdomen and
fundoscopy. BP should be measured and urinalysis performed. Weight and height
should be recorded to allow calculation ofBMI.
2.12 Diagnosis.
BP is usually measured non-invasively using a cuff placed around the upper arm,
measuring the pressure indirectly in the brachial artery. The BP cuff size is
important to ensure an accurate reading; the cuff bladder should be 80% of width and
40% circumference of upper arm 347,348. The patient should be comfortable rested and
relaxed, seated or supine, the arm horizontal at mid sternal level. A cuff that is too
small will overestimate the pressure and one that is too big can underestimate the
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pressure. Diagnosis should not be made on the basis of a single recording, at least
two separate measurements on 2 separate occasions require to be done 347'348.
2.12.1 Investigations.
No simple blood test is diagnostic of hypertension, however blood tests may be
important to exclude underlying pathology. Investigation should be used to exclude
any underlying cause for hypertension that could be treated primarily, and should be
targeted on clinical grounds, or to elucidate evidence of end organ damage. Thus
renal function, urinalysis and ECG's are usually checked.
2.13 Treatment.
Non-pharmacological treatment of hypertension should ideally be instigated, with
lifestyle measures including weight reduction, alcohol restriction, sodium restriction,
exercise and behavioural therapy.
The pharmacological treatment of hypertension varies with the range of drugs
available increasing rapidly. Finding the most appropriate drug for a patient may
take time and ideally mono therapy is preferable, however often a combination is
required. The British Hypertension Society has produced guidelines for the
treatment of hypertension 349.
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2.14 OSAHS and its Effect on Blood Pressure.
2.14.1 Pulmonary Arterial Hypertension and OSAHS.
The effect of OSAHS on the pulmonary vascular bed has been investigated in
previous studies. In less than 20% of OSAHS cases daytime elevated pulmonary
artery pressures develop and this may progress to right ventricular hypertrophy and
rarely to cor pulmonale, especially in those subjects with pre-existing lung disease
350,351
Early work from Hong using divers who were able to breath hold for up to 4 minutes,
he reported the effects of this breath hold on alveolar gas exchange 352. He showed a
gradual decrease in Pa02 while PaC02 increased during the first 30 seconds after
which it levelled off. In OSAHS with each apnoea the gas-exchange is affected it
would be reasonable to assume in a similar way to Hong's divers, with alterations in
Pa02, PaC02 Although it must be remembered that the divers were young and fit
and therefore are a different population to the majority of OSAHS patients.
Pulmonary vasoconstriction occurs in response to alveolar hypoxia in order to
maintain lung perfusion with ventilation, resulting in repeated surges of pulmonary
arterial hypertension overnight.
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2.14.2 Systemic Blood Pressure and OSAHS.
2.14.2.1 Introduction.
The effect of OSAHS on systemic blood pressure has been the subject of many
different studies, examining the effects on both night-time and daytime BP. The
investigation of systemic daytime BP in OSAHS has provided considerable indirect
evidence suggesting that OSAHS may lead to daytime hypertension, cardiovascular
disease and cerebrovascular disease 65'7y'S2'353"35\ Despite the association suggested in
the large epidemiological studies, OSAHS has not been proven to cause sustained
daytime hypertension and whether it does is hotly debated w':15:!'354'359.
2.14.2.2 Mechanisms of Acute Rise in Blood Pressure.
Acute rises in blood pressure around apnoea termination have been described by
Davies et al 360, and these swings have a direct effect on mean night-time BP. The
mechanisms involved in the genesis of the acute BP rise in OSAHS are complex with
contributions from neuronal, hormonal, autocrine, paracrine events, along with
effects of hypoxia and arousal361.
The effect of arousal from sleep cannot be underestimated with marked changes in
blood pressure which is the trigger for the repeated cascade of pathophysiological
events that form the entity of OSAHS and the generate the sequelae of the disorder.
Apnoeas result in hypoxaemia and hypercapnia and thus stimulate the peripheral
chemoreceptors, which in turn activate the sympathetic nervous system, increase
cardiac output, increase systemic vascular resistance and blood pressure. As the
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apnoea progresses SBP increases further, probably secondary to the hypoxia, and the
heart rate drops (secondary to the diving reflex). Stimulation of the carotid body in
the absence of stretch receptor activity reduces heart rate (Mueller manoeuvre), and
at the moment of apnoea termination a further increase in SBP is seen. The
maximum changes occur just after the apnoea termination, when the increase in
systolic pressure could be more than 50%, increasing further with larger degrees of
desaturation 362. The BP rise takes 10-12 seconds to reverse after termination of the
apnoea, via the carotid body and brain due to the circulation time 363. SBP is usually
lowest during the early and middle of the apnoea, with the pressure gradually
increasing with a sudden rise at the apnoea termination 364. With apnoeas of 40
seconds or more in duration the cardiac output falls by approximately a third 365. This
combination of increased SBP and reduction in cardiac output is associated with an
increase in systemic vascular resistance 176.
Systemic vasoconstriction is believed to be mediated by sympathetic neural activity
l76. The drop in p02 along with apnoea termination result in catecholamine release,
which increases systemic BP and pulmonary BP, and the resulting sympathetic
neural response leads to impaired cardiac sympathetic function and integrity.
Termination of apnoea and the associated cortical and subcortical arousal leads to a
rapid rise in the heart rate, which reflects the withdrawal of vagal tone due to
baroreflex stimulation 366, systemic and pulmonary blood pressure rise 364, release of
the hormones of homeostasis is triggered and arrhythmias can be initiated 367'368. The
generation of negative intrathoracic pressure during an apnoeic event results in
sympathetic withdrawal and an initial reduction in systemic BP, because the
sympatho-excitatory effects of the chemoreflex are unopposed, probably secondary
to a reduction in stroke volume, with associated cardiac deceleration 365. The stress of
the swinging nocturnal BP, associated with apnoeas and hypopnoeas is thought in
particular to exacerbate pre-existing ischaemic heart disease and cerebrovascular
J- 369disease .
The nocturnal changes can possibly produce a carry-over effect, which may persist
into the daytime 370"372. Therefore accurate timing of measurement is extremely
important when performing investigations and it is important that the timings are
consistent within a study. Increasing SNS activity, reducing baroreceptor sensitivity,
accentuating vascular responsiveness, along with abnormalities in salt and water
metabolism, all of these elements can contribute to hypertension, but whether they
are affected by OSAHS per se remains unclear. The question of whether intermittent
(sleep related) changes in BP (as seen in OSAHS) can lead to long-term elevation of
daytime BP and structural cardiovascular changes also remains elusive.
The complex consequences of apnoea are illustrated in figure 2.3 overleaf.
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2.14.2.3 Possible Mechanisms of Sustained Daytime
Hypertension in OSAHS.
The possible mechanisms of sustained daytime BP in OSAHS is the continued
subject of debate and ongoing research, it involves many complex inter-related
mechanisms. Earlier investigations have tried to control for BMI however they were
small studies 207,373. In performing this type of study it is important to take into
account the variability of BP, and SDB, and the pattern of deposition of body fat.
Obesity associated hypertension is thought to be secondary to a combination of
mechanisms inducing insulin resistance. Obesity and an increased caloric intake
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increase the activation of the sympathetic nervous system secondary to
hyperinsulinaemia. These increased insulin levels increase renal tubular sodium
absorption and therefore sodium retention; it also results in vascular hypertrophy and
attenuated vasodilatation in skeletal muscle.
One hypothesis for the evolution of hypertension is that SDB increases sympathetic
nerve traffic. Clinical studies in SDB have shown patients with SDB have increased
levels of sympathetic activity both in sleep and during wakefulness l63'374, this is
discussed further in section 2.15. The acute increases in sympathetic traffic in
apnoea and in the immediate post-apnoeic period have been demonstrated 375~377.
There also may be increases in sympathetic activity with arousal from sleep. It is
important to dissect the mechanism of the sympathetic system involvement. Resting
daytime sympathetic traffic is increased with OSAHS 378,379. These studies although
suggestive are small in size and not all have controlled for confounders 376,379 nor
provided an adequate control population 374,377,37S. MNSA is a particularly difficult
technique and the size and design of these studies in part reflects this. There has also
been work looking at the biochemical markers of SNS activity which is further
discussed in section 2.15.1.
These studies support a causal role of the SNS in the aetiology of hypertension in
OSAHS patients. The aetiology of the increase in sympathetic drive is not clear but
both hypoxia - acting via arterial chemorecpetors - and arousal from sleep have been
implicated.
Chemoreceptors respond to episodic hypoxia and stimulate the sympathetic nervous
system. The chemoreceptors may undergo adaptation to the long-term hypoxia and
hypercapnia, thereby altering basal BP. Augmented ventilatory response has been
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shown to hyperoxic conditions that can result in the inactivation of chemoreceptors
38°. A greater pressor response to hypoxia has been reported in OSAHS compared to
non-OSAHS patients with hypertension 381.
Baroreceptor function seeks to maintain systemic BP at a given level. However this
level may be reset. Whether the acute increase in BP seen with an apnoea can when
repeated many times a night for years, reset baroreceptors leading to a higher daytime
waking BP is unclear. From Brooks canine model there is some suggestion that the
baroreceptor slope is not altered but is shifted to the right resetting at a higher
pressure without a change in sensitivity 382, as is often seen in hypertension.
Other mechanisms for the development of hypertension in SDB include impairment
of vascular endothelial function 383. This has been studied using the model of forearm
blood flow and vascular resistance to reflect vascular endothelial vasodilatation.
Results suggested that endothelial dependant vascular vasodilatation is reduced in
SDB subjects whilst awake 384.
There is emerging evidence that SDB may be associated with metabolic
abnormalities, which are risk factors for hypertension, e.g. impaired glucose
tolerance, insulin resistance, and altered cortiocotrophic function 385,38S.
2.14.2.4 Does OSAHS Cause Daytime Hypertension?
Some investigators feel that the arousal from sleep is the critical factor in the possible
development of hypertension in OSAHS patients 364'387. However work by Brooks 388,
using the dog model ofOSAHS has suggested that hypoxia is a dominant force in the
evolution of sustained daytime hypertension in this group of dogs at least. In their
69
study they did find an acute rise in systemic BP, both following apnoeic arousal and
following sound induced arousals. However there was no sustained rise in daytime
BP in the dogs exposed to acoustic arousal but there was when aroused by apnoea
388,389
Hypoxia is sensed by the carotid chemoreceptors, which results in bradycardia,
arteriolar constriction and catecholamine release, all of which cause transient
hypertension l76. Hypoxia is promoted as an important factor in the development of
hypertension in the OSAHS patient, however patients with chronic hypoxia e.g. those
who live at high altitude, or cyanotic congenital heart disease, do not seem to develop
systemic hypertension 39°, the reasons for this remain unclear.
2.14.2.5 Epidemiology.
Data from epidemiological studies demonstrates that hypertension is common in
OSAHS patients 5 I88-207'391 395 with incidences ranging between 48-96% of patients; and
OSAHS is common in the hypertensive population with a quoted incidence of a 30-
40°/ 188'207,393,396'397
Larger epidemiological studies have been done; Carlson reported a cohort of 377
subjects, concluding that age, BMI and AHI are independent predictors of
hypertension, and quoting relative risks (RR) of hypertension at 4.3 with age, obesity
at 2.1 and OSAHS 2.1 398. Grunstein 54 in his cross-sectional study of 1469 subjects
showed that AHI related to morning BP independently, and obesity and AHI were
independent risk factors for hypertension. Hoffstein et al used multiple linear
regression analysis to try and tease out the causes ofhypertension in OSAHS, obesity
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came out as the strongest predictor in his study. In the non-dipping OSAHS
hypertensive patient, the mean 24-hour BP increased with RDI 9'399.
Hla et al 65'353'400 in a study of 147 normal working subjects, monitored 24-hour BP,
defining hypertension as a SBP > 140, or DBP > 90 mmHg, controlling for age and
weight. They reported a graduated rise in BP associated with an increase in apnoea
frequency, and concluded that there was an association of hypertension in the
OSAHS patients, even in the non-obese group, which was also independent of age
and sex, reporting the relative risk of hypertension as between 1.5 and 2.5.
The Wisconsin sleep cohort continues to provide information in their prospective
observational study. Young reported that seated BP increased linearly with AHI in
their cohort of 1060 subjects 40°, with an odds ratio (OR) for hypertension associated
with an AHI of 15 events/hour slept as 1.8. Young et al 359 demonstrated a gradual
rise both in ambulatory daytime and sleeping BP dependant on the AHI. This
indicated that epidemiologically there is an increase in BP as OSAHS severity
increases and conceptually that the severity of OSAHS is intrinsically linked to BP
even in the normotensive patient. In Young's study 359 they showed that SBP and
DBP increased with SBD severity in the unadjusted data. Using a multiple linear
regression model to control for confounders their study continued to show that SDB
severity measured as AHI was significantly related to both systolic and diastolic BP.
They even demonstrated small changes in the mild cases with AHI's between 5-15,
which is perhaps surprising. However as BMI increased the association was weaker
40°. Sorting out the dilemma of SDB and hypertension remains difficult because of
the commonality of confounders. There have been 5 recent studies by Peppard 40',
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Nieto 402, Lavie l9°, Bixler 403 and Davies 404, concluding that there is an independent
relationship between SDB and hypertension.
Peppard reported a follow-up from the Wisconsin sleep cohort401. The cohort has
been followed up for 4 years in 709 patients and 8 years in 184 patients. They
adjusted for baseline hypertension status, BMI, neck and waist measurement, age,
sex, alcohol consumption and cigarette consumption. At follow-up the odds ratio for
hypertension in comparison to an AHI of zero was: AHI < 4.9: OR 1.4; AHI 5 -
14.9: OR 2.03; and AHI > 15: OR 2.89.
The Sleep Heart Health Study is a large multi-centre prospective cohort study of
SDB looking at risk factors for hypertension and cardiovascular disease 402. Their
cohort of 6132 subjects had seated BP and overnight PSG performed. Hypertension
was defined in this study a BP of 140/90 mmHg and above, or the use of anti¬
hypertensive medication. BMI, neck measurement, waist-to-hip ratio, alcohol and
smoking were all adjusted for. Between an AHI > 30 and an AHI <1.5 there is an
OR of 1.37 for hypertension. They also showed that the percentage sleep that the
subject desaturated to < 90% pO, had an OR of 1.46 for hypertension. Although a
very useful study it remains an observational one, with the BP recorded as an 'office'
BP rather than a 24-hour recording. The authors did try to control for confounding as
much as possible.
Lavie also reported a large prospective observational study of 2677 subjects who
underwent PSG and BP recordings having been referred to a sleep centre l9°.
Therefore these patients were not representative of the normal population as they
must have been symptomatic to a degree to be referred to a sleep centre. Multiple
regression analysis of BP was performed on subjects who were on no medication and
suggested that AHI predicted SBP, DBP after adjustment for age, BMI and sex. For
every extra respiratory event, the OR of hypertension increased by 1%, and a 10%
reduction in apnoea related desaturation increased the OR for hypertension by 13%.
Bixler 403 reported a population study, performing random telephone interviews on
16,583 subjects, selecting a subset of 1741 on the basis of having risk factors for
SDB for a second phase. Sleep studies were performed on this cohort and they were
stratified on the basis of their AHI; reporting SDB was independently associated with
hypertension even when confounders were controlled for by logistic regression
analysis. However the strength of this association decreased with increasing age and
was in proportion to the severity of SDB. The BP recorded was supine 'office' BP
taken after ten minutes of resting before the sleep study. Hypertension was defined
in the study as SBP > 140, DBP > 90 or the taking of anti-hypertensive medication.
The OR ofmoderate-severe (AHI > 15) SDB having hypertension was 6.85, and with
mild (AHI 0.1 - 14.9) SDB the OR was 2.29, comparing to their 'normal' control
group. This study does not include a formal control group, the patients who had
normal sleep studies were utilised, however by definition they had to be symptomatic
or to have risk factors of the disorder, no attempt to match this population was made.
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2.14.2.6 Studies in Hypertensive Populations.
Uncontrolled case reports of the resolution of daytime systemic hypertension in some
treated OSAHS patients 405,406 support the causal role of apnoea in hypertension.
Furthermore studies performed in the hypertension clinics have reported a higher
incidence of SDB than seen in the population as a whole 407"410.
Olsen studied 441 subjects comparing BP in the hypertensives and hypertensives
with OSAHS, and showed an OR of 3.8 with hypertension in patients with an AHI >
15 events/hour slept, however when adjusted for confounders this became
insignificant 74, but the numbers of subjects with hypertension in this study were
relativity small.
Kraiczi 411 performed a treatment trial of hypertension in SDB, in an alternative
approach to the problem. Forty patients were enrolled in an incomplete balanced
block design study. There were 5 agents from different classes of drugs studied, with
each subject receiving two different medications for six weeks each, off CPAP
therapy. BP was measured both in the clinic and with an ABPM, patients also
underwent a sleep study. A significant reduction was seen in DBP with atenolol, the
other drugs did not show any significant reduction in BP before and after
introduction of the medication. Because the [l-blocker was the only drug that
reduced the DBP significantly the authors suggested that the sympathetic nervous
system must therefore be involved in the pathogenesis of SDB 411. Caution has to be
observed with interpretation of these results as not all the data were supplied in the
paper, despite recording 24-hour BP this was not included, and their primary
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outcome was clinic DBP. Furthermore CPAP was not included as a possible
treatment.
Worsnop et al studied a hypertensive clinic population to measure the prevalence of
SDB in this population and compared them normotensive subjects 4I2. They conclude
that there is a relationship between OSAHS and hypertension, although in part they
felt that this was explained by the confounders. The authors attempted to control for
confounders, however the patient group contained both treated hypertensive and
normotensive patients.
A cross-sectional study was reported by Grote et al4I3, recruiting 599 subjects from a
hypertension clinic and concluded that SDB should be considered in resistant
hypertension especially in the younger patients (age < 50 years). Clinic BP was
recorded and patients had two home sleep studies performed. Once more this is
observational data providing useful information but still lack the high level of
evidence. The potential importance of considering OSAHS in refractory
hypertension is also suggested in a study by Isaksson et al414.
2.14.2.7 Studies in OSAHS Populations and Problems with
Confounders.
There have been several studies which have suggested that the link is just co¬
incidental S2354'4'5, and mainly due to confounders, however the studies were small in
size and often lacked a control group. In general stronger relationships have been
found in the under 50 age group 4l6. There has also been several reviews looking at
the association of OSAHS and diurnal BP 67-4l7"423; suggesting OSAHS may be a causal
factor for hypertension, however the problem of confounding variables exists, which
can be difficult to control for. It is a difficult area to study as cuff BP react too
slowly to show the lability of the nocturnal pressure in the situation of cyclical
variation in OSAHS 424. The nature of cuff BP can artificially elevate BP especially
nocturnally using the ABPM however acclimatisation can occur, office BP can be
elevated because of the 'white coat' effect. It is not clear which is the best predictor
for the associated vascular sequelae, it is also not clear if the elevated BP associated
with SDB has the same outcomes as elevated BP from other causes although it would
be reasonable to assume that this is the case however no evidence to support this as
yet. The increases noted in the nocturnal BP alone may be responsible for the
possible increases in cardiovascular sequelae reported.
Increasing obesity is associated with increasing BP, especially if there is upper body
fat deposition. The variation in night-to-night AHI makes the investigation of
OSAHS more problematic as does the monitoring of BP in this group. This has been
shown to weaken the relationship between BP and OSAHS by regressional dilution
bias 425.
Pankow et al 426 recruited 93 subjects from their sleep clinic population, approaching
alternative patients referred to the clinic. They performed 24-hour BP using an
ABPM taking recordings at 15-minute intervals after the patients had attended for
their sleep study. The sleep studies performed were limited relying on an oxygen
desaturation index to diagnose SDB. They concluded that the desaturation index was
significantly related to SBP and DBP both in the daytime and night-time. Utilising a
multiple regression model they showed an independent association of oxygen
desaturation and age to the daytime BP. The authors did not include any control
group in their study, comparing the different levels of oxygen desaturation index
within his patient group. The patients were by definition symptomatic to some
degree as they were attending a sleep clinic and therefore does not represent a normal
population.
Grote et al427 also recruited patients from a sleep clinic (n = 1190) to study the effect
of SDB on BP. They recruited consecutive patients and recorded their office BP and
performed home sleep studies. The authors report that RDI is independently and
linearly associated with SBP, DBP and HR. The RR for hypertension increased with
increasing SDB severity; OR of 4.15 for RDI > 40 versus RDI < 5. The RR was
increased in the younger population (age < 50 years). They concluded that from their
cross-sectional clinic data there is a relationship between SDB severity and SBP,
DBP, and HR after controlling for confounders (BMI, age, alcohol consumption,
cigarette smoking, cholesterol, daytime p02, and pC02). They did not include a
formal control population in their study.
Mendelson retrospectively reviewed 619 consecutive admissions to a sleep centre 428,
reporting that in the OSAHS patients the absolute minimum arterial oxygen
desaturation was the most significant contributor to waking DBP, with weight also
being additive. The authors did not control for confounders and did not attempt to
include a control population. The author later reported further observational data in a
further 265 patients 429. Reporting that across the spectrum of SDB differences in
DBP were associated with weight primarily, age and gender. In OSAHS DBP was
associated with measures of SDB, namely AHI and minimum oxygen saturation.
Once again no control population was included in the study, and confounders were
not well controlled for.
Lavie et al recruited 38 consecutive patients from their sleep centre who had a
diagnosis of OSAHS made from sleep study 43°. The authors monitored 24-BP 10
days after the diagnosis of OSAHS was made. They report that their results support
a causal relationship between the severity ofOSAHS and systemic hypertension, and
that the severity of OSAHS is directly inked to the degree of hypertension. Once
again no control population was included in the study, although the authors did try to
control for confounders. The patient group was heterogeneous containing both
normotensive and hypertensive patients on medication.
2.15 Sympathetic Nervous System in OSAHS.
Sympathetic discharge via the central and peripheral chemoreceptors during apnoea
may be potentiated by the presence of hypoxia and hypercapnia, as the inhibitory
influence of the thoracic afferent nerves are eliminated, and by arousal.
Consequently the sympathetic vasopressor response increases with marked rises in
BP with each apnoeic event431. This may be as a consequence of impaired baroreflex
sensitivity, as baroreflexes exert an inhibitory influence on the chemoreflex response
to hypoxia. Both hypoxia and hypercapnia exert local vascular effects resulting in
vasodilatation, however these effects are opposed by the increase in the sympathetic
neural traffic. This increased sympathetic activity seems to carry over into wake
time, possibly leading to systemic hypertension. The vasoconstriction that occurs
leads to an increase in venous return and therefore cardiac output (CO) is increased.
This increased CO enters the vasoconstricted peripheral circulation raising arterial
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pressure further. During apnoeic events the increased sympathetic activity in
hypertensive patients is about 12 times the normal subject response 431.
There have been concerns previously that obesity alone may explain the increase in
the MNSA suggesting that body fat was a major determinant of sympathetic neural
discharge 432. However in a study looking at 30 healthy obese subjects comparing
them with 25 'normal weight' controls, no difference was demonstrated in MNSA in
the different patients groups, OSAHS having been excluded using PSG 283, surmising
that it must be related to apnoea. Fletcher reported that recurrent episodic hypoxia
appeared to stimulate carotid chemoreceptors which in turn stimulates sympathetic
nervous activity, which may remain stimulated after the event, giving a more
prolonged effect 433.
Hedner et al 434, and Fletcher et al 435 both produced data to suggest that repetitive
hypoxaemia plays a role in the aetiology of hypertension related to abnormal
sympathetic tone, but it does not explain why the chronically hypoxaemic subject
does not develop systemic hypertension. Hedner showed a potent pressor response to
hypoxia in OSAHS patients that is not present in normotensive controls, which is in
part related to the ventilatory response, suggesting a dependence on chemoreceptor
function and sympathetic activation 381. However this sympathetic response to
hypoxia is demonstrated in healthy controls where BP remained unchanged, therefore
perhaps the BP response in the OSAHS is more pronounced due to unopposed
sympathetic activation or by another as yet unidentified mechanism. This suggests
that sympathetic adrenergic activity is responsible at least in part for the increases in
blood pressure 436. Guilleminault et al suggested that SDB may be associated with
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abnormal sympathetic discharge using muscle nerve sympathetic activity but also
postulated that there may be impairment of local vascular endothelial mechanisms 437.
Narkiewicz studied the effects of chemoreflex activation on MNSA 438. Controls
were matched with OSAHS patients, concluding that tonic activation of the
excitatory chemoreflex afferents may contribute to increased efferent sympathetic
nerve activity to muscle circulation in this group of patients 439. They also
demonstrated increased sympathetic activity while awake, which increased further
during sleep, and was reduced with CPAP treatment, however not back to normal
levels. The controls were not matched for weight, only for age and sex. It is
debatable whether the use of a split night study is adequate as patients had just
commenced treatment, and sleep would not have been 'normal' 376. It would possibly
be better to allow the patients to have been established on CPAP for some time, or to
restudy them at a later date to see if the MNSA had reduced further 376. It is also
interesting that work from the same centre reports a reduction in MSNA in OSAHS
with CPAP use only after 6 and 12 months, which was not evident after 1 month of
therapy 44°. This is contradictory to their previous study 376.
2.15.1 Biochemical Markers in OSAHS.
There has been many studies published in the literature looking at ADR, NA and
ANP as markers of sympathetic nervous activity in OSAHS but these studies have
their problems, as so many other things affect the levels of these hormones.
Catecholamines levels in OSAHS have been demonstrated to be elevated and it was
thought that these have a role in the genesis of the hypertension.
There is evidence in the OSAHS literature surrounding the measurement ofADR and
NA levels both in the urine and plasma providing data with conflicting results.
Fletcher et al showed that urinary catecholamines were reduced in patients with
obstructive sleep apnoea and hypertension comparing pre and post tracheostomy
values, and the absent diurnal variation of catecholamine excretion prior to
tracheostomy returned post operatively 441. Some investigators have found no
reduction in urinary NA excretion 442, others have shown a marked decrease 443 in
patients with OSAHS. Hedner reported raised NA levels in OSAHS patients during
the daytime and Dinsdale et al also showed that 24-hour levels of urinary NA were
significantly increased in apnoeics, but found no difference in plasma levels 444. This
study attempted to control for confounders, and included both normotensive and
hypertensive patients with and without OSAHS. Ziegler 445 measured NA in
'normals' and in patients with OSAHS and hypertension in a study comparing NA
levels when breathing room air, then a hypoxic gas mixture. This showed that the
NA levels were increased in the apnoeics, with a greater response during hypoxia,
concluding that the apnoeics were more susceptible to the transient increases in SNS
activity, and the hypertensives maintained a higher baseline NA level.
ANP levels have also been measured showing that treatment with oxygen did not
diminish the plasma level of ANP in SAHS 446. This was a small study of only nine
OSAHS patients and the authors did not report any evidence of increased ANP
levels. This is contradicted by Krieger et al 447 who report a reduction in ANP levels
in patients with OSAHS after the commencement of CPAP therapy. This was also a
small study of 9 patients with severe OSAHS (mean AHI 94). No control group was
included in either study.
2.15.1.1 Nitric Oxide in OSAHS.
Hedner performed studies looking at forearm plethysmography trying to work out the
impact of NO on vascular tone in the OSAHS patient. The study reported an
impairment of NO-dependant vasodilatation in the OSAHS patient independent of
hypertension compared to matched controls, which is more marked in the
hypertensive OSAHS patient 28644\ Fletcher et al 435 looked at hypoxia in rats and
demonstrated potentiation of the pressor response to hypoxia, concluding that NO
mediated vasodilatation may be an important regulator of BP response to active
hypoxaemia. Nitric oxide (NO) mediated vasodilatation was impaired in a study
looking at OSAHS patients compared them to normals 286. The changes in the
sympathoadrenergic system and the vasodilatory action of the NO-dependant
vascular relaxation may be of importance in the development of sustained
hypertension in the OSAHS subject 449. Schulz et al showed that plasma NO levels
were reduced in OSAHS and were increased after commencement of CPAP both in
the short and long term 45°, this has also been reported by Ip et al451.
Techniques have been developed to look at the exhaled breath NO, these have been
utilised to study OSAHS patients, in a study by Olopade et al, they reported that
exhaled nasal NO levels are increased after sleep in patients with moderate-severe
OSAHS 452. However conflicting results exist with a further study reporting no
difference in exhaled NO in OSAHS patients compared to controls 453. The control
group had OSAHS excluded on 'clinical' grounds (no sleep study was performed)
but were not otherwise matched, patients with OSAHS were older, heavier, and had
higher SBP and DBP.
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2.15.2 Baroreceptor Function in OSAHS.
A potential mechanism in the genesis of hypertension in OSAHS patient is the
adaptation of the baroreceptor function in response to repeated swings of BP with
apnoeic events and variation of p02. In disease there may be resetting of the
baroreceptors peripherally or centrally which may be slow to return to normal levels,
and perhaps do not fully normalise with treatment of the underlying disorder.
Parati et al 454 concluded that spontaneous baroreceptor reflex sensitivity was
depressed in severe OSAHS, suggesting that in such patients baroreflex dysfunction
and chemoreceptor stimulation by hypoxia may be involved in the increase of
sympathetic nerve activity occurring during sleep. Carlson showed a reduction in
baroreceptor sensitivity, both in normo and hypertensive OSAHS subjects, and
showed an impaired response to hypotensive stimuli. Results suggested that this
represented an adaptive response to the changes in blood pressure or hypoxia
associated with the nocturnal apnoeas, which may contribute to the increased MNSA
305. A further study of matched OSAHS patients with controls looking at the
baroreflex control ofMNSA and HR was performed. The authors concluded that the
patients with OSAHS have impaired baroreflex sympathetic modulation, but the
control ofHR was not impaired 455.
In the canine model of OSAHS, Brooks demonstrated the resetting of baroreceptors
to a higher pressure but did not show any change in the baroreflex sensitivity 382.
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2.15.3 Muscle Nerve Sympathetic Activity in OSAHS.
Microneurographic studies in both OSAHS and hypertension have provided data
suggesting a 24-hour dysfunction may exist in the control of the autonomic nervous
system with an abnormal number of sympathetic discharges at a high level not only
during sleep but also in wakefulness 3I0'37S'456'457. This abnormal and continuous
stimulation by sympathetic nerves may increase peripheral vascular resistance and
can be associated with the development of hypertension. An increase in nerve traffic
has been demonstrated during apnoeas, peaking early in the recovery period and
thereafter shutting off abruptly 376. This occurs probably as a result of the interaction
between the peripheral chemoreceptor stimulation and cortical arousal.
Carlson et al also examined MNSA recorded in wakefulness in a small group of 11
patients with OSAHS, half ofwhom were also hypertensive and on anti-hypertensive
medication which was stopped, followed by a washout period of at least 3 weeks
prior to study commencement. MNSA recordings were increased in these patients
compared to matched controls, and no difference was found between the
normotensive versus the hypertensive OSAHS groups. SBP but not DBP correlated
with MNSA. The authors did not investigate the effect of at a treatment on MSNA
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Hedner 458 examined sympathetic activity, cardiac structure and blood pressure in
severe OSAHS patients on CPAP. This study demonstrated in a small group of
patients with well-matched controls, elevations in sympathetic neural activity with
each apnoeic event, with a decline in activity at the termination of the event.
Furthermore they showed that treatment of OSAHS with CPAP led to a reduction in
MSNA, suggesting that sympathetic control of vascular tone may be modified in
OSAHS. This study also postulated that the response might involve the release of
circulating catecholamines as well as a neural sympathetic response mediated via a
carotid body reflex. They monitored CPAP use by self-reporting, and measured
plasma NA, both in the day and at night, along with MNSA and cardiac structure.
The authors concluded that a decrease of sympathetic activity was not associated
with blood pressure change or cardiac structural change, thus contradicting previous
reports 459. However it was a small study (n = 6) with subjective CPAP use, and the
tests were performed during the daytime, which may have confounded results.
Waeavdekar et al 460 examined muscle nerve sympathetic activity in OSAHS.
Activity was measured in wakefulness before and after at least one month of
compliant CPAP therapy. Although this uncontrolled study had a small sample size
(n = 7), a reduction in MNSA was reported. This reduction was most marked in
patients who used their CPAP for > 4.8 hours a night, and there was no change in the
non-compliant patients 457.
The role of the SNS in the aetiology of hypertension in OSAHS remains unclear.
The current data provides conflicting results, which are partially due to the study
designs and a reflection on the difficulties in performing the investigations, and
recruiting patients into the trials.
2.16 Endothelin in OSAHS.
There is no increase demonstrated in ET-1 levels in OSAHS in a study by Grimpen
and colleagues 292. This study looked at 29 patients with matched controls measuring
the ET-1 levels before and after treatment with CPAP. It was a mixed group of
patients including treated hypertensives and patients with cardiac disease, though
they attempted to match for this in the control group. They did not show any
difference in the ET-1 levels. However much of the ET-1 is produced ablumenally
and therefore may not be recorded in a plasma sample, and the short half life of the
hormone makes the measurement difficult, requiring prompt handling of the blood
samples.
A smaller study was reported by Saarelainen et al 293, including a mixed group of
OSAHS patients both with and without hypertension, comparing ET-1 levels with an
unmatched population of normal controls. They showed that patients with OSAHS
have higher levels of ET-1, but this did not decrease with CPAP therapy. More
recent work by Phillips 291 also showed increased levels of ET-1 in patients with
OSAHS, however they also demonstrated a reduction of ET-1 with CPAP therapy.
This was contradictory to Grimpen's data. Their protocol differed from the previous
studies as they employed a split night sleep study/CPAP titration study, so sleep
stage effects could confound the result. The patient group in both studies also
included treated hypertensives, even allowing for medication withdrawal and
washout, some irreversible changes may have been present which all adds to further
confound the results. It is clear from these conflicting results that further work needs
to be done in this area.
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2.17 Animal Models.
Using an animal model can be useful in studying OSAHS, allowing more
sophisticated experiments to be undertaken that would not be possible on human
subjects. The first animal model of OSAHS was developed in the rat by Fletcher 461,
who induced severe hypoxia without airflow obstruction and demonstrated a
sustained systemic BP rise. However this was only seen in certain strains of rats,
suggesting there is a probable genetic influence. The rats were exposed to short
repetitive bursts of hypoxia and demonstrated considerable sympathetic activation,
and they concluded that the hypoxia alone may be responsible, however they were
not able to demonstrate the elevated NA levels seen in other studies 461. BP changes
were blunted by chemical sympathectomy, and with carotid denervation no BP
increase was noted 462. These studies suggested that chemoreceptor function plays an
important role in the genesis of the hypertensive response 435,463. Although a very
useful model for OSAHS, the animals exposed to repeated hypoxia did not suffer all
the physiological events of the frustrated respiratory events.
The best animal model to date is the canine model developed by Brooks 388, which
comprises a complicated set up of telemetered EEG, and a tracheostomy that
occludes automatically when the dogs EEG indicates sleep, opening up once again
when the dog arouses from sleep. This is all performed remotely so that the dogs are
'free living'. The studies simulated an AHI of approximately 60 events per hour, for
8 out of 24 hours. This study demonstrated for the first time a direct link between
sustained daytime hypertension and apnoeas, and also demonstrates that recurrent
acoustic arousal from sleep did not cause daytime hypertension in dogs at least 388,
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although acoustic arousal did result in transient "nocturnal" blood pressure rises.
Brooks demonstrated a mean increase in diurnal BP of 15 mmHg over 100 days. The
group also demonstrated that these levels fall back to pre study levels after the study
was completed and apnoeic insults were removed, occurring at different rates in the
different dogs. It was a small study with only 4 animals so far.
O'Donnell et al 464 also produced a canine model of OSAHS reporting an increase in
MAP over time with airway occlusion in a sleeping dog, which could be accentuated
by prior sleep deprivation, and that this raised MAP is sustained for at least 2 hours
after airway patency is normalised. Their model was similar to the Brooks one,
however the dogs were a little more restricted as telemetry was not employed and the
dogs were therefore chronically instrumented and wired up to the equipment.
Brooks study 388 was the first to show in a prospective manner evidence of OSAHS
being a causal factor for daytime hypertension. Mechanisms responsible for the
conversion of acute pressor responses to nocturnal apnoea into daytime systolic
hypertension remain elusive but theories exist to a causal role; with arousal, hypoxic
chemoreceptor stimulation, and the large swings in intra-thoracic pressure all
featuring.
In the Brooks study acoustic arousals alone did not show the daytime increases in BP
seen in the OSAHS model with the apnoeic arousal 3S8. This, combined with
Fletcher's data in the rat model 435'462'463, suggests that for nocturnal respiratory events
to result in daytime hypertension, hypoxaemia is a necessary component.
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2.18 OSAHS Treatment and its Effect on Blood Pressure.
Many studies 356'357'405 434-442-465-466 have an attempted to try and unravel the association
between OSAHS and hypertension. Only one study by Engleman included a proper
control population 242.
Early studies looking at BP changes are based on tracheostomised patients, and later
studies were performed looking at the effect of CPAP on BP in this patient group.
Several "before and after" studies published in the late 1970's reported OSAHS
patients treated with tracheotomy then in the 1980's with CPAP, demonstrated an
improvement in hypertension, and/or a reduction in the medication requirements
357,465,467,468 ^ reduction in BP after tracheostomy was shown in adults by Lugaresi et
al 459, who reported two non-obese patients showing that their breathing pattern
normalised post treatment and their pulmonary arterial pressure normalised.
Guilleminault also wrote a review in the mid 1970's stating that it had been shown
that OSAHS caused hypertension, by reductions in BP in tracheostomised patients
383,467 motta et aj4(17 reported the receding of hypertension after tracheotomy in adult
OSAHS patients. He studied 6 patients with OSAHS before and after tracheostomy,
and showed that the haemodynamic effects and hypoxia noted in the patients pre
procedure improved with the tracheostomy. The patients were studied on single
nights, and it was not clear if there was a lag before the subject was restudied post
tracheostomy. Although these studies are suggestive of a link between OSAHS and
hypertension they were uncontrolled case reports and thus do not provide an
adequate level of evidence.
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CPAP abolishes the nocturnal BP swings and reduces mean nocturnal pressure 406'470.
However the effect of CPAP on the daytime or overall 24-hour pressures has
remained unclear with conflicting evidence being published. Tilikan reports a
reduction of both SBP and DBP during the daytime following CPAP treatment as did
395, Motta 467, Suzuki 465, and Wilcox 357 but again these studies were neither
randomised nor controlled.
Akashiba reported 5 case studies, measuring BP every 20 minutes for 10 days after
commencement of CPAP therapy. Only severe OSAHS patients were studied, and
for analysis the patients were separated on the grounds of their BP into dippers and
non-dippers. The conclusion was that CPAP caused a nocturnal drop in BP in both
groups. The study was small and patients were not randomised to take part and no
control group was included 468. Akashiba reported a further study with 30 OSAHS
patients, a third of which were hypertensive- who had their medication stopped 3
days prior to study entry 466. The hypertensive group had a higher BP at baseline,
they were treated with 2 weeks of CPAP therapy, then had a single BP recorded
between 10-1 la.m. using the same observer. CPAP use was not reported and there
was no control group or placebo arm included. The study concludes that daytime
hypertension was partially induced by OSAHS and it was reversible with CPAP
therapy. Although a bigger study it still contained flaws with the short treatment
time, lack of control or randomisation. In addition major bias must be introduced
with the single readings of BP.
After effective treatment ofOSAHS with CPAP, Guilleminault et al reported that BP
was reduced but not back to 'normal' levels 248. Jennum 405 found that morning and
night BP decreased in 14 OSAHS subjects treated for 7 days with CPAP. The study
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group was selected from the sleep centre cohort, and had to be on no medication, BP
recordings were taken invasively with an intra-arterial line, no randomisation was
performed neither was any form of control included into the study. Mayer 406 treated
12 men with OSAHS for 6 months and observed a significant drop in systemic
pressure with treatment. A further study by Hedner et al 434 looked at a similar group
over 20 months and showed no decline in 24 hour blood pressure or left ventricular
mass, despite showing a significant drop in adrenergic activity. However no
objective CPAP use was recorded.
A study by Wilcox 357, showed that BP was reduced at 8 weeks in patients who used
their CPAP, both in hypertensive and normotensive groups. This was a small study
(n = 9), which included both normotensive and hypertensive patients with OSAHS.
BP was recorded using an automated ambulatory device, and patients acted as their
own controls. The authors excluded non-CPAP compliant patients. Reporting a drop
in SBP in the daytime as well as night, and DBP in the daytime only, not surprisingly
patients who did not comply with therapy demonstrated no drop in BP. They
concluded that OSAHS was an independent factor in the development of
hypertension.
A further study by Mayer 406, reported a reduction in SBP, DBP and reduction in
variability of BP, in both sleep and wake times, he concluded that hypertension in
OSAHS was reversible at least partially. This was also a small study (n = 12), which
included hypertensive patients who had their medication stopped prior to study
commencement. BP was measured at baseline and after 6 months of CPAP therapy.
Patients were therefore off their hypertensive medication for at least 6 months. It is
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debatable that they would not perhaps need the drugs if their OSAHS were treated
however this is as yet unproven.
Suzuki reported data from 9 patients with OSAHS 465, recording their BP before and
during CPAP therapy for 48 hours using an ambulatory device. This small group
was heterogeneous including both hypertensive and non-hypertensive patients. He
concluded the decrease recorded in the BP was seen only in the hypertensive group
not the normotensive population, as was the reduction in HR. The authors concluded
that CPAP improved BP in some hypertensive OSAHS patients. The study included
no control population and it was not randomised 465.
A study of 60 hypertensive patients with OSAHS concludes that reductions in BP in
this group are more closely linked to weight reduction than CPAP use 356. It was not
a well-designed study; many of the patients were asymptomatic as they were
identified from the hypertensive clinic population. The patients self selected which
group they would go in with half the patients declining CPAP therapy, and were then
just given advice on weight loss. BP recording were taken from GP records for
baseline, and recorded last thing at night and first thing in the morning manually,
which introduced observer error. The authors failed to comment on how many
different people were involved in collecting the data and whether inter-observer error
was an issue.
Ali studied a small cohort of patients (n = 8), using a portable beat-by-beat BP
device, and compared BP during wake, OSAHS, OSAHS with supplemental oxygen,
and with CPAP therapy. He concluded that CPAP did not reduce MAP but reduced
the oscillations. The study was not randomised, and the recordings were only taken
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for a period of 30 minutes each, which may not reflect the true severity of the
disorder, as this data collection method does not take account of sleep stage 470.
Dimsdale et al471 reported data from 39 patients, from their parallel study employing
'sham CPAP'. Patients had ambulatory BP monitoring at baseline and after a week
of CPAP therapy. Results demonstrated a reduction in daytime MAP in both groups
and a reduction in night MAP with CPAP therapy. It is a little surprising to discover
that CPAP is as good as 'sham CPAP', suggesting that the placebo effect is strong.
Stradling et al approached the problem from a different direction, trying to see if
OSAHS is a causal factor for hypertension 372. They selected 6 patients from their
clinic with OSAHS, already established on CPAP therapy, and altered the CPAP
pressure between therapeutic and sub therapeutic (down to 3 cmH,0) over 5
consecutive nights, keeping the proportion of therapeutic CPAP constant for each
night. BP was recorded after the 5th night, using an automatic device by the same
observer. They concluded that acute changes in awake BP can be caused by OSAHS,
and that the effect may wear off as the day goes on. It is an interesting approach to
the problem, but once again the study was small. In providing sham CPAP this may
in effect treat some of the events, and the patients for part of each night received
correct pressure CPAP therapy. Both these factors may have masked the effect on
BP.
There is a school of thought that the increase in the nocturnal BP is carried over into
the morning and resolves by late afternoon or evening. However later studies by
Guilleminault and Suzuki 8 do not show a significant decline in blood pressure with
CPAP after 4 months therapy.
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Hedner 459 studied 12 patients over a 20-month period on CPAP therapy and did not
demonstrate any reduction in 24-hour BP or LV mass, but showed a significant
reduction in sympathetic activity. CPAP therapy was not objectively recorded.
Wilcox 357 studied 19 subjects and showed a reduction in BP after 8 weeks of CPAP
in a compliant group. Jennum 405 looked at a very small group (n = 14) and showed a
reduction in BP, this however disappeared when the data was controlled for weight.
The only prospective controlled trial was from our own centre 242, which was small (n
= 13), and compared CPAP with an oral placebo measuring 24- hour BP at the end of
each treatment limb. No decrease in BP was noted, however a small but significant
drop in daytime MAP was found.
Davies carefully matched 19 severe OSAHS patients and 19 snorers without OSAHS
with normal controls 472, and showed no difference in 24-hour BP between the
groups, although did show a significant increase in night-time SBP in the untreated
OSAHS patients. LV mass between the groups was not significantly different.
OSAHS patients were restudied with 24-hour ABPM after commencement of CPAP
therapy, and showed a significant fall in nocturnal SBP. Echocardiography
measurement of LV mass is difficult and is calculated from a formula after
dimensions are measured echocardiographically. There are several areas open to
observer error with this method of LV mass estimation. The authors did attempt to
allow for this and performed reproducibility studies.
Davies et al performed a study of 45 patients with OSAHS carefully matched
controls without OSAHS, matching for BMI, age, alcohol consumption, cigarette
smoking and IHD. 24-hour ABPM was performed and showed a significant increase
in daytime and night-time DBP and night-time SBP in OSAHS patients. There was a
slight difference in body fat distribution between groups, with the control group
having more upper body obesity 404.
In contrast to these uncontrolled and non-randomised studies Engleman et al 242
looked at a small group of 13 patients who received three weeks of CPAP (mean use
4.3 hours) in a randomised placebo controlled crossover design. 24-hour BP was
recorded using ambulatory devices. No significant decline in BP was observed over
the 24-hour period but the power of this study is relatively low, and it included a very
heterogeneous group ofpatients.
Stradling et al concluded in a review that OSAHS will be shown to be a small
independent risk factor for daytime hypertension 424, and perhaps its associated
complications.
The BP's did not all return to normal with treatment and this fact has been used in
the argument that there was no interaction between SDB and increased BP 67. It is
possible that the trigger factor for BP increase is the SDB, perhaps triggering a
cascade of events, some of which may be irreversible, or that the length of time
suffering for SDB without treatment leads to irreversible (hypertensive) damage as a
result of which BP levels cannot fully come back to 'normal' levels. However the
recent large epidemiological studies have helped reinforce the role of SBD as a
probable independent risk factor for hypertension 353. It is possible that these poor
results reflect the irreversible vascular damage that preceded treatment ofOSAHS, or
that studies did not take in to account the potential of the confounding factors.
The diversity of the different studies and their conflicting results is a reflection of the
difficulty in providing a good level of evidence with well-constructed properly
powered trials in this area. When the studies reported in this thesis were designed
there were no adequately powered, randomised-controlled studies of the effect of
treatment for OSAHS on 24-hour blood pressure.
2.19 CPAP and The Sympathetic Nervous System.
Current evidence suggests that OSAHS causes increases in sympathetic traffic; so
treating patients with OSAHS should result in a decrease in SNS traffic. Several
studies have examined the effect of CPAP on the sympathetic nervous system in
OSAHS.
Jennum reported a reduction of plasma NA and normalisation of BP after 7 days of
CPAP in an uncontrolled study 405. Hedner studied twelve severe OSAHS patients in
an open long term follow up study. 24-hour BP was monitored along with NA levels
in the plasma and urine. The study concluded that in untreated OSAHS the sleeping
and wake levels of SNS activity were elevated although falling with CPAP treatment
the levels did not return to normal 456. The study was small with only 14 subjects,
was not randomised nor controlled and analysis was not performed on an intention to
treat basis with one patient being excluded because of poor CPAP use. A mixed
group of patients were enrolled including a hypertensive population, withdrawing
anti-hypertensive medication for 3 weeks prior to study. A reduction in the
biochemical markers of sympathetic function was noted. The study failed to show a
change in either BP or LV mass index (computed from echocardiography
measurements). However BP was studied after only one night ofCPAP and this may
have been too early find the maximal response. This work was echoed by Somers 376,
who produced a study comparing MSNA in patients in wakefulness and sleep before
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and after CPAP therapy 376. He also showed the high resting wake sympathetic neural
levels, which increased further with the onset of sleep and demonstrated a reduction
in sympathetic neural activity with one night ofCPAP treatment.
Waravdekar et al studied at a small group of 7 patients with OSAHS measuring
MSNA in wakefulness before and after one month of CPAP. He showed a reduction
in MSNA in patients who complied with therapy 460. Narkiewicz went on to study the
MSNA in patients before and after 1, 6 and 12 months of treatment with CPAP,
comparing them to an untreated group of OSAHS patients. They did not have a
control group of 'normals', nor did they match their untreated group with the CPAP
group. They reported no changes in either heart rate or BP over the study period in
either group 440. They demonstrated a drop in sympathetic traffic in the CPAP group
at 6 and 12 months compared to the untreated group, concluding that CPAP
decreases MSNA in OSAHS patients with prolonged therapy. The numbers studied
are small with only 11 patients in the CPAP group and 9 in the untreated group.
Interestingly this conflicted with data produced by the same centre which showed a
drop in sympathetic traffic with CPAP during a split night sleep study 376. The small
numbers partly reflect the difficulty in recruiting patients to this invasive study and
the technical problems carrying it out. This study also raises ethical concerns about
not treating OSAHS patients for a year while the study is underway, however they
used the patients who declined CPAP treatment, therefore producing selection bias,
and did not offer any other form of therapy. The BP recordings were taken over a
10-minute period at 1-minute intervals using an automatic sphygmomanometer.
There was no comment about the time of day and whether this was constant between
the different recordings and different patients. The CPAP use was self reported and
therefore not objective, and this may in part explain the lack of changes in HRV and
BP, as the patients generally tend to overestimate CPAP use 473 and may have been
poorly compliant.
2.20 Discussion.
The regulation of BP is a complex process, which involves many different systems.
OSAHS invokes a range of physiological actions that also affect BP. Patients with
untreated OSAHS have hundreds or even thousands of blood pressure swings per
night. However with the number of confounding factors it is very difficult to prove
whether OSAHS itself is a determinant of BP, and also whether it has effects that
continue on into the waking hours. It is also apparent that there have been no
adequately powered randomised controlled trials on the effect of CPAP on BP in
OSAHS.
How could nocturnal alteration in blood pressure lead to daytime hypertension?
Target organ damage in hypertensive disease is related not only to the MAP but also
to its variability, and the loss of dipping 27M7\ Could the resulting vascular damage
lead to sustained daytime hypertension? Alternatively, is baroreceptor function reset
as a result of the intermittent nocturnal hypertension?
The major question this thesis set out to answer was to see if OSAHS is a
determinant of daytime increases in BP. If it is proven that OSAHS is a cause of
sustained hypertension this will have significant Public Health implications.
With the exception of Davies study 404, the recent studies are observational in design,
although giving good epidemiological data on an association between OSAHS and
hypertension, good evidenced based studies still need to be done. The mechanisms
of BP control and the abnormalities in OSAHS remain elusive 284. Further
investigation into:
□ The effect of episodic hypoxia and hypercapnia on chemoreceptors and
the sympathetic nervous system;
□ Resetting ofbaroreceptor function;
□ Modification within the cardiovascular system;
□ The effects of stress from arousal and sleep disruption;
□ Endothelial cell changes and vascular remodelling
are all required to improve the knowledge base and aid our understanding of the
disorder. The development of hypertension in the OSAHS patients is a slow process





The effect of sleepiness on daytime function has been reported, and the impact on
day-to-day living has been increasingly recognised. Marked sleepiness can be
associated with accidents in the home, the workplace and on the road. Large
epidemiological studies have investigated the impact of SDB on neuropsychological
function l37, concluding that the degree of SDB correlated significantly with the
deficiency in psychomotor function. Cognitive impairment has also been shown in
this patient group 4 l35 l4,-,43 l44'475'476j with significant improvements when treated with
CpAp ' 33,135,136,144,239,477
3.2 Measures of Daytime Sleepiness.
3.2.1 Epworth Sleepiness Scale.
The Epworth sleepiness scale (ESS)478 was developed as a tool to measure subjective
sleepiness, in an attempt to distinguish between tiredness and sleepiness in a variety
of day-to-day situations. This was also introduced to provide a universal tool to
allow easy comparison between different treatments and between different research
projects. It does not however differentiate between different causes of sleepiness. It
. i . j 129,130,132,479,480has been validated
100
It is a subjective self reported questionnaire, in which the subject are asked to score
themselves on a scale of 0-3 in eight different situations, 0 corresponding to never
falling asleep in that situation, to a maximum of 3 corresponding with always falling
asleep in the situation. The maximal score being 24, the higher the score the sleepier
the individual. The scale is included in figure 3.1 overleaf.
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Figure 3.1: The Evworth Sleepiness Scale.
How likely are you to doze off or fall asleep in the following situations, in contrast to
feeling just tired? This refers to your usual way of life in recent times. Even if you
have not done some of these things recently, try to work out how that would have
affected you. Use the following scale to choose the most appropriate number for
each situation.
Scale
0 = would never doze
1 = slight chance of dozing
2 = moderate chance of dozing
3 = high chance of dozing
Situation Chance of dozing
Sitting and reading.
Watching TV.
Sitting inactive in a public place.
(e.g. a theatre or a meeting).
As a passenger in a car for an hour without a break.
Lying down to rest in the afternoon
when circumstances permit.
Sitting talking to someone.
Sitting quietly after lunch without alcohol.
In a car, when stopped for a few minutes in the traffic.
Total
Thank you for your co-operation
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3.3 Quality of Life.
Quality to life (QoL) is an important factor in general wellbeing, both physically and
emotionally. Many different tools exist to measure quality of life, in this study a
sleep specific questionnaire is employed. Previous studies have tried to quantify the
impact ofOSAHS on QoL l46'156"159. These studies have all concluded that OSAHS has
a significant impact on quality of life, some comparing OSAHS with other common
illnesses, such as asthma and showed that the different domains improve with
treatment48'.
3.3.1 Functional Outcomes of Sleep Questionnaire.
The functional outcomes of sleep questionnaire (FOSQ) 482 is a sleep specific
questionnaire developed by Weaver et al, designed to try and quantify the impact of
EDS on day to day life. It comprises a self-administered questionnaire that contains
30 questions (encompassing 74 items), taking approximately 15 minutes to complete.
For this study the optional questions on sexual health were omitted as it was felt that
my patients may be uncomfortable with them. A copy of the questionnaire is
included in appendix 1.
The definition of functional status chosen by the authors was "everyday behaviours
encompassing the areas of physical, mental, and social functioning in daily life".
The words sleepy and tired are defined in the instructions read by the patients before
completing the questionnaire. Subjects are then asked to mark the most appropriate
score pertaining to themselves at the time of the study in reply to each question stem,
ranging from "no difficulty" to "extreme difficulty". The questionnaire is then
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scored using a mean-weighted system, within each subscale using only those
activities that are participated in, allowing for skipped questions. These scores are
amalgamated to produce a global score. The lower the score the more sleepiness is
impacting on the QoL in that individual.
The five different domains are:
□ activity level (9 questions),
□ vigilance (7 questions),
□ intimacy and sexual relationship (4 questions),
□ general productivity (8 questions),
□ social outcome (2 questions).
With the mean weighting system each of these domains provides a score out of 4,
resulting in a global score of 20 (16 in our case). The normative data for this test is
taken from a group of normal subjects who did not have OSAHS. Global scores in
this group of normals are all above 17.5 (ex 20), with normal scores for the
individual domains being > 3.5 (ex 4)l45.
3.4 Performance Measures.
3.4.1 Steer Clear.
This is a vigilance test developed to be a driving related performance measure. It is
not a driving simulator. It comprises a computer based monotonous task of avoiding
obstacles (cows), on a two-lane road, pressing the space bar on the computer to
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change lanes and therefore avoid the cow. It is run for 30 minutes and the cows
intermittently appear in either lane, and for three 2-minute periods during the test
there are no cows to increase boredom. The score is expressed as a percentage of
cows hit, therefore the lower the score the more vigilant the subject.
Normative data was assimilated by Findlay et al who designed this vigilance test,
from age and sex matched controls in included in their studies l74. They report a
normal score as < 1.8% obstacles hit, a poor score as >1.8% but < 4.5 % obstacles hit
and a very poor score as > 4.5% obstacles hit. Examples of steer clear results for a




This is a test from the Wechsler batteries 483'484, and is one of the most commonly used
test of short-term memory, reflecting the span of immediate recall. This test allows
two trials at each span length485.
This test comprises two different tests; digits forward and digits backward, which
involve different mental activities that could be affected differently. Each test
contains seven pairs of random number sequences, each pair being different. Each
string of numbers is read aloud at one digit per second, and therefore attention skills
and short-term memory are tested. The overall score is calculated by combining both
the forward and backward scores with the participant gaining a point for each string
of numbers that they recall correctly. The test has some limitations with the pooling
of the forward and backward data, as it could mask differences in brain dysfunction
as the overall score would not reflect a large difference in the forward and backward
scores and therefore may underestimate a degree of brain dysfunction 4S6. Therefore
to gain the most meaningful information the data in this study has been left in the
'forward' and 'backward' scores, subtracting forward from backward scores, as well
as a global score.
Subjects are given a string of numbers and are asked to repeat them exactly as heard,
or in reverse, and the examiner continues until the subject fails both strings of the
same length. The 'normal' range for forward scores is 6 ± 1 486, a score of 4 is
borderline and 3 is defective. Anxiety can reduce the number of digits recalled. The
normal range of a backward score is 4-5, with 3 being borderline, and 2 defective.
These scores can be affected by the patients educational background, and by their age
in later life. This has not been taken into account during this study as the patients act
as there own control. The format of the test is included in figure 3.2 overleaf.
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Figure 3.2: Digit Span.
Discontinue after failure on both trials of any item.






































3.5.2 Stroop Colour Word Test.
This is a common neuropsychological assessment method, and helps tease out the
motor skill aspects of a task. It tests the ease at which a person can shift their
perceptual set to cope with changing tasks to perform an unusual task over a habitual
one. It is a multi modal test, testing verbal function, executive function, cognitive
flexibility, concentration and selective attention. It is based on the finding that it
takes longer to call out the colour of printed words rather than read them. It is a
measure of concentration, with the ability to register the colour of the word whilst
blocking out the reading of the word. There are a number of versions of this test, I
used one of the Dodrill formats 139'487, which consisted of 176 colour word names (11
across and 16 lines down) randomly printed in these colours.
The test format used in this study comprised two trials. The first in which the chart is
read only, with the words being printed in ink of different colours and the second
reading with the same chart, naming the colours of the printed words rather than
reading the text itself 488. The examiners record sheet contains the correct names and
these are marked off during the test. The test is included in figure 3.3 overleaf.
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Fieure3.3: Stroop Colour Word Test.
Red Blue Yellow Green
Yellow Red Red Yellow
Blue Yellow Yellow Red
Yellow Green Yellow Green Green
Blue Green Green
Red Blue Blue Yellow
Blue Yellow Yellow Blue
Yellow Blue Red Yellow
Yellow Red Yellow Blue
Green Blue Green Red Green
Blue Green Yellow Red
Green Red Blue Green
Red Yellow Blue Green Yellow
Red Yellow Yellow Blue
Blue Red Green Red Yellow
Yellow Blue Green Green
Green Yellow
Green Red Yellow Green
Blue Red Red Yellow
Yellow Blue Red Blue
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Scoring is made by time, with the subject being told if they are incorrect during the
test and having to correct themselves, therefore taking longer to complete the test.
Dodrill evaluated the subjects' performance by looking at the total time to complete
the first part and the difference between both parts (part 2 - part 1). It has to be
remembered that this test assumes that the patient is able to read and to see the chart,
and the patient must not have red/green colour blindness.
Normative data for this form of the test has not been published. This test was
constructed to evaluate the difference between the functions of a subject during a trial
of some kind. In my study I was looking for a difference between two treatments
rather than an absolute value.
3.6 Discussion.
Measuring subjective sleepiness is useful in this study to show improvements with
the different treatment modalities and to compare one with the other. Measuring
quality of life using the FOSQ is also useful in continuing validation of this very
useful sleep specific questionnaire. Utilising tests of neuropsychological function is
a complex process with many different tests being available. The different tests can
be used to discriminate between the different brain dysfunction's, it is however not
desirable in this study to dedicate a large amount of patients time to different tests as




Methods of Measurement and Recruitment.
4.1 Body Measurements.
Body length measurements were made using a standard dressmaker's measuring
tape. The waist was measured at the umbilicus, the hips were measured at the level
of the iliac crests, and the neck was measured at the level of the crico-thyroid
membrane. Height was recorded from a standard scale, to allow calculation of body
mass index (BMI = weight/height2). Weight was measured using the standard Sleep
Centre scales (Seca, Germany) which are calibrated annually. Measurements are
recorded in centimetres (cm) and kilograms (Kg) respectively. Patients were
weighted at each visit to ensure that there was no significant change in their weight
during the study.
4.2 Nocturnal Polysomnography.
Overnight PSG studies were performed at the Sleep Centre situated in Ward 48 of
The Royal Infirmary of Edinburgh. PSG consisted of continuous recording of
electroencephalogram (EEG), electro-oculogram (EOG), electromyogram (EMG),
leg movement sensor, airflow via a thermistor, a microphone for snoring noise,
inductance plethysmography for abdominal and respiratory effort, and oxygen
saturation using a finger pulse oximeter (Ohmeda 3700e, Colorado, USA). A
computerised system is employed to record and store the data utilising a
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Compumedics package (S system, Compumedics, Melbourne, Australia). These data
files are backed up onto optical discs.
4.2.1 Sieep Study Scoring.
The trained sleep technicians score all the recordings manually. In house inter-rater
reliability testing is performed monthly. Apnoeas are defined as a complete cessation
of airflow lasting > 10 seconds 394. Hypopnoeas are defined as the reduction of at
least 50% of the sum amplitude of the thoraco-abdominal inductance signal l9.
Arousals associated with sleep disordered breathing events are defined as an increase
in EEG frequency lasting at least 1.5 seconds (Cheshire) with a concomitant rise in
EMG activity however brief. Sleep is staged according to the criteria of
Rechtschaffen and Kales 489.
Using these criteria, studies were sleep staged along with respiratory and EEG
arousals marking to allow formal scoring and the calculation of an apnoea/hypopnoea
index (AHI), and an EEG arousal index per hour slept. Sleep efficiency was also
reported as a percent of the time asleep against the total available sleep time, to
ensure enough time was slept. The nadir in oxygen saturation overnight was reported
along with a starting saturation.
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The hypopnoeas are marked with the boxes in the figure showing the frequent events
in this 5-minute exert of a sleep study. The oxygen desaturation is evident on the
saturation trace at the bottom of the diagram, the scale of which is 0-100%.
4.2.2 Desaturation Index.
The desaturation index is calculated from the PSG recording. Each PSG trace is
reviewed manually and any areas of oxygen saturation artefact edited out. The
number of 4 % oxygen desaturations are counted during the total sleep time (wake
periods are excluded). This total number is then divided by the total sleep time in
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minutes and multiplied by 60, giving the number of events per hour slept, so called
the desaturation index (DI).
4.3 CPAP Titration.
This was performed overnight in the Sleep Centre using a computerised system
(Auto Set, ResMed, Sydney, Australia), which set the ideal CPAP pressure required
to abolish apnoeas, hypopnoeas and flow limitation. Performing the CPAP titration
overnight in the centre allows an opportunity to sort out any common mask problems
and set the treatment pressure, it was hoped that this would improve compliance.
The pressure the CPAP units were set at was usually the 95lh centile from the
computer printout, i.e. abolishing 95% of events.
4.4 Blood Pressure.
4.4.1 Ambulatory Blood Pressure Monitoring.
The ambulatory BP system, (Ultralite ABPM, 90217, SpaceLabs Medical Ltd.,
Redmond, WA, USA) is a small lightweight battery powered microprocessor, which
stores data collected via an arm cuff. The ABPM measures 2.8 x 11.4 x 8.6cm and
weighs 347g. It has on the front panel a four-digit liquid crystal display, a manual
start/stop button and attachment for the BP cuff. The rear panel contains a serial
communications port and the on/off switch. The data can be transferred to a personal
computer via a PC interface for formal analysis and production of a hard copy of the
data. The monitors are carried in pouches, which are worn either with a belt or a
shoulder strap.
The monitors can be programmed to various features, displaying cuff pressure at
each bleed step, and displaying systolic, diastolic, mean arterial pressure and heart
rate at the end of each cuff inflation. They continue to bleed to 40 mmHg rather than
stopping at the diastolic value, and although they can bleep before and after each
recording is taken, the bleep is disarmed during this study. The machine takes
Korotoff sounds one and five for the recordings 49°. The monitor bleeds air in discrete
steps (approx. 4 mmHg) using the oscillometric method of BP determination. The
monitor measurement ranges are: heart rate 40-180 mmHg; systolic BP 70-280
mmHg; diastolic BP 40-200 mmHg; and mean arterial BP 60-240 mmHg.
The microprocessor can be programmed to take recordings at intervals of 6 to 120
minutes, in our case every 30 minutes. It takes approximately 30-50 seconds to make
a recording, and after any failed attempt, the monitor is programmed to try a further
recording one-minute later. The cuff pressure inflates to 170 mmHg initially, then to
30 mmHg above the previous systolic recording. The microprocessor is programmed
to distinguish between pressure signals, patient movement and respiratory artefact.
The pressure transducer channel automatically zeros before taking a recording. The
cuff is inflated with an automatic pump, and the bleed rate is also controlled via the
microprocessor. The device contains a real time clock, which is recalibrated with
each monitor initialisation. The monitor is initialised before being fitted to each
patient, this ensures that the time clock is correct and allows the patients
identification data to be stored with the collected data. The microprocessor auto-
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edits aberrant results. For safety purposes the measurement cycle is limited to 180
seconds, and the absolute maximum pressure of the cuff is 310 mmHg.
The accuracy of BP recordings detected with this device is equivalent to those
obtained by a trained observer using a manual cuffmethod m34l,49°. The validity and
accuracy ofABPM's has been documented m341-490-493_
There are two important sources of variation in blood pressure, the biological
variation and measurement error variation. The latter needs to be controlled for as
much as possible. The ABPM will take recordings in a variety of settings. However
because the recording is done automatically it removes observer bias 490'494. The data
produced by these machines has been shown to be reproducible 493'495. There are
several different ambulatory devices available, one study compared 4 of these along
with intra-arterial recordings showing that their accuracy is similar at rest but during
exercise some of the ambulatory monitors are less suitable. The SpaceLabs device is
favourable in this respect as it uses the oscillometric method of recording 491'492'496,497.
There are some concerns with the ambulatory monitors that they may overestimate
DBP, however in our case this is not a major issue as such, because the difference
between measurements with different treatments is the important outcome in this
study. Accurate measurements might not be obtained because of patient movement,
incorrect cuff position/size, extreme HR or BP, arrhythmias, vibration or other
environmental stimuli, but again using the patient as their own control should
minimise the effect of these confounders on the differences sought. Side effects from
wearing the device are minimal and include pain, skin irritation, noise,
inconvenience, haematoma, and altered sleep quality49S.
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Accuracy of the device is checked at least yearly using a full sized mercury
sphygmomanometer, a T-tube and a rigid cylinder. The cuff is placed around a rigid
cylinder and attached to the ABPM via a T-tube, with the second part of the tubing
being attached to the sphygmomanometer. The ABPM is then activated manually
and readings compared as the monitor bleeds air stepwise, the readings need to be
within 3 mmHg of each other.
Patients were asked to continue with normal daily activities whilst wearing the
monitor, and were permitted to remove it for bathing only. Instructions on how to
reposition the cuff correctly were also supplied. They were also requested to stop
what they were doing when the monitor started to take a reading and ensure their arm
is straight, until the cuff deflates once more. Patients were asked to keep an activity
diary whist wearing the monitor and to abstain form caffeine containing products
during this time also. For statistical analysis data was transferred to Microsoft Excel
for further analysis.
A major problem with monitoring blood pressure during sleep is that non-invasive
methods can cause an arousal and therefore artificially elevate blood pressure 499'500,
although this is thought to lessen over time. Intra-arterial methods are more accurate
and do not cause an arousal from sleep per se. However such techniques are invasive
and have all the associated risk factors and problems of an intra-arterial line. It
would be much more difficult, if not impossible for the patient to conduct normal
activities with an arterial line in situ, and would therefore not be an accurate
reflection of normal circadian blood pressure.
I decided to accept the imperfect nocturnal blood pressures we would achieve with a
cuff technique, realising that it may result in overestimation of the nocturnal blood
pressure but also in minimisation of any decrease in blood pressure at night resulting
from CPAP. This could occur because sleep quality would be expected to be better
on CPAP and thus blood pressure might be expected to be lower without the arousal
related surges in pressure. Measurements with a cuff are possibly made in
wakefulness 4"; and in interpreting data from such studies this must not be forgotten
as the benefits of CPAP may be minimised. A sample printout for the ABPM is
included in Appendix 1.
4.4.1.1.Validity of ABPM Recordings.
It is important to show that the ABPM's give reproducible results, as the BP
measurements are the crux of this thesis. Therefore I subjected the units to reliability
testing. I recruited 3 subjects from our staff in the sleep centre who volunteered to
wear the ABPM's for a 48-hour period. Their data are presented in table 4.1
overleaf.
It is clear to see that the ABPM's provide reproducible results. Co-efficient of
variation is calculated as the standard deviation divided by the mean multiplied by
100 so that it is expressed as a percentage.
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Table 4.1: Co-efficient of variation ofABPM a measure of validity.
Is' 24-hours 2nd 24-hours Mean (SD)




Subject 1 131 129 130(10.5) 8
Subject 2 127 123 125 (11.5) 9
Subject 3 112 110 111 (13.9) 13
DBP
Subject 1 79 77 78 (9.8) 13
Subject 2 78 82 80(10.3) 13
Subject 3 69 65 67(12.3) 18
MAP
Subject 1 96 94 95 (9.6) 10
Subject 2 94 94 94 (9.8) 10
Subject 3 82 80 81 (12.0) 15
HR
Subject 1 87 85 86 (7.0) 8
Subject 2 69 69 69(12.0) 17
Subject 3 68 66 67 (12.6) 19
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4.4.2 Beat-by-beat Blood Pressure.
The Finapress (Datex-Ohmeda) is a device that measures beat-by-beat blood pressure
from a finger cuff. This device depends on a pneumatic servo-controlled cuff, which
is inflated to keep the infrared absorption in the finger constant by the correction of a
photoplethysmogram. The infrared absorption in the finger alters due to variation in
blood volume in the finger, changes in cuff pressure are therefore required to keep
the photoplethysmogram constant, which reflects changes in the intra-vascular
pressure. It is an accurate method of monitoring short-term changes in BP, and can
track the changes that occur during the Valsalva and Mueller manoeuvres, atrial
fibrillation and OSAHS. Digital arterial pressure however differs from brachial
artery pressure because of the hydrostatic effects of the hand position, and the normal
change of the BP along the vascular tree, the plethysmographic volume clamp is best
used as an index ofchange in BP rather than of absolute pressure.
The cuffwas attached to the middle finger of the left hand, using an appropriate sized
cuff. Patients were allowed to acclimatise with all the equipment running, and rested
unstimulated for 30-minutes before any recordings were made. The servo-self adjust
(in-built calibration mode) was disabled on the Finapress device during each 5
minute test run. It was then reactivated, if there was more than a 5 mmHg difference
in the readings the test was re-run. Data for the whole time period was recorded,
however the analysis was only performed on the five-minute time blocks. Three sets
of recordings, lasting 5 minutes each, were taken for every patient during both visits.
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4.5 Baroreceptor Reflex Sensitivity.
The assessment of this entity assumes a positive correlation between a stimulus and a
response, e.g. change in blood pressure and change in pulse interval (PI). It therefore
reflects the ability to alter the vagal activity in relation to the sympathetic activity in a
reciprocal manner. It has been previously shown that BRS is diminished in several
diseases most notably hypertension (1452).
The patients were asked to abstain from alcohol, smoking and caffeine for the 12
hours prior to attending for the study. All baroreceptor studies were performed
between 8am and 1pm. The patients were placed in the supine position in a quiet,
dimly lit room and left unstimulated. Electrocardiographic recordings were taken
from chest leads in position II. The skin was prepared using an exfoliating gel and
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wiped with alcohol before the electrodes were placed to ensure good contact. Beat
by beat blood pressure was recorded using the method described above. Data from
the ECG and Finapress were recorded on a PC using a special montage in the
Compumedics software described previously. Data from these files were backed up
onto optical discs.
Figure 4.3: Example ofBaroreceytor Recording:
Finapress
Blood pressure VJ\j v
Time (30 second page)
Data were further analysed using a power spectral analysis technique utilising an
especially in-house written computer program, which also included the calibration
and editing of the stored data. This allowed the calculation of pulse interval (PI),
pulse interval power (Pip), and the different low frequency (LF), very low frequency
(VLF) and high frequency (HF) bands. It also allowed the calculation of baroreflex
sensitivity (BRS), and allows the calculation of the ratios of BRS LF/HF, and LF/HF
Pip.
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Patients underwent this study at the end of each treatment limb before crossing over
onto the alternative treatment. Data were further analysed using the SPSS statistical
program to compare the different treatments.
Power spectral analysis was also performed on the beat to beat BP and PI, the signals
being transformed into the frequency domain with a fast Fourier transform algorithm
as discussed in section 2.7.6.
4.6 Epworth Sleepiness Score.
This subjective sleepiness questionnaire previously discussed in Chapter 3 was given
to the patients who were asked to give themselves scores from 0-3 in eight different
situations, giving a maximum score out of 24. They complete the questionnaire
when alone and were asked to refer to their performance in the previous month. It
was completed at the start of the study before the CPAP titration to allow
familiarisation and at then end of each treatment limb.
4.7 Functional Outcomes of Sleep Questionnaire.
Patients were asked to complete this 26-question survey based on how they had been
feeling in the previous month. They were alone whilst completing the task. The
FOSQ was completed at the start of the study to allow familiarisation and at the end
of each treatment limb.
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4.8 Steer Clear.
The patient was placed in front of a computer screen in a quiet darkened room to
perform the steer clear test as described in chapter 3. The computer screen was
blank; the patient needed to press the spacebar with the dominant hand to commence
the test. This test ran for thirty minutes, and terminated automatically. This test was
also performed at the start of the study to allow familiarisation and at the end of each
treatment limb.
4.9 Digit Span.
This was a further test of concentration and mental dexterity as described in chapter
3. Patients were told that some numbers would be said to them and they would be
asked to repeat them back, initially forwards, then later in the test backwards, and
that the string of numbers would get progressively longer. The patients were given
an example to illustrate the test. Patients completed this test at the start of the study
to allow familiarisation and at the end of each treatment limb.
4.10 Stroop Colour Word Test.
The patient was given a card with a copy of the Stroop test on it (Figure 3.4).
Patients were then asked to read the card on two occasions, the first time to read the
words going left to right across the page as if reading a paragraph in a book, then
name the colours the words are printed in. This test was run at the start of the study
to allow familiarisation and at the end of each treatment limb.
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4.11 Urinary Microalbumin.
This was measured from a spot urine sample collected from the patients at their first
study visit to the centre. The sample was sent to the Biochemistry Laboratory of the
Royal Infirmary of Edinburgh who performed a radioimmunoassay to determine the
concentration of albumin and creatinine in the sample so that a ratio of albumin to
creatinine excretion can be derived. This will be discussed further in chapter 9.
4.12 Recruitment.
Consecutive patients who attended the Sleep Centre at Edinburgh Royal Infirmary
meeting the inclusion criteria were approached. Patients were contacted in person in
the centre, or by telephone, explaining the objectives of the study and what was
involved. If patients agree to participate they were then given an information sheet
on the study (appendix 1), and a date to come back for the CPAP titration study.
Patients told that the study was to compare two different potential treatments for
OSAHS, one established and one new. They were told that the capsules may affect
upper airway tone and therefore reduce the number of breathing pauses, they were
informed that some patients had done well with the medication, and others had not
felt the medication had helped at all. Patients were also informed that we wanted to
look at the effects of both treatments on their blood pressure. The placebo was
actively sold to our patients as a possible active treatment. This had ethical approval.
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Table 4.2 Recruitment Criteria.
Inclusion Criteria
AHI >15 events per hour slept
Two major symptoms of OSAHS 501
Between the ages of 20 and 80 years
Exclusion Criteria
> 50 miles from the sleep centre
Taking any medication which affects blood pressure
Any disorder which affects blood pressure e.g. diabetes
Had fallen asleep at the wheel within the last 5 years
Once patients agreed to participate in the study and provide written informed
consent, they were invited to a CPAP education session followed by a CPAP titration
study. The education session comprised viewing a video about OSAHS and CPAP
followed by a mask fitting with our specialist nursing staff or technicians, ending
with a 30-minute trial of CPAP. The patients attended for their overnight CPAP
titration and they were asked to complete the ESS, and FOSQ. Weight was recorded
and the measurements are taken as previously discussed. Patients were then
acclimatised to Stroop, Digit Span and Steer Clear tests.
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The CPAP titration study was performed overnight using the automated AutoSet
system. The morning following the CPAP study the patients were randomised into
the study, randomisation is performed using a balanced block design with four
patients per block. Randomisation allowed half of patients to start with CPAP and
half to start with the oral placebo.
Once randomised patients received CPAP or the placebo for a month, at the end of
each month block they attended the Sleep Centre and completed ESS and FOSQ
questionnaires, performed psychometric testing and had the ABPM fitted. The
ABPM was worn for 48-hours during which the current treatment was continued.
The ABPM was then collected from the patient's home and the treatment for the next
month issued. Patients were contacted by telephone at least twice during each
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treatment limb and a home visit was performed if necessary. At the end of the study
all patients had CPAP therapy offered. Patients were given contact telephone
numbers for the Sleep Centre, in case of any problem during the study. The patient's
general practitioners were also kept fully informed by letter regarding their patient's
participation in the study with contact details in case of any problems or concerns.
Included in this information was a sealed envelope containing details of the oral
placebo in case of an emergency.
4.13 Data Analysis.
Data for all 68 patients were entered into a large data base using Microsoft Excel.
Data were analysed using a variety of statistical tests on a PC statistics package
(SPSS for windows, Version 10, 1999, SPSS, Chicago, IL, USA).
4.13.1 Blood Pressure Data.
The data were normally distributed. The blood pressure equipment provides a result
for each 30-minute time point, resulting in a huge number of data entries for each
perameter; SBP, DBP, MAP, HR and PP. I was concerned that with this number of
data points significant findings may be found as a result of chance. Therefore the
data was grouped into 4 hourly means at the advice of the Professor of Medical
Statistics, after which a repeated measures general linear model was used, which
allowed me to take into account the order to ensure there was no order effect, and to
enter all the results. All data were analysed on an intention to treat basis. Missing
data points were filled in using imputation, this affected < 1% of results. Data were
blinded to me prior to imputation, by anonymising and batching, and prior to formal
statistical analysis being performed.
Prior to data analysis two a priori end points were chosen, CPAP use >3.5 hours a
night, a figure chosen based on previous work from our sleep centre. Furthermore a
desaturation index of > 20 was chosen as the second a priori end point, looking at a
more severe group ofpatients. The decision to look at patients who desaturated more
was based on the work done by Brooks 388. In the dog model of OSAHS, they
showed that dogs who desaturated developed sustained daytime hypertension,
compared to the dogs who only has their sleep fragmented without hypoxia being
induced.
4.13.2 Baroreceptor Data.
The data collected from this sub study is outlined in section 4.10. These data were
normally distributed. The results of the spectral analysis were analysed using the
MANOVA. The two treatment modalities are compared.
4.13.3 Psychometric Tests.
These data were differently distributed, both the Steer clear and Stroop colour word
test were asymmetrically distributed therefore non-parametric Wilcoxon tests were
utilised. Digit span was normally distributed and therefore the MANOVA was
employed in further analysis.
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4.13.4 Quality of Life Questionnaires.
These data were normally distributed and were analysed using a MANOVA taking
order into account to ensure there was no order effect of the treatments.
4.14 Patient Group.
One hundred and seven consecutive patients were approached to participate in this
study, 78 patients agreed to participate. Prior to commencement in the study 7
patients withdrew for a variety of work and personal commitments. Seventy-one
patients started the study, 3 were lost during the study one during the placebo limb
and two during the CPAP limb. In total 68 patients completed the study. It is the
data from these 68 patients, which will be included in the next three chapters. Two
smaller subsets of this main group were further studied looking at baroreceptor
function (chapter 8) and urinary microalbumin (chapter 9), details of these groups are
included in the relevant chapter.
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4.14.1 Demographics.
The demographics of the patients who completed the study are included in table 4.3
below.
Table 4.3: Demographics of Study Population.
Mean SEM Range
Age(years) 49 1.2 27-72







BMI (Kg/m2) 31 0.8 21-55
Neck (cm) 41 0.5 33-55
Waist (cm) 105 1.8 76-155
Hips (cm) 109 1.5 93-160





Of the sixty-eight patients who completed this study, 55 were male and 13 female.
5.2 Statistics.
Statistical analysis is performed as described in section 4.13.
5.3 Results.
5.3.1 Intention to Treat Results.
The results of analysis of the mean 24-hour BP from all data sets irrespective of
compliance with therapy are shown (table 5.1).
Table 5.1: Mean Blood Pressure for Study Cohort.
CPAP Placebo P-value
Mean SEM Mean SEM
SBP
(mmHg)
126.9 1.3 128.2 1.2 0.19
DBP
(mmHg)
77.8 1.0 79.2 0.9 0.04
MAP
(mmHg)
94.4 1.0 95.5 0.9 0.20
HR
(bpm)
76.2 1.1 76.8 1.1 0.43
PP 49.3 0.9 49.1 0.9 0.78
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DBP is the only significant variable changed by CPAP therapy when analysing the
full 24-hour data. I then examined the different times of day to see if these DBP
changes are more marked at any specific time of day or night. As part of the
statistical analysis for the general linear model all the data points were grouped into
4-hourly means, using these time blocks the data are compared in table 5.2 below.
Table 5.2: Mean DBP in 4-hour Time Blocks.
Time block CPAP Placebo p-value
Mean SEM Mean SEM
18.00-21.59h 80.9 1.2 82.3 1.2 0.24
22.00-01.59h 73.6 1.1 74.5 1.2 0.43
02.00-05.59h 67.9 1.2 69.8 1.1 0.03
06.00-09.59h 75.5 1.3 78.5 1.3 0.02
10.00-13.59h 83.6 1.3 84.9 1.3 0.34
14.00-17.59h 84.3 1.1 85.3 1.2 0.41
The main change in the DBP in the 24-hour period is between 02.00h and 09.59h.
The average wake time reported by the patients during the study was 7 a.m. (range
04.45 - 11.00 h) and so the 06.00 to 09.59 block contains a significant portion of
wake time.
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5.3.2 CPAP use > 3.5 hours night.
32 patients used their CPAP >3.5 hours per night and a sub analysis is done on their
data and the results are included in table 5.3 below.
Table 5.3: Mean BP of Patients Who Used CPAP > 3.5 hours Per Night.
CPAP Placebo P value
Mean SEM Mean SEM
SBP
(mmHg)
129.9 2.1 131.0 1.8 0.41
DBP
(mmHg)
79.6 1.2 81.5 1.2 0.03
MAP
(mmHg)
96.6 1.4 97.7 1.2 0.30
HR
(bpm)
76.3 1.7 76.6 1.6 0.78
PP 50.3 1.6 49.5 1.5 0.31
DBP is significantly reduced with CPAP treatment compared to oral placebo in these
better CPAP users, and the magnitude of the change is marginally greater in this
group (mean 1.9 v 1.4 mmHg).
5.3.3 Desaturation Index > 20 events Per Hour Slept.
The second a priori group included those patients with a desaturation index > 20
events per hour slept, and 14 patients fulfilled this criteria. Their data are sub
analysed (Table 5.4).
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Table 5.4: Mean BP of Patients With a Desaturation Index > 20 events Per Hour
Slept.
CPAP Placebo P value
Mean SEM Mean SEM
SBP 129.1 2.1 133.1 2.8 0.009
DBP 77.4 2.1 82.4 2.1 0.002
MAP 95.2 1.8 98.6 1.9 0.012
HR 78.0 3.2 76.7 3.3 0.626
PP 51.7 2.4 51.0 2.5 0.418
Post hoc, I examined a less severe group of patients with a desaturation index of > 10
4% desaturation's per hour slept to see if this decrease in SBP, DBP and MAP is
sustained. Their data are included in table 5.5 below, and includes 30 patients.
Table 5.5; Mean BP of Patients With a Desaturation Index > 10 events Per Hour
Slept.
CPAP Placebo P value
Mean SEM Mean SEM
SBP 127.3 1.9 130.5 1.8 0.015
DBP 76.8 1.4 80.5 1.3 0.001
MAP 94.1 1.3 96.9 1.2 0.014
HR 77.4 1.8 76.5 1.7 0.543
PP 50.3 1.7 50.4 1.6 0.882
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These patients who desaturated less than the a priori group have significantly lower
SBP, DBP and MAP with CPAP therapy compared to oral placebo. Even though
these data include some patients who are less than compliant, CPAP use 3.5
hours/night (range 0.1 - 8.1 hours/night), a significant drop in SBP, DBP and MAP
is seen.
5.4 Discussion.
This study shows that DBP is significantly reduced in patients with CPAP therapy,
although the mean drop is small (1.4 mmHg). However looking at the compliant
patients with a CPAP use > 3.5 hours/night, the drop in DBP elicited is greater (1.9
mmHg). One of the main findings of the study is that nocturnal hypoxaemia is a key
determinant of the decrement in blood pressure with CPAP therapy. Both in the a
priori severely hypoxaemic group and in the less hypoxaemic post-hoc group, the
SBP, DBP and MAP are all significantly reduced.
OSAHS undeniably causes transient rises in nocturnal BP, leading to an elevated
sleeping MAP S7. Transient post apnoeic rises can be as much as lOOmmHg, at least
partly due to the repetitive arousal from sleep. BP lability makes the interpretation of
the night-time BP recordings in non-OSAHS patients using inflating cuff techniques
difficult, partly because they are set up to take interval BP rather than continuous BP,
and they do not record the acute swings in BP seen in this patient group. There is
also considerable debate in the literature about the effect of ABPM's on sleep
quality, and whether they can lead to awakening from sleep 499-502 503 or not 504, partially
because of the pressure of the cuff on the arm and partially from the noise of the
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motor unit. If the device does cause awakening from sleep this in turn may elevate
the BP 499,500 or not 502'503. However acclimatisation does occur 482. This type of
monitoring device is being more frequently employed in sleep research to examine
the effect of the disorder on BP.
This study performs recordings over a 48-hour period in an attempt to minimalise the
affects of the ABPM on BP and sleep quality. The other thing that must be
remembered with these ambulatory BP devices is that they can cause awakening
from sleep. This awakening can affect the BP, it may also have an impact on sleep
fragmentation, which in turn may affect any test results done on the day following
wearing the device overnightl93,482.
Some studies have also examined the BP changes (associated with the different
stages of sleep) in relation to SDB events. Davies et al87 performed a study looking
at BP changes in OSAHS, quantifying the severity of OSAHS by the number of
oxygen desaturations > 4%. They looked at two periods of ten minutes each
overnight, with the same body position, looking at NREM sleep periods only. The
mean values were averaged over the twenty minutes. However three of the 18
OSAHS patients were taking anti-hypertensive medication, as were two of the 16
snorers and one of the 34 controls. The study shows that there was a significant
increase in BP in the patients with OSAHS compared to controls. They also
demonstrated that the resting pre-sleep BP was elevated in the OSAHS group
compared to matched controls.
Davies et al reported a further study looking at 24-hour BP in 6 normal subjects to
see if the ABPM's caused an arousal from sleep and any change in beat by beat BP
4". Each subject was studied twice, at least 2 weeks apart with the different ABPM's,
with 30-minute interval BP recordings. During the sleep time the patients also had a
Finapress device fitted on the opposite arm to the ABPM, to record beat-by-beat BP.
EEG recordings were also taken to allow sleep to be staged and arousals to be
identified. The duration of each arousal from sleep that was due to the ABPM cuff
inflation was noted. The Finapress recordings were taken after no hand movement
was observed for 60 seconds after the cuff has started to inflate, and six periods of 10
seconds were recorded. The effect of the rise in BP due to the ABPM from the start
of inflation to the result being displayed was demonstrated with the Finapress. They
demonstrated that both ABPM devices caused arousal from sleep with mean arousal
lengths of 8 and 16 seconds for the two machines. Some cuff inflation's were shown
not to cause any EEG arousal, and the average duration of arousal reduced as the
sleep deepened. They also showed that BP increased even if there was no
demonstrated EEG arousal with the cuff inflation. Interestingly they showed that
mean DBP remained on average unchanged, but mean SBP was elevated which may
suggest that perhaps the SBP measured in my study be artificially high, and possibly
confound the results further. They argue that the time to take DBP recordings was
longer therefore it has longer to return to 'normal' as the patient returns to sleep.
Therefore SBP was probably overestimated during "sleep" using an ABPM, and BP
varies during the different stages of sleep and among individuals. This study looked
at the Oxford Medical ABP and the A&D TM2420 which were different from the
SpaceLab device I employed, however the length of measurement cycles are
comparable at approximately 60 seconds. But the study did not comment on daytime
recordings. Transient auditory and tactile stimuli in sleep have been shown to
increase BP briefly even if no EEG arousal is seen 364.
Davies et al 472 using a group of very carefully matched controls, looked at 24-hour
BP profiles in 18 men with severe OSAHS, and their LV mass. This was one of the
first studies to have tightly matched controls and shows an increase in BP in patients
with OSAHS in NREM sleep compared to the pre sleep wake BP. The blood
pressure changes of OSAHS are very rapid therefore they are not suited to
intermittent cuff measurement, however the ABPM's can be used to give average
BP's and the trend in BP. This study however only looked at a very small time
window compared to the whole night, all in NREM sleep. The severity of the
OSAHS was not included, nor the impact of apnoeas or hypopnoeas on the recording.
There is also some concern that ABPM's can cause arousals, halting the apnoea or
hypopnoea and therefore change the sleep BP profile, but if anything it could
underestimate the change by reducing the severity of the length of the apnoea or
hypopnoea. This study also looked at the daytime blood pressure using ABPM, 472,
and did not demonstrate any differences in the daytime BP in their patient groups. In
addition some of their study population were taking anti-hypertensive medication.
My data combined with recent epidemiological data indicates that OSAHS can
elevate BP. This adds to the already long list of consequences of OSAHS and
reinforces the need for OSAHS to be considered an important medical disorder.
However it is not clear at what threshold of AHI significant cardiovascular
consequences occur. Patients with an AHI > 15 events/hour or >10 4%
desaturations/hour are usually offered treatment if symptomatic and this is backed by
evidence from randomised controlled trials 236'238-240-
There is evidence of improvement in health status achieved by treating symptomatic
patients with an AHI between 5-15 events/hour 239. What then is the current threshold
for treatment? The objective data for symptomatic patients indicates those with more
than 5 events/hr can benefit from treatment in the short term. However longer term
study indicates that half of the patients with 5-15 events per hour will quit CPAP
within 3 years 229, thus long-term benefit may not be achieved in all these patients
with currently available therapy.
There is at present no evidence of benefit from treating asymptomatic patients with
frequent apnoeas and hypopnoeas 244. The current study demonstrates a reduction in
blood pressure with CPAP in symptomatic OSAHS patients and cannot be
extrapolated to asymptomatic subjects. Further randomised-controlled studies are
needed in such individuals.
Oxygen desaturation was thought to be important in the pathogenesis of the transient
BP changes during sleep in OSAHS. Ringler et al 233 studied blood pressure response
in patients with obstructive sleep apnoea, with and without supplemental oxygen to
abolish the hypoxia associated with the apnoea, and a blood pressure rise was still
recorded. This suggested there were additional factors involved in its pathogenesis,
and the hypoxia alone did not explain all the events. This was supported by work
from Fletcher who studied hypoxia in rats 461. However when oxygen is given to
OSAHS patients to prevent the hypoxia, the BP profile seems to be unchanged 363'470.
It is clear from the canine model that the hypoxaemia is necessary to see the





Health status has been previously discussed at length. It was measured in this study
to see if there were benefits to my treatment groups as previously reported in the
literature. It was measured using two subjective questionnaires, the ESS and the
FOSQ. The data collected is presented in tables 6.1 and 6.2 below.
6.2 Study Subjects.
68 patients completed the study, their data are included in this chapter.
6.3 Statistical Analysis.
The data were analysed using a MANOVA as described in chapter 4 as they are
normally distributed.
6.4 Results.
6.4.1 Epworth Sleepiness Score.
Using this standard subjective sleepiness score, the results included in table 6.1 were
obtained. There is no order effect (p = 0.321).
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Table 6.1: ESS and Partner ESS Scores.
Baseline CPAP Placebo CPAP v
Placebo
p-value
Mean SEM Mean SEM Mean SEM
Patient ESS
(ex 24)
15 0.6 10. 0.7 13 0.8 0.001
Partner ESS
(ex 24)
14 0.7 11 0.7 13 0.8 <0.001
6.4.1 Conclusion.
CPAP improved both the patient's and their partner's interpretation of their ESS
scores. The placebo also showed a significant improvement in ESS scores of the
patient (p < 0.001) but not in the partner's estimation (p = 0.109). This is possibly a
reflection of a combination of the placebo effect, the desire to help in the project, and
the hope of improvement with the medication, it also may reflect the patients desire
to take a capsule rather than use CPAP. It also shows that when a partner is available
for corroboration their assessment is very valid. It must also be noted that the ESS
did not return to 'normal' values (usually taken as < 10), with CPAP treatment, I
suspect this is a reflection in the low compliance with CPAP.
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6.5 Functional Outcomes of Sleep Questionnaire.
CPAP improves the sleep specific health status (table 6.2).
Table 6.2: FOSQ Scores Pre-treatment, on Placebo and on CPAP.
Domain Baseline CPAP Placebo CPAP v
Placebo
p-value
Mean SEM Mean SEM Mean SEM
GP
(ex 4)
3.0 0.1 3.3 0.1 3.2 0.1 0.070
SO
(ex 4)
2.8 0.1 3.3 0.1 3.1 0.1 0.010
AL
(ex 4)
2.6 0.1 3.0 0.1 2.8 0.1 0.004
V
(ex 4)
2.4 0.1 2.9 0.1 2.7 0.1 0.029
Total
(ex 16)
11 0.4 13 0.4 11.6 0.3 0.010





It is clear to see from these results all domains with the exception of general
productivity are significantly improved in patients treated with CPAP. This is in
keeping with previous reports in the literature l45'159. It also shows that the placebo
effect is strong with the placebo being better than baseline levels. However this is
outweighed by the significant improvement with CPAP compared to placebo. There
is no order effect (p = 0.287).
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6.6 Discussion.
Health status is an important area, it reflects a person's well being, and is an indicator
of the impact of a disorder on life, both physically and emotionally. The use of
standardised questionnaires has made it easier to see the impact on QoL in the
research setting comparing two different treatment modalities and also allows
comparison between different studies, and between different disorders. In this study
I chose only the ESS and the FOSQ, which are both sleep specific. However in
retrospect it may have been useful to have also included a general measure such as
the SF-36, to allow easy comparison with other common disorders where there has
been good evidence on the impact of the diseases on quality of life. I was aware of
the amount of time and paperwork the study demanded of the patients and felt that
this extra questionnaire might overload them, especially as there are other data on the





Psychometric testing was included in the study to show the effects of treatments on
vigilance and cognition, and to see if this study agreed with the previous literature.
7.2 Study Group.
The data included in this chapter refers to the 68 patients who completed the study,
demographics ofwhich are included in section 4.14.
7.3 Statistical Analysis.
All data were analysed as described in section 4.13 utilising a MANOVA for the





Utilising the digit span test as previously described in chapters 3 and 4, the results are
listed in table 7.1 below. This table includes data from the test run at baseline, and at
the end of the placebo and CPAP limbs. The data are normally distributed.
Table 7.1: Digit Span Results Pre-treatment. on Placebo and on CPAP.
Baseline CPAP Placebo CPAP v
Placebo
p-value
Mean SEM Mean SEM Mean SEM
Forward
(ex 14)
8.0 0.2 8.3 0.3 8.3 0.2 0.736
Back
(ex 14)
6.1 0.3 6.9 0.3 6.5 0.3 0.040




14.2 0.4 15.4 0.5 14.9 0.5 0.095
f-b - forward minus backward scores
7.4.1.1 Conclusion.
There are no differences in the global digit span scores for the CPAP versus oral
placebo, which differs from previous literature 4'505, although there is a trend in the
global score. Recent work from Bardwell did not show any significant difference
after a week of CPAP l39. He studied 36 patients, allocating in a randomised manner
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to either CPAP or placebo CPAP, the treatment period before restudy was relatively
short, and CPAP compliance was objectively measured.
However on looking at the two components of the test, there is a significant
improvement in the CPAP versus placebo in the backward score, but this difference
is very small. It is surprising that there is such a significant improvement comparing
baseline with placebo (global score baseline v placebo p = 0.006), but no order effect
is present (p = 0.44). It should be noted that the mean scores are within the normal
range for this test, and therefore perhaps the patients are little affected in this domain
and thus it is difficult to elicit a difference.
7.4.2 Steer Clear.
Performance on this vigilance test is not significantly better on CPAP compared to
placebo (table 7.2). This table includes data collected from baseline, and at the end
of each treatment limb of CPAP and oral placebo. The data are not normally
distributed therefore non-parametric tests are used for analysis.
Table 7.2: Steer Clear Results at Baseline, on Placebo and on CPAP.
Baseline CPAP Placebo CPAP v
Placebo
P-value
Mean SEM Mean SEM Mean SEM
% hit 10.9 1.5 7.1 1.3 7.7 1.3 0.322
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7.4.2.1 Conclusion.
This test shows a significant improvement in score in patients on placebo compared
to baseline (p < 0.001), however no significant difference is elicited between CPAP
and placebo. There is no order effect (p = 0.15).
Previous literature has provided conflicting results, with some showing an
improvement in Steer Clear performance l68'477, and some not 136. Findley studied 12
OSAHS patients against 12 matched controls and showed that the OSAHS patients
hit more obstacles in the test, and when 6 of them went onto CPAP for at least 3
months, they reduced the number of obstacles hit significantly ,68. This was a small
study, taking a population from their sleep clinic, the OSAHS patients were a more
severe group compared to my population (mean AHI 83 v 44/hour slept), there was
no placebo arm included nor was the control group studied a second time. The
number of obstacles hit in the untreated group was similar to my population (% hit
6.0 v 7.7), there was no comment whether his study population was familiarised with
the test, and the big change may be in part a learning effect. CPAP compliance was
not included, so the improvement in score may just reflect a learning effect if the
patients were non-compliant.
In a prospective study by Kingshott et al, 62 OSAHS patients were studied at
baseline and after 6 months of CPAP therapy. The severity of OSAHS was more
severe than my cohort with a mean AHI of 62 v 44/hour slept. A highly significant
improvement in Steer Clear hits was reported. CPAP use was objectively measured
(mean use 4.8 hours/night), however their study was not a RCT.
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A prospective randomised single blind, placebo controlled, crossover trial of CPAP
versus an oral placebo with one months treatment limbs did not show any significant
change in Steer Clear hit rate 136. The study exposed the subject to the test at baseline
to allow familiarisation then at the end of each treatment limb. The study included
23 patients, and CPAP use was objectively reported at 3.2 hours night. The severity
of the OSAHS was similar to my cohort at and AHI of 43 v 44 /hour slept.
I think one of the reasons my study did not show any improvement in Steer Clear hit
rate was partially that compared to the two positive studies my patient group was less
severe. I also studied the patients after a month; the two positive studies were not
studied until at least 3 months therapy, however I attempted to allow for
familiarisation, which these two studies did not.
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7.4.3 Stroop Colour Word Test.
Stroop results (table 7.3 below) are no different with CPAP compared to placebo.
The results are not normally distributed; therefore Wilcoxon non-parametric tests are
used.
Table 7.3: Stroop Scores at Baseline, on Placebo and on CPAP.
Base ine CPAP Placebo CPAP v
Placebo
p-value
Mean SEM Mean SEM Mean SEM
Read
(sec)
61.0 3.3 56.4 1.8 58.4 2.4 0.589
Colour
(sec)
132.8 4.6 114.6 3.9 113.2 3.7 0.184
Diff
(sec)
71.7 3.7 58.2 2.9 54.8 2.6 0.249
Diff- difference between colour and read times.
7.4.3.1 Conclusion.
Using the Stroop colour word test I found no significant difference between the times
on and off CPAP, there is no order effect (p = 0.482). One other study using the
Stroop test showed significant impairment compared to matched controls, however
they had a small sample of 17 in each group, and used a slightly different format of
the test 143. In a more recent study, Bardwell did not show any significant
improvement in the Stroop test after a week of CPAP in their randomised-controlled
study of 36 patients l39. A different format of the test was also used, and the
treatment duration before re-testing was relatively short. Educational level is
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important in this test and it was matched for in Naegele's study, that was not
necessary in my cohort as the patients act as their own controls.
7.5 Discussion.
The subject of neuropsychological dysfunction has been extensively studied in
OSAHS, the importance of providing good quality results cannot be over emphasised
using the basis of large randomised controlled studied to provide the most robust
data. Utilising the correct test is important, as there are a huge number of different
tests available, testing a variety of parameters. The data obtained from my study did
not show any significant improvements with CPAP compared to oral placebo except
in the backwards digit span test. These results are in agreement to some previous
work and contradictory to others, the reasons for this are not clear, however some of
the possible conclusions have been discussed above. The other possible reason for
the differences reported in the literature and this study may reflect the time of day
that the testing was performed. Within this study I tried as much as possible to
perform the neuropsychological testing at the same time of day for all patients and to
be consistent with each patient. The data included in this thesis comes from a





The long-term consequences of OSAHS remain controversial. The mechanism of
changes in nocturnal blood pressure remains a source for debate, as does the
mechanism for impact on daytime BP. There has been data suggesting the role of
sympathetic modulation in this process 303'304-455'506< I therefore wanted to explore this
concept further within the context ofmy existing study.
The last 22 patients who were recruited into the main study were also asked to
participate in an additional experiment designed to reflect sympathetic tone and
baroreflex sensitivity. This study required an extra 2 hours of the patient's time on 2
separate days at the end of each treatment limb and 14 of the 22 patients agreed to
take part. One set of data was incomplete due to technical difficulties on the day of
measurement, therefore 13 complete sets of data were collected. The patient group
was no different from the main study population.
The patients had baroreceptor function assessed both on CPAP and placebo by




The demographics of this cohort are included in table 8.1; 12 of the 13 subjects were
male, and 7 patients had CPAP first and 6 had placebo first.
Table 8.1: Demographics of patients Taking Part in The Sympathetic Study.
Mean SEM range
Age (years) 45 3.2 27-63
AHI/hr slept 55 11 17-129
EEG arousals/ hr slept 57 8.0 22-128
4% Dl/hour slept 24 8.3 1-93
ESS (ex 24) 14 1.3 9-24
Partner ESS (ex 24) 15 1.2 7-24
BMI (Kg/m2) 31 2.3 23-55
Neck (cm) 41 0.9 37-46
Waist (cm) 109 4.5 95-155
Hips (cm) 110 4.3 100-155
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8.3 24-hour Blood Pressure Results for This Sub-group.
There are no significant differences in BP on CPAP compared to oral placebo (table
8.2). This may reflect the small sample size with this part of the study, and therefore
been underpowered. CPAP use within this group was good at 4.5 hours/night (SEM
0.7).
Table 8.2: Mean 24-hour BP Values for BRS Cohort.
CPAP Placebo CPAP v
placebo
P-value
Mean SEM Mean SEM
SBP 127.9 2.9 127.1 2.6 0.65
DBP 78.2 1.7 79.0 1.8 0.59
MAP 95.0 2.1 94.3 1.7 0.72
HR 76.8 2.9 76.5 2.3 0.63
PP 49.6 2.0 48.1 2.0 0.82
Despite good CPAP use there is no significant differences in the variables included
in table 8.2 between CPAP and placebo.
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8.4 Spectral Analysis Results.
Using the ECG and the Finapress data collected, power spectral analysis was
performed as previously discussed in chapter 4. At the end of the study all the data
were analysed using the software described, and the two data sets are compared using
a MANOVA. The results in table 8.3 overleaf are the values computed comparing
CPAP therapy and oral placebo.
155
Table 8.3: Spectral Analysis Results.
CPAP Placebo P-value
Mean SEM Mean SEM
Mean PI 986 38 956 34 0.13
Mean SBP 119.7 3.8 123.3 5.4 0.49
Total PI
power
7360 1493 6614 1423 0.50
Total SBP
power
113.6 23.6 117.9 28.1 0.87
VLF PI
power
1918 384 1521 370 0.30
VLF SBP
power
62.0 14.4 63.8 20.4 0.92
BRS VLF 6.2 0.7 5.9 0.9 0.63
LF PI
power
2198 555 1642 326 0.17
LF SBP
power
30.9 8.6 28.9 7.8 0.82
BRS LF 9.0 1.1 9.0 1.1 0.98
HF PI
power
1607 456 1720 55 0.77
HF SBP
power
5.7 1.0 5.6 1.0 0.96
BRS HF 16.9 3.1 15.2 2.1 0.29
Alpha 12.9 2.0 12.1 1.5 0.40
BRS
LF/HF
0.59 <0.01 0.63 <0.01 0.56
LF/HF PI
power
2.1 0.5 2.1 0.5 0.94
Lesend: PI - pulse interval;
SBP - systolic BP;
VLF - very lowfrequency;
LF - low frequency;
HF - high frequency;
BRS - baroreflex sensitivity.
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8.5 Discussion.
This study showed no alteration in baroreceptor function with CPAP compared to
placebo. While this may reflect relatively low power in this small component of the
overall study, this finding is compatible with the data from Brooks' dog model of
sleep apnoea in which there was an effect on 24-hour blood pressure but no change in
baroreceptor function.
Conflicting evidence has been produced postulating that patients with OSAHS have
high sympathetic activity during wakefulness and during sleep and this has been
shown experimentally 376'458. Cardiovascular stress tests have also reinforced this
observation of high sympathetic discharge in the daytime compared to 'normal'
controls 507"509. Sachs et al studied 13 OSAHS patients, 9 narcoleptics with age-
matched controls, showing that both conditions are associated with autonomic
dysfunction. There was marked inter-individual variations, suggesting a more multi¬
factorial aetiology 507. There were differences between the two sleep disorders in the
dysfunction's found and the controls were not as closely matched as would be ideal.
The main differences were found in heart rate and blood flow in the resting limb on
muscle activation, and respiratory sinus arrhythmia, which were diminished
compared to healthy controls. These results suggested that there was impairment of
the balance between sympathetic and parasympathetically mediated cardiovascular
reflexes, possibly at a central level. The patients were not restudied after treatment
had been initiated to see if the degree of impairment altered 507.
Cortelli studied 21 normotensive OSAHS patients and 20 age matched controls
looking at cardiovascular reflex tests. This study also showed abnormalities in
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autonomic function in the OSAHS patients, they did not go on to study a treated
group of patients 509. A further study of autonomic function on OSASHS patients is
reported by Veale, who studied 33 patients attending for sleep study 508. They studied
the group night and morning, i.e. before and after their sleep study. In the severe
OSAHS patients (n = 12; median AHI 44/hour slept) significantly more of the
autonomic tests were abnormal, compared to non OSAHS patients (n = 11). They
did not include a control group and did not attempt to match the normals, who were
studied. Because the patients were attending for sleep study, it would not be
unreasonable to assume that they were symptomatic in some way, therefore are not a
good control population.
Khoo et al 315 looked at the alterations in SNS activity in OSAHS compared to
matched controls attempting to control for the altered respiratory activity in this
patient group, they show a marked increase in sympathetic activity and a reduction in
parasympathetic activity. This alteration to the parasympathetic activity may also be
one of the factors in the development of cardiac arrhythmias in this patient group. It
has previously been shown that CPAP reduced the sympathetic activity in patients
with OSAHS 376.
Heart rate variability (HRV) and baroreceptor sensitivity (BRS) are markers of the
autonomic control on the heart, HRV reflecting cardiac vagal tone, and BRS
reflecting vagal reflexes. BRS assumes a connection between a stimulus and a
response, and represents the capacity to reflexively increase vagal activity and
sympathetic activity in response to a sudden increase in blood pressure.
There is increasing interest in the role of the ANS in triggering sudden cardiac death
following myocardial infarction 510 and it could be related to the rare sudden deaths in
OSAHS, which may be cardiac in origin. Proven alterations in the ANS in this
patient group would strengthen this argument.
A difference in BRS may have not been elicited in my study for several reasons,
including that:
□ The study population is too small, noting that there is no significant
difference in BP in this sub group ofpatients.
□ Daytime BRS may be unaffected by the nocturnal swings in BP in the
untreated OSAHS patient. The evidence of change in daytime BP in the main
study is relatively weak and in addition it is possible to affect BP with out
affecting the BRS slope.
□ The relatively short duration of the study, however this is less likely as it has
been previously shown that here may be a reduction in SNS traffic almost
immediately on starting CPAP 440.
The effects of hypoxia on the SNS have also been described 3I0'5" and it is difficult to
explore which of these insults is the dominant problem in this patient group. The DI
for this group was certainly at a level that changes in BP would be expected to be
seen comparing the data from the chapter 5.
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Chapter 9.
Microalbumin as a Marker for Renal Disease in OSAHS
Patients.
9.1 Introduction.
It has been recognised in recent times that even slight increases in the urinary
albumin excretion can be a valid predictor ofpremature morbidity and mortality from
cardiovascular diseases. In addition increases in albumin excretion provide an early
sign of nephropathy in diabetics (both insulin and non insulin dependant) and in the
hypertensive population 512~517. It is a marker used in many diabetic clinics to identify
those patients requiring early intervention. I therefore wanted to examine urinary
microalbumin in a subgroup ofmy patients to see if this simple test could perhaps be
used as a marker for those patients who might be more at risk of the long-term
consequences ofOSAHS.
The aim of this study was to measure urinary microalbumin in a sub group of
OSAHS patients to determine if it was a reliable marker of long-term health
consequences of the disorder. It is a relatively cheap test at approximately £7.00 per
sample, simple to perform and if it provides a useful method of predicting those
patients who run into trouble with end organ damage it might be worthwhile to add
to the battery of investigations done when assessing the OSAHS patient.
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9.2 Microalbuminuria.
Proteinuria is a common indicator of renal disease; it can be detected by dipstick
testing using an appropriate kit. These dipsticks detect a protein content of >200
pg/min and they react primarily to albumin, and are relatively insensitive to
globulin's and Bence-Jones proteins. In the urine, albumin is normally present in
concentrations of < 20 pg/min, and the range of 20-200 pg/min is referred to as
microalbumin, which is therefore by definition not picked up by dipstick testing.
Microalbumin is therefore defined as a urinary albumin excretion rate of 20-200
pg/min. To convert this figure to mg/24 hours it is multiplied by a factor of 1.44.
For spot urinary concentrations it is assumed that the average person passes 1.5 litres
of urine per day, therefore the mg/24 is divided by 1.5 and is expressed as mg/1.
Microalbumin is measured in a spot urine sample by radioimmunoassay. Our local
laboratory measures microalbumin, quoting levels of > 10 mg/1 as abnormal. Total
24-hour urinary excretion may be measured, and microalbumin is then defined as an
excretion rate between 20 and 200 pg/min. Assuming a normal urinary output this
corresponds to albumin concentrations of> 15 or 20 mg/15I8.
Normal reference ranges exist for albumin excretion in normal subjects 519. Several
studies have been published both in adults and children. Taking the data from five
adult studies 5I9, 323 individuals were studied and the range of normal (95% of
population) albumin excretion was from 1.6 to 3.9 mg/1, in this cohort. This is the
standard reference source used 5I9. Confounding factors exist; the urinary albumin
excretion rate is variable in itself and can be affected by urinary tract infections,
cardiac decompensation, hypertension, exercise and poor metabolic control. In this
study group we have excluded cardiac failure, hypertension and diabetes and
unfortunately our patient population is not renowned for taking vigorous exercise, so
these are already factored out with the recruitment criteria.
9.3 Methods.
Consecutive patients were invited to participate in this study. It was added on to the
main BP study at a later stage with the final 21 patients taking part, providing a spot
urine samples for analysis.
9.3.1 Samples.
A random urine sample was obtained from patients prior to CPAP commencement.
The samples were analysed by the Biochemistry Department in the Royal Infirmary
of Edinburgh, which measured the urinary albumin (mg/1) and creatinine (mmol/1) by





The characteristics of the 21 patients are included in Table 9.1.
9.4.2 Demographics.
Of the 21 patients providing urine samples 19 were male and 2 female. CPAP use in
this patient group was 4.0 hours/night (SEM 0.7).
Table 9.1: Demographics of Patients Participating in The Microalbumin Study.
Mean SEM
Age (years) 49 2.6
AHI/hour slept 49 8.0
EEG arousals/hour slept 51 6.3
4 % Dl/hour slept 20 6.0
BMI kg/m2 29 0.9
ESS (ex 24) 14 1.2
Partner ESS (ex 24) 15 1.0
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9.4.3 Urine Results.
Table 9.2 contains the urinary data from this sub-population. In the majority of
patients this was <10 mg/1 and therefore insignificant, and hence no ratio could be
calculated. However in 35% ofpatients the results were abnormal.
Table 9.2: Random Urine Results for Study Population.
Patient reference Urinary Albumin Alb/creat ratio Urinary creatinine
number (mg/1) (mg/mmol) (mmol/1)
150 <10 * 6.2
151 <10 * 7.1
152 10 <0.1 10.8
153 30 1.4 21.1
154 <10 * 6.2
155 <10 * 14.7
156 11 1.2 9.1
157 16 2.3 6.9
158 <10 * 10.3
159 <10 * 3
160 48 1.9 25
161 <10 * 8.1
162 44 2.8 15.8
163 <10 * 1.5
164 <10 * 6.3
165 12 <0.1 23.4
166 <10 * 15.9
167 <10 * 8.8
168 <10 * 5.2
169 29 <1.0 30.1
170 <10 * 10.7
*denotes unable to calculate ratio
Normal albumin/creatinine ratio is 0-3.5 mg/mmol from our local biochemistry
laboratory.
The mean value of urinary albumin in the eight patients who had abnormal results is
23.6 mg/1, with a range of 10-48 (SEM 4.9).
9.4.4 Relationship Between Urinary Albumin Concentration
and OSAHS Measures.
Pearson's bivariate correlation's are used to compare urinary albumin concentration
and primary OSAHS outcome variables (Table 9.3). There is no significant
correlation between urinary microalbumin and the OSAHS variables listed below
however there is a trend to significance with BMI (p=0.06). It is therefore not clear
whether it is the OSAHS or the BMI that is the important factor in urinary
microalbuminuria.
Table 9.3; Correlational Relationships Between Urinary Albumin and OSAHS
Variable.
OSAHS variable Urinary albumin concentration
(mg/1)
p-value
AHI (events hr/slept) 0.24 0.53
EEG arousals (hr/slept) 0.48 0.20
ESS 0.25 0.52
CPAP use 0.30 0.42
BMI 0.65 0.06
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9.4.5 24-hour Blood Pressure.
The 24-hour BP profiles are available for this subgroup of patients and the results are
included in table 9.4 below. This subgroup of the cohort had no significant
difference in SBP, DBP, MAP, heart rate or pulse pressure with CPAP. This may
just reflect that the sample size is too small, resulting in an underpowered study.
Table 9.4: 24-hour Blood Pressure in This Subgroup.
CPAP (SEM) Placebo (SEM) CPAP v Placebo
p-value
SBP (mmHg) 126.9 (2.0) 126.6(1.9) 0.82
DBP (mmHg) 77.9(1.2) 78.5 (1.4) 0.59
MAP (mmHg) 94.4(1.5) 94.0(1.3) 0.80
Heart rate (bpm) 77.2 (2.3) 77.1 (2.1) 0.78
Pulse pressure 48.9(1.4) 48.1 (4.5) 0.29
9.5 Discussion.
In this pilot study 35% of the patients had abnormal urinary microalbumin results. It
is not clear whether the OSAHS was the cause of the abnormal results or whether
they are as a consequence of another problem. With the selection criteria for the
study the common problems that would normally lead to microalbuminuria were
excluded. Therefore the presence of microalbuminuria may reflect occult disease in
this group of patients. There is a trend to significance with correlation with BMI,
and perhaps the abnormal results are a reflection of obesity rather than OSAHS.
Although these results are interesting the sample size is small. Further work is
needed in this area studying a larger population. Perhaps by going on to perform
more complex renal investigations to see if OSAHS alters renal blood flow per se or
to see if the consequences of OSAHS are to blame with the nocturnal swings of
blood pressure having an adverse effect on the kidney. Furthermore going on to
study if there would be any improvement once treatment with CPAP had been
established. It has also to be remembered that the urine samples taken are spot
samples, and it would be more accurate to perform 24-hour collections to look at
protein content and creatinine clearance. However this would be a much more
cumbersome study and less attractive to patients to participate, and the object of this
study was to see if utilising this simple test was useful in this disorder. The spot
urine samples also introduce more variability, with variable urine outputs between
patients and therefore the concentration of the urine differs. There is also variability
of urinary microalbumin at time of day, with the levels generally being lower during
the night. In this study I tried to collect all the samples first thing in the morning.
The calculations performed assume an average daily urine volume of 1.5 litres,
thereby inducing error. The hope was to see if this simple test was a useful predictor
in identifying a possible high-risk population attending the Sleep Clinics. I have
raised more questions than answers at present.
Data has been provided in the diabetic, hypertensive and elderly populations trying to
predict the usefulness of microalbumin measurements. In the hypertensive
population microalbumin has been used as a predictor for cardiovascular mortality 520.
In this large study (n = 439) performed over 6 years, they concluded that
microalbuminuria is an independent predictor for cardiovascular mortality in treated
hypertensive men with non-insulin dependant diabetes. However it was macro-
albuminuria i.e. proteinuria, that predicted mortality in the non-diabetic group.
Further data from the same group with a sample of 333 treated hypertensive men
who did not have diabetes; show microalbuminuria to have a low sensitivity as a
marker for concomitant cardiovascular disease 521. It was associated with insulin
resistance, which may reflect why our data is trending towards an association with
BMI.
There was conflicting data from a large cross-sectional study of 1254 hypertensive
patients attending a hypertension clinic, including a variety of other diagnoses,
concluding that microalbuminuria was a pressure dependant functional phenomenon
in the renal tract, and it was associated with permanent atherosclerotic abnormalities
in the whole vascular system 522. Other studies published have suggested that
microalbumin was associated with early cardiovascular morbidity and mortality
513,514,516,523
Although the evidence to date is contradictory there is no doubt that microalbumin is
a useful marker in the diabetic population, possibly in the hypertensive population.
However its role in the OSAHS population needs further study.
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Chapter 10.
Compliance on Study Treatments.
10.1 Introduction.
CPAP was introduced more than 20 years ago 228 and has remained the standard
treatment for OSAHS. Over the years there has been a considerable amount of data
discussing the use of CPAP. CPAP has been well validated as a treatment of
OSAHS both in terms of improvements in sleepiness l3l,52\ cognitive function l36'144,
driving 525, and health status 155'526. There has been a variety of study designs over the
this time, the most informative studies have taken the design of a randomised
controlled trial either using a crossover design or a parallel group, providing the best
•i r rvr x 4. 135,136,140,159,173,177,235,238-240,505,527-529evidence for the efficacy of this treatment
10.2 Methods.
The two 'treatment' modalities that were chosen for this study are standard CPAP
and an oral capsule, as a placebo. These modalities are discussed below in detail.
10.2.1 Continuous Positive Airway pressure.
CPAP is currently the best-proven treatment for OSAHS as discussed in Chapter 1.
For the purpose of this study all patients were issued with Sullivan-V elite CPAP
machines (ResMed, Australia). These machines allow calculation of average nightly
use using in-built pressure sensitive time clocks, giving the number of hours the
machine is within 2.0 cmH:0 of the prescribed pressure per night. Thus the use time
recorded has to genuinely reflect the patient's use and cannot result from the patient
leaving the machine switched on in the corner of the room. The machine also
contains an automatic stop feature that when the mask is removed the machine shuts
down. The elite machines store data for 200 days, which can be downloaded to a PC
via an interface, using compliance (SCAN 2.0) software. This allows calculation of
an average nightly use of the CPAP units during the study, as well as the night-by-
night data. This facility allows compliance to be objectively measured, which is
often omitted in earlier studies, which have relied on self-reported compliance which
over estimates patients use.
The machines are attached to the patients with a hose and a nasal or full-face mask, a
variety of masks are used during this study to facilitate the best fit for the patients to
optimise comfort whilst minimising leak. Mask fitting was initially done by
specialist nursing staff or technicians during the education session, or by myself.
Mask refitting was done if necessary during the study by myself to ensure the best
possible mask fit, comfort, and therefore maximise CPAP use.
10.2.2 Placebo.
Lactose capsules were purchased from Nova laboratories Ltd, Leicester. The
capsules are plain white and packed in tubs of 28. Patients were told that they were
an experimental treatment that might affect the muscle tone in their upper airway and
therefore possibly improve their symptoms. Patients were asked to take their
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medication before going to bed. Any left over medication was collected at the end of
the capsule treatment limb to allow calculation of compliance.
The patients general practitioners were supplied with a sealed envelope containing
details of the capsule to be opened in the event of an emergency or if there was a
problem and the patient was unable to contact the Sleep Centre for advice. During
this study no envelopes required to be opened. The general practitioners were asked
to destroy the envelope at the end of the study.
10.3 Results.
10.3.1 CPAP Use.
In this study the mean CPAP use was 3.3 hours per night (SEM 0.3), with a range of
0 to 8.1 hours per night. CPAP use during the two nights that the patients were
wearing the ABPM was also analysed, which showed a CPAP use of 3.7 (SEM 0.3)
hours per night with a range of 0 to 9.1 hours. Using a paired t-test there is a
significant difference in CPAP use in the month compared to the two nights when the
ABPM was worn (p= 0.007). This presumably reflects the patients being aware that
they would be visiting the centre and have their CPAP use examined. Overall CPAP
use was lower than I would ideally like. However it is similar to the use previously
observed in intention to treat trials, recruiting consecutive patients l35136-239-242'530
The patient group reported the common minor side effects ofmask discomfort, nasal
stuffiness, noise disruption for both the patient and the partner. The majority of these
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were dealt with the simple measures of mask refitting, intra nasal steroid, Olbas oil
instilled into the filter, humidification and position of the CPAP unit.
The patient group varied from mild to severe disease, both in terms of AHI and
symptoms. I went on to look at the more severe cases in terms of AHI and showed
the CPAP use increases with increasing AHI, as previously reported. The figures are
demonstrated in table 10.1 with the CPAP use increasing to 4.7 hours per night
(SEM 0.7) in patients with an AHI > 60 events per hour slept.








>30 44 3.5 0.3 0.1-8.1
>40 28 3.8 0.4 0.1-8.1
>50 18 4.0 0.5 0.6-8.1
>60 12 4.7 0.7 0.6-8.1
Another way to look at increasing severity is the desaturation index, however this did
not correlate with CPAP use, (r= 0.052, p=0.676). The ESS is not a useful predictor
for CPAP use (r=0.163, p=0.185) in this study.
10.3.2 Capsule Use.
Capsule compliance was monitored by collecting any left over medication at the end
of the treatment limb. The median number of capsules missed was 0 with a range of
0-10 (Confidence interval 0.5-1.56). This is a very crude method, however there is
no easy way to check compliance with oral medication, if the patient wishes to
deceive it would be easy as the capsules could be disposed of rather than returned.
However the patients were not informed that any left over medication would be
collected at the end of each treatment limb.
10.4 Long Term Follow-up.
Sixty of the sixty-eight patients who completed the study remain on CPAP therapy
after a year. Seven have returned their CPAP units, five of these have been referred
for MRS devices and one has been lost to follow-up. The patients who continue to
use CPAP have a mean compliance of 3.75 hours/night (range 0-9). This is in
keeping with previous studies, with the usual spread of CPAP use, or even a little
better as the work by McArdle showed 20% of patients give up CPAP use in the long
term, in this group so far it is 12% 229. This patient group received extra support at
the start of CPAP therapy, which has been shown to improve compliance 230'231,
although their nightly compliance was not as good as I would ideally like, so far the
patients are remaining on therapy for longer. It has to be remembered that generally
patients who participate in studies are a more compliant population than the
population as a whole, which may be reflected in the continued CPAP use.
10.5 Discussion.
An oral placebo was chosen for this study. There is no ideal placebo for CPAP; the
options are either 'sham' CPAP or an oral agent. 'Sham CPAP' uses the CPAP unit
set at a low pressure, i.e. subtherapeutic. At the inception of this study there were
some concerns that sham CPAP may even make patients worse 53and because of
this I chose an oral placebo.
I was also concerned our patients might be able to distinguish the difference between
'sham CPAP' and therapeutic CPAP. If patients are able to distinguish between the
different pressures they would cease to be blinded in a cross over study which is why
the Oxford group have performed parallel group studies using sham CPAP 404'537. A
CPAP unit set at minimum pressure might theoretically stabilise the airway
sufficiently to treat some episodes of upper airway narrowing, and therefore reduce
the effect of a true placebo as it provides partial treatmentl03, further biasing results.
The other reason an oral placebo was chosen was that a CPAP machine set at sub¬
therapeutic pressure might keep the patient awake, thus falsely raising blood pressure
and predisposing to finding false benefit from real CPAP. This does not appear to be
the case in more severe patients 532 but there is as yet no evidence in milder patients.
I was also concerned that patients would use 'sham CPAP' less than active CPAP as
they would not perceive any symptomatic benefit to counterbalance the
inconvenience, and thus a true placebo benefit might not be obtained at the end of the
study limbs when the key measurements were made. If the patients did not derive
benefit from the sub-therapeutic CPAP they may be less compliant with therapeutic
treatment, as it has been well documented that the early use of CPAP predicts long-
term use 229'533. If the patient was on the sub-therapeutic limb first they would not
necessarily derive any benefit and they would perhaps be less willing to persevere
with the treatment limb of the study as my study was of crossover design. The way
round this would be to do a parallel group study as done in other centres, but then
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you are confronted with matching controls to the study groups, rather than using each
patient as their own control.
There are also disadvantages with an oral placebo:-
□ There is no matching for the machine, which may have some mystical effect.
□ Some patients do not like taking "medicine".
□ The patients needed an explanation why they were trying a tablet and we
agreed with approval of the ethics committee to tell them that "the medication
might improve their upper airway tone thereby reducing the number of
apnoeas and therefore reduce their symptoms". This view has been
challenged 534 and in turn we have rebutted these claims 201. These are difficult
issues to which there is no clear answer and I can honestly say I have tried an
approach I believe is valid and reasonable.
To provide a good evidence base as we are increasingly asked to do, the best
evidence comes from the basis of randomised controlled trials (level A evidence-
SIGN). This study was formulated with this in mind. There was no long-term
intention to deceive the patients, however they had to believe the oral capsule was an
active treatment otherwise it would not have been a true placebo. All patients who
participated in this study were informed by letter of the contents of the capsule at the
time of study completion. At the end of each patient's trial they were told of their
own results, and any abnormal BP results were copied to the patients general
practitioner.
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Overall the size of the placebo effect found in our studies for ESS is similar to that
found with sham CPAP suggesting that placebo tablets are as effective placebos as
sham CPAP. I believe there is no perfect placebo for CPAP.
The CPAP compliance is lower than ideal as previously stated, this may have been as
a result of many factors. This study included a very heterogeneous group of patients
with a variety of symptoms and spectrum ofAHI's. It was an intention to treat study
and consecutive patients are recruited to the study, they were only excluded on the
grounds mentioned in Chapter 4, so all suitable patients are approached. It has to be
remembered that the Sullivan V elite machines measure time at pressure only, so
when the mask is off the face, or there is a large leak this will not appear on the time
clock. Also the ramp times do not appear either, as the machine is not at pressure.
The majority of patients utilise the 20-minute ramp time. If a patient takes longer to
get to sleep, often they tend to restart the ramp time, or if up in the night; on getting
back to bed the ramp time can be reset. This results in an underestimate of time
wearing the mask, and for example with three 'ramp periods' a further hour would
not be recorded.
There has been evidence showing night-to-night variability in OSAHS, which with
standard treatment, a single pressure is set which attempts to treat all events.
Because of this variability of the disorder CPAP units have been developed to
provide a variable pressure, in an attempt that it will make CPAP more comfortable
and therefore improve compliance. These units or 'Auto CPAP' vary pressure
according to the level of obstruction present, to keep the airway patent.
A recent systematic review of the literature defined three types of placebo,
pharmacologic (as in our case), physical (e.g. a manipulation), or psychological (e.g.
a conversation). One hundred and thirty trials were identified, of which the authors
looked at 114, excluding 16 on the basis they lacked relevant outcome data. These
trails included data from 8525 patients. In conclusion they found no evidence that
any placebo had marked clinical effects, they possibly had some benefits in studies
with subjective outcomes 535. It must also be remembered that the research setting
itself can change behaviour. There has also been some concern raised about the
ethics of using placebos generally. The first placebo-controlled trial was probably
performed in 1931 in the treatment of tuberculosis. Since then there has been
controversy surrounding their use. One major concern was that patients who
received a placebo of any sort is denied the active treatment, this is especially a
concern if a trial is of considerable length. There remain two schools of thought one
stating that a placebo should only be used if there is no increased risk of death
associated with its use, and the other suggests placebo use should be banned if an
effective therapy already exists "6.
I felt justified in using an oral placebo in this study for the reasons stated above. The
patients were not denied active treatment for any significant length of time, and in
excluding hypertensive patients I obviated the need to stop any medication to permit
washout, and therefore there was no need to leave hypertensive patients off their anti¬
hypertensive medication. This latter method has been used in many studies in this




This study raises more questions than answers. The mechanisms for change in BP
need to be teased out further, with further investigation of the sympathetic nervous
system, the parasympathetic system and vascular reactivity and remodelling. A
better method for measuring BP that does not either affect sleep or cause an arousal
from sleep affecting results would provide an ideal tool for further studies. There is a
device on trial which could possibly fulfil this role (Innerspace device). This sort of
device would be ideal, as it would provide a true reflection of BP profile beat by
beat.
It would also be interesting to follow up the patients after they had been on CPAP for
a significant time to see if their BP was sustained or indeed whether it fell further.
The changes in BP with different treatments for OSAHS, such as the mandibular
repositioning splints should be investigated to determine if similar BP changes were
seen with these devices.
The microalbumin data is very limited, only a very small number of patients were
studied. Further work looking more sophistically at renal function would be
informative and to perform a much larger cohort study examining the results, also
correlating them with blood analysis of renal function and blood glucose levels.
The changes of daytime BP in OSAHS are starting to be clearer with the evidence
available from the dog data 388, data from our study 153 which has been complimented
with the data from both the Oxford group 404,537 and the Marburg group (verbal
communication). The canine data provided very convincing results with the BP
returning to baseline values when the apnoeic insult was removed, but this was a very
acute study in another species. In humans the BP may not change back to 'baseline'
as some irreversible damage may be done by the insidious onset of the disease, and
often the long time to diagnosis and treatment. Further studies are needed to try and
work out what these factors are and see if there are any mechanisms to make them
reverse. Perhaps by looking specifically at vessel wall stiffness or examining
markers such as endothelin or vasopressin might provide some answers. In addition
this pilot data on baroreceptor function and on micro-albuminuria needs extending.
There is no doubt that there remain many unanswered questions in the
pathophysiology ofOSAHS and the scope for further research is huge.
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Functional outcomes of sleep questionnaire (FOSQ).
Example ofABPM printout.
Example of steer clear printout of a sleepy patient.
Example of steer clear printout of the same patient after one month ofCPAP therapy.
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PATIENT INFORMATION SHEET
What the study would involve is:
I am looking at a capsule, which may improve the upper airway tone against the
conventional treatment of Continuos Positive Airway Pressure (CPAP for short). I
am also looking at changes in blood pressure both in the day and during the night in
patients with Sleep Apnoea.
You would get either the capsule first followed by CPAP or vice versa. Each
treatment period lasts for 28 days i.e. 56 days in total. I will see you at the start of the
study on the night you are due to come up to the Sleep Centre in Ward 48. I will do
some tests with you in the evening before bedtime and then the CPAP machine will
be set up for you overnight as normal. I will keep in touch by phone on day 5 and 15
of each month and come and visit you at home if necessary. You will then be asked
to visit the Sleep Centre in Ward 48 on the evening of day 26 to perform some
concentration tests and to allow me to attach a blood pressure monitor, which you
will wear for the next 48 hours. I will visit you on day 28 to collect the machine and
give you the equipment for the next month. The second month of the trial will run in
the same fashion. After the trial period you will receive a CPAP machine to use and
be followed up in the clinic as normal.
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I will also be asking you to fill out some questionnaires. At each visit to the Sleep
Centre I will be asking you to perform concentration tests. I will also measure your
weight and waist and neck size at each visit to the Sleep Centre.
This study will involve two extra trips to the Sleep Centre for you, on top of your
overnight study to get the CPAP machine set up for you. These extra visits are to
allow me to perform the concentration tests and to fit the blood pressure monitors. I
will refund travelling expenses for these extra visits.
You are under no obligation to participate in this study and you can withdraw at any
time without detriment to your future care.
All data collected will be confidential. Your General Practitioner will be informed of
your participation in the study and of any abnormal results.
You can contact me at the Laboratory at any time to discuss this further on 0131 536
4192 or 0131 536 2355.
You can also contact Dr T.Mackay on 0131 536 1000 for unbiased advice on aspects
of this study.
Dr J.F. Faccenda
Research Fellow to Prof. N.J. Douglas
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Name: Date:
FUNCTIONAL OUTCOMES OF THE SLEEP QUESTIONAIRE
(FOSQ)
Some people have difficulty performing everyday activities when they feel tired or
sleepy. The purpose of this questionnaire is to find out if you generally have
difficulty carrying out certain activities because you are too sleepy or tired. In this
questionnaire, when the words "sleepy" or "tired" are used, it means the feeling that
you can't keep your eyes open, your head is droopy, that you want to "nod off', or
that you feel the urge to take a nap. The words do not refer to the tired or fatigued
feeling you may have after you have exercised.
DIRECTIONS: Please put a tick (□) in the box for your answer to each question.
Select only one answer for each question. Please try to be as accurate as possible.
All information will be kept confidential.
1 Do you have difficulty concentrating
on the things you do because you are
sleepy or tired?
2 Do you generally have difficulty
remembering things, because you are
sleepy or tired?
3 Do you have difficulty finishing a meal
because you become sleepy or tired?
4 Do you have difficulty working on a
hobby (for example, sewing, collecting,
gardening) because you are sleepy or
tired?
©Weaver, September 1996
Functional Outcomes of Sleep questionnaire (FOSQ)
(0) (4) (3) (2) (1)
I don't do No Yes, Yes, Yes,
this activity difficulty a little moderate extreme
for other difficulty difficulty difficulty
reasons
□ □ □ □
□ □ □ □
□ □ □ □
□ □ □ □ □
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(0) (4) (3) (2) (1)
I don't do No Yes, Yes, Yes,
this activity difficulty a little moderate extreme
for other difficulty difficulty difficulty
reasons
5 Do you have difficulty doing
work around the house (for
example, cleaning the house,
doing laundry, taking out the
rubbish, repair work) because
you are sleepy or tired?
□ □ □ □
6 Do you have difficulty operating
a motor vehicle for short
distances (less than 100 miles)
because your sleepy or tired?
□ □ □ □ □
7 Do you have difficulty operating
a motor vehicle for long
distances (greater than 100
miles) because your sleepy or
tired?
□ □ □ □ □
8 Do you have difficulty getting
things done because you are too
sleepy or tired to drive or take
public transportation?
□ □ □ □ □
9 Do you have difficulty taking
care of financial affairs and
doing paperwork (for example,
writing cheques, paying bills,
keeping financial records, filling
out tax forms, etc) because you
are sleepy or tired?
□ □ □ □ □
10 Do you have difficulty
performing paid or volunteer
work because you are sleepy or
tired?
□ □ □ □ □
11 Do you have difficulty
maintaining a telephone
conversation because you
become sleepy or tired?
□
©Weaver, September 1996Functional Outcomes Of Sleep Questionnaire (FOSQ)
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12 Do you have difficulty visiting
with your family or friends in
your home because you
become sleepy or tired?
13 Do you have difficulty visiting
with your family or friends in
their home because you
become sleepy or tired?
14 Do you have difficulty doing
things for your family or






















□ □ □ □ □
□ □ □ □ □
□ □ □ □ □
15 Has your relationship with
family, friends or work
colleagues been affected
because you are sleepy or tired?
(4) (3) (4) (5)
No Yes, Yes, Yes,
a little moderately extremely
□ □ □ □
In what way has your relationship been affected?
16 Do you have difficulty
exercising or participating in a
sporting activity because you are
too sleepy or tired?
(0) (4) (3) (2) (1)
I don't do No Yes, a Yes, Yes,
this activity difficulty little moderate extreme
for other difficulty difficulty difficulty
reasons
□ □ □ □ □
17 Do you have difficulty watching
a film or videotape because you
become sleepy or tired?
□ □ □ □ □
©Weaver, September 1996
Functional Outcomes of Sleep Questionnaire
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18 Do you have difficulty enjoying
the theatre or a lecture because
you become sleepy or tired?
19 Do you have difficulty enjoying
a concert because you become
sleepy or tired?
20 Do you have difficulty
watching TV because you are
sleepy or tired?
21 Do you have difficulty
participating in religious
services, meetings or a group or
a club because you are sleepy or
tired?
(0) (4) (3) (2) (1)
I don't do No Yes, a Yes, Yes,
this activity difficulty little moderate extreme

















22 Do you have difficulty being as
active as you want to be in the
evening because you are sleepy
or tired?
□ □ □ □
23 Do you have difficulty being as
active as you want to be in the
morning because you are sleepy
or tired?
□ □ □ □
24 Do you have difficulty being as
active is you want to be in the
afternoon because you are
sleepy or tired?
25 Do you have difficulty keeping
pace with others your own age
because you are sleepy or tired?
©Weaver, September 1996









(1) (2) (3) (4)
Very low Low Medium High
26 How would you rate your
general level of activity? □ □ □ □
©Weaver, September 1996
Functional Outcomes of Sleep Questionnaire (FOSQ)
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Example of Steer Clear Printout in The Same Patient After
One Month of CPAP Therapy.
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Randomized Placebo-controlled Trial of Continuous
Positive Airway Pressure on Blood Pressure in the
Sleep Apnea-Hypopnea Syndrome
JACQUELINE F. FACCENDA, THOMAS W. MACKAY, NICHOLAS A. BOON, and NEIL J. DOUGLAS
Respiratory Medicine Unit and Cardiovascular Unit, University of Edinburgh, Royal Infirmary, Edinburgh, Scotland, United Kingdom
Arterial blood pressure rises at apnea termination, and there is in¬
creasing evidence that the sleep apnea-hypopnea syndrome (SAHS)
is associated with daytime hypertension but no randomized con¬
trolled trial evidence of whether SAHS treatment reduces blood
pressure exists. We, therefore, conducted a randomized placebo-
controlled cross-over study of the effects of 4 wk of continuous
positive airway pressure (CPAP) or oral placebo on 24-h blood
pressure in 68 patients (55 males, 13 females; median apnea-hy¬
popnea index [AHI], 35) not receiving hypotensive medication.
Ambulatory blood pressure was recorded for the last 48 h of each
treatment. Epworth Sleepiness Score (ESS) and Functional Out¬
comes of Sleep Questionnaire (FOSQ) were also recorded. All pa¬
tients were normotensive. There was a small decrease in 24-h dias¬
tolic blood pressure (placebo, 79.2 (SE 0.9] mm Hg; CPAP, 77.8 (SE
1.0] mm Hg; p = 0.04) with the greatest fall occurring between
2:00 a.m. and 9:59 a.m. The observed decrease in 24-h diastolic blood
pressure was greater in two a priori groups, CPAP use s? 3.5 h per
night (81.5 [SE 1.2] mm Hg; 79.6 [SE 1.2] mm Hg; p = 0.03) and
those with more than twenty 4% desaturations per hour (82.4 [SE
2.1] mm Hg; 77.4 [SE 2.1] mm Hg; p = 0.002). Systolic pressure
also fell in the latter group (133.1 [SE 2.8J mm Hg; 129.1 [SE 2.1] mm
Hg; p = 0.009). Desaturation frequency was the best predictor of
diastolic blood pressure fall with CPAP (r = 0.38; p = 0.002). Both
ESS and FOSQ domains improved. Thus, CPAP can reduce blood
pressure in patients with SAHS, particularly in those with noctur¬
nal oxygen desaturation, but the decrease is small.
The sleep apnea-hypopnea syndrome (SAHS) occurs in 1-4%
of the middle-aged population (1). causing sleepiness, daytime
cognitive deficits, impaired mood, and road traffic accidents (2).
Randomized placebo-controlled trials have shown that contin¬
uous positive airway pressure (CPAP) therapy significantly
improves symptoms, sleepiness (3,4). cognitive function, mood,
and quality of life (5) while controlled trials suggest that
CPAP significantly improves driving simulator performance (6).
Considerable uncertainty, however, remains about the ef¬
fects of the sleep apnea-hypopnea syndrome on the cardio¬
vascular system (7, 8). Apneas and hypopneas are immedi¬
ately followed by acute rises in blood pressure coincident with
the arousal from sleep (9). It is not clear, however, whether
this episodic nocturnal hypertension results in sustained day¬
time hypertension or increased cardiovascular risk. About 50%
of patients with the sleep apnea-hypopnea syndrome have day¬
time hypertension (9, 10) but many have other risk factors for
hypertension, including obesity and alcohol consumption. Ep-
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idemiological studies, which have tried to factor out these con-
founders, have concluded that there is (11—14) or is not (15,
16) an independent association between sleep apnea and day-
lime hypertension. Intervention studies have shown that
CPAP can normalize nocturnal blood pressure in patients with
the sleep apnea-hypopnea syndrome (17), but the effect of
CPAP on daytime blood pressure is unclear. Previous studies
of the effects of CPAP on daytime blood pressure have been
difficult to interpret because of the difficulty of matching con¬
trols (18-21) or, in the one case in which a randomized pla¬
cebo-controlled design was used, were inadequately powered
(22) with only 13 patients studied and no clear conclusion.
Studies of animal models have strongly suggested that
sleep apnea may cause sustained hypertension (23, 24). They
suggest that while arousal from sleep may cause transient noc¬
turnal hypertension, sustained daytime hypertension occurs
only if there is coexisting intermittent nocturnal hypoxemia
and not if there is merely sleep fragmentation alone (24,25).
We have, therefore, carried out a randomized placebo-con¬
trolled trial of CPAP therapy on 24-h blood pressure in pa¬
tients with the sleep apnea-hypopnea syndrome. At the same
time we have also examined the effects of CPAP on subjective
sleepiness and quality of life.
METHODS
Patients
Consecutive patients referred to the sleep center were considered for
inclusion, provided they had at least two major symptoms of SAHS
and an apnea-hypopnea index (AHI) 5 15 on polysomnography using
our previously described techniques (26) recorded on a computerized
system (5 system; Compumedics, Melbourne, Australia). Hypopnea
was defined as a 2= 50% reduction in thoracoabdominal movement
sum signal (27). Exclusion criteria included problems with sleepiness
when driving, living more than 50 miles from the center, shift work, di¬
abetes, or the taking of medication that would alter blood pressure.
One hundred and seven patients were approached and 78 agreed to
participate in the study, the remainder declining because of work or
family commitments. None of these patients had taken part in any of
our previous studies (Figure 1).
Weight and height were measured to allow calculation of body
mass index (kg/m2). The Epworth Sleepiness Scale (ESS; 28) and the
Sleep-specific Quality of Life Scale—Functional Outcomes of Sleep
Questionnaire (FOSQ: 29) were completed at the start of the study to
allow familiarization, and at the end of each trea tment limb.
ESS: Subjects score themselves, on a scale of 9-3, on how easily they
would fall asleep in eight different situations, giving an overall score be¬
tween 0 and 24; the higher the score the sleepier the individual
FOSQ: The FOSQ is a sleep-specific questionnaire developed to
reflect the impact of sleep disorders and excessive sleepiness on activ¬
ities of daily living. It focuses on five different domains: General Pro¬
ductivity, Social Outcomes. Activity Level. Vigilance, and Sexual Re¬
lationships and Intimacy. The optional questions on intimacy and
sexual relationships were excluded in this study. The questionnaire
comprises 26 questions set at a 10-yr-old reading level, which takes
approximately 15 tnin to complete. Each question has a four-point
scale with an appropriate column to be checked. The results are pro¬
cessed to give a mean-weighted item score for each of the four suli-




29 patients declined participation



































Figure 7. Trial profile.
groups (ex4). which when added together produce a global score. The
lower the score the more dysfunctional the individual secondary to
sleepiness.
Ambulatory Blood Pressure Monitoring
Patients were fitted with a lightweight microprocessor to collect the
BP data via an arm cuff (Ultralite ABPM; SpaceLabs Medical. Red¬
mond, WA) at the end of each treatment limb. The ambulatory blood
pressure monitoring (ABPM) module is a small unit weighing 347 g,
which is carried on a belt or shoulder strap, connecting to the arm cuff
via a rubber hose. A cuff of appropriate size was fitted to the nondom-
inant upper arm. with instructions provided on how to readjust, if nec¬
essary. Subjects were asked to continue their normal daily activities,
recording these in a diary. The monitor was worn during the whole 48 h,
removing it only for bathing. The monitor recorded systolic blood
pressure (Psyst), diastolic blood pressure (Pdias), and mean arterial
pressure (Pa).
Protocol
All patients underwent a full-night CPAP titration study using an au¬
tomated pressure setting device (Auto Set; ResMed, Sydney, Austra¬
lia). The following morning the patient was randomized, using a bal¬
anced block design, to receive either CPAP or an oral capsule for the
first limb, and crossed over alter 1 mo to the alternative treatment for
the second limb. The capsule was a placebo, which patients were told,
with the permission of the local ethics committee, might improve the
tone in the upper airway muscles. The CPAP units used for home
therapy were Sullivan V Eliies (ResMed), which were downloaded at
the end of the treatment period to obtain a real-time record of the
TABLE 1
DEMOGRAPHICS OF 68 PATIENTS STUDIED
Median Range
Age, yr so 29-72
AHI/h slept 35 15-129
4% Desaturation index/h slept 7 0-128
EEG arousals/h slept 42 12-129
BMI, kg/m2 30 21-53
Neck, cm 40 33-55
Waist, cm 104 81-145
Hips, cm 108 93-160
ESS, ex24 IS 6-24
Partner ESS 14 " 4-24
time when the patient was using the device at the appropriate pres¬
sure (time at pressure).
Forty-eight hours before the end of each limb, the patients were
fitted with the ABPM module. The monitors were fitted in the early
evening to all patients, and programmed to record every 30mill for 48 h.
Patients were asked to abstain from caffeine-containing products dur¬
ing this time. Data gathered before 6:00 p.m. on the second evening
were discarded to allow for acclimatization. The analysis was per¬
formed with the second 24 h of data (6:00 p.m. to 6:00 p.m.). All data
were manually checked for artifact by an observer who was blinded lo
the treatment status of the patient.
All patients gave written informed consent to participation in the
study, which was approved by the Lothian Ethics ofMedical Research
Committee.
Data Analysis
The ESS, FOSQ. and blood pressure data (grouped into 4-h means)
were analyzed by repeated measures analysis of variance, using the
general linear model (SPSS for Windows, version 9,1998; SPSS. Chi¬
cago, 1L). When this showed significant difference, MANOVA was
used to identify time points when blood pressure altered with CPAP
use. Data were analyzed on an intention to treat basis, including all
data obtained even if patients were known not to be complying with
CPAP therapy. A subanalysis was also performed, using an a priori
agreed cut point of 3.5 h per night lor reasonable CPAP compliance
(3). Because of the animal data indicating the importance of intermit¬
tent hypoxemia in the pathogenesis of hypertension in sleep apnea
(23.24). we also used an a priori cut point of twenty 4% desaturations
per hour lo indicate those patients with significant nocturnal hypox¬
emia. Pearson correlation analysis was performed on data that had
been shown to be normally distributed.
RESULTS
Of the 78 patients (65 males, 13 females) who agreed to partic¬
ipate, 7 withdrew prior to randomization for personal reasons
and 71 started the study. Of the 71,3 withdrew during the study
(1 in the placebo limb and 2 in the CPAP limb). Sixty-eight
(55 males. 13 females) completed the trial (Table 1) and their
data are reported. Mean CPAP time at pressure in the 4 wk of
the study was 3.3 h per night (range, 0 to 8.1 h per night). Cap¬
sule counting showed the patients missed a median of 0 tablets
(95th percentile. 1.4 tablets) over the month on placebo. There
was no significant change in weight between the two limbs (p >
0.8). There was no evidence of either order or carryover ef¬
fects (p > 0.3).
Over the 24-h period, on an intention to treat analysis,
there was no significant change in systolic pressure but a sig¬
nificant 1.5-mm Hg reduction in diastolic blood pressure on
CPAP therapy (p = 0.04; Table 2). Analysis of the 4-h time
blocks showed that diastolic blood pressure was significantly
lower in the 2:00 a.m. to 5:59 a.m. (p = 0.03) and 6:00 a.m. to
9:59 a.m. (p = 0.02) blocks; there were no other significant
changes (p > 0.1). These data are available in the online data
supplement to this article at www.atsjournals.org. There were
no significant changes in either heart rate (placebo, 77 [SE
TABLE 2
MEAN BLOOD PRESSURE OVER 24 h IN ALL 68 PATIENTS
CPAP Placebo Differences
p ValueMean SEM Mean SEM Mean 95% CI
Psyst, mm Hg 126.9 1.3 128.2 1.2 -1.3 -3.3 to 0.7 0.19
Pdias, mm Hg 77.8 1.0 79.2 0.9 -1.5 -3.0 to -0.1 0.04
Pa, mm Hg 94.4 1.0 95.5 0.9 -1.0 -2.6 to 0.6 0.20
Definition of abbreviations: AHI = apneas hypopneas per hour slept; BMI = body
mass index (kg/m2); EEG = electroencephalogram; ESS = Epworth Sleepiness Score.
Definition of abbreviations: CI - confidence interval; Pa — mean arterial pressure;
Pdias = diastolic blood pressure; Psyst = systolic blood pressure; SEM = standard error
of the mean.
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TABLE 3
MEAN BLOOD PRESSURE IN PATIENTS USING
CPAP s 3.5 h PER NIGHT*
CPAP Placebo Differences
p ValueMean SEM Mean SEM Mean 95% CI
Psyst, mm Hg 129.9 2.1 131.0 1.8 -1.1 -3.6 to 1.4 0.41
Pdias, mm Hg 79.6 1.2 81.5 1.2 -1.9 -3.7 to -0.1 0.03
Pa, mm Hg 96.1 1.4 97.7 1.2 -1.0 -3.1 to 1.0 0.30
Definition of abbreviations: CI = confidence interval; Pa = mean arterial pressure;
Pdias — diastolic blood pressure; Psyst - systolic blood pressure; SEM standard error
of the mean.
* n = 32.
1.1], CPAP 76 [SE 1.2]; p = 0.4) or pulse pressure (p = 0.8)
with CPAP.
Thirty-two patients used their CPAP machines for more
than the a priori cut point of 3.5 h per night on average and
showed a mean decrease in 24-h diastolic blood pressure (Ta¬
ble 3). There was no significant change in 24-h systolic blood
pressure in this group. In the 14 patients with 4% desaturation
frequencies above 20 per hour on the baseline sleep studies,
CPAP therapy produced highly significant falls in 24-h sys¬
tolic, diastolic, and mean arterial pressures (Table 4).
Using intention to treat data for all 68 patients, the de¬
crease in 24-h diastolic blood pressure between placebo and
CPAP was significantly correlated with the frequency of 4%
desaturations in the baseline sleep study (r = 0.35; p = 0.002)
and withAIII (r = 0.23; p = 0.032). Multiple regression analy¬
sis showed that desaturation frequency was the only indepen¬
dent predictor of drop in diastolic blood pressure with CPAP
(r = 0.38; p = 0.02).
There was a significant drop in ESS with treatment (Table
5; p < 0.001). The FOSQ data (Table 5) show that three of the
four different domains improved significantly with CPAP, as
did the overall total.
DISCUSSION
This study shows that CPAP results in a significant fall in 24-h
diastolic blood pressure, but when analyzed in all patients on
an intention to treat basis, the fall in diastolic pressure is only
1.5 mm Hg. However, the falls in blood pressure were greater
in those patients with intermittent nocturnal hypoxemia in
whom systolic pressure over 24 h dropped by 4.0 mm Hg and
diastolic pressure by 5.0 mm Hg.
Potential problems with this study include the type of pla¬
cebo used, the lack of a washout period, dropouts, the 1-mo
treatment duration, the large number of potential compari¬
sons, and the fact that the patients were normotensive. Nor-
motension was not an entry criterion, but it was requred that
no patients be receiving hypotensive therapy, and none
proved to be hypertensive on entry. We excluded patients tak¬
ing hypotensive drugs to avoid any confounding effects of hy¬
potensive medication, and did not feel ethically justified to
stop hypotensive therapy for the duration of a study in known
hypertensives. CPAP therapy is relatively obtrusive and could
conceivably have an effect merely due to "machine mystique,"
which was not found in our tablet placebo. One study has used
a CPAP set at a subtherapeutic pressure to investigate day¬
time function in SAHS (4). Interestingly, the magnitude of the
placebo effect with sham CPAP on symptoms in that study
was similar to that found by our group with placebo tablets
(ESS, Jenkinson and coworkers [4] baseline 15, sham CPAP
13; Engleman and coworkers [5] baseline 13, placebo tablet
11), suggesting that there is no specific "machine mystique"
effect of a sham CPAP placebo that our tablet lacks. Further¬
more, we used a tablet that was actively "sold" to our patients
as an agent that might be effective, with ethics committee
agreement, on the basis of the following points.
1. A CPAP machine set at subtherapeutic pressure might
keep the patient awake, thus, falsely raising blood pressure
and predisposing to finding benefit from real CPAP.
2. We were concerned that patients would use sham CPAP
less than active CPAP, as they would not perceive any symp¬
tomatic benefit to counterbalance the inconvenience, and thus
a tme placebo benefit might not be obtained at the end of the
study limbs when the key measurements were made.
3. At the time the study was designed, there were reports
that subtherapeutic CPAP might cause dangerous hypoxemia
(30).
4. A CPAP unit set at minimum pressure might stabilize
the airway sufficiently to treat some episodes of upper airway
narrowing.
5. Sham CPAP has also to be "sold" to patients as poten¬
tially active therapy.
Although we did not include a formal washout period, no
measurements were made until 26 d after cross-over. Thus, it
is unlikely there would be any carryover effects, especially as
in the dog model of sleep apnea, blood pressure normalizes
within 1-3 wk of apnea termination (24). Further, any carry¬
over effect would bias against the positive findings in our
study. We believe the dropout rate of 3 of the 71 patients ran¬
domized, while undesirable, was acceptable and will not have
influenced the blood pressure results reported. Patients used
CPAP for 4 wk and thus the data from this study cannot be ex¬
trapolated to long-term treatment. However, early CPAP use
predicts later CPAP use and 95% of those patients using
CPAP for more than 4 h at 1-3 mo after CPAP initiation are
still using CPAP 7 yr later (31). This suggests that at least in
our good user group, sustained treatment is likely.
TABLE 4
MEAN BLOOD PRESSURE IN PATIENTS WITH MORE THAN
TWENTY 4% DESATURATIONS PER HOUR*
CPAP Placebo Differences
p ValueMean SEM Mean SEM Mean 95% CI
Psyst, mm Hg 129.1 2.1 133.1 2.8 -4.0 -7.0 to -4.0 0.009
Pdias, mm Hg 77.4 2.1 82.4 2.1 -5.0 -7.3 to -2.4 0.002
Pa, mm Hg 95.2 1.8 98.6 1.9 -3.4 -6.3 to -0.6 0.012
Definition of abbreviations: CI — confidence interval; Pa — mean arterial pressure;







(ex4) (mean SEM) Placebo p Value
General Productivity 3.2 (0.2) 3.1 (0.2) 0.070
Social Outcomes 3.3(0.1) 3.0 (0.2) 0.010
Activity Level 3.0 (0.1) 2.7(0.2) 0.004
Vigilance 2.9(0.1) 2.7 (0.2) 0.029
Total (ex16) 12.4 (O.S) 11.6(0.7) 0.010
ESS(ex24) 10.1 (0.7) 12.5 (0.8) 0.001
Definition of abbreviations: ESS = Epworth sleepiness scale; FOSQ = functional out¬
comes of sleep questionnaire; SEM - standard error of the mean.
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The study generated a large amount of data, with 13.056
blood pressure recordings (68 X 2 limbs X 48 times [systolic +
diastolic]) and thus has potential for finding significant differ¬
ences due to multiple comparisons. We have adopted a con¬
servative statistical approach, using only intention to treat or
two a priori, subgroup analysis along with conservative data
analysis. Furthermore, the data are internally consistent, show¬
ing significant changes in the whole population that are larger
in the subgroups, in whom greater benefit was predicted. Thus,
we believe the number of data points is a strength of our study.
We excluded patients receiving treatment for hypertension,
lest this interfere with the effects of CPAP on blood pressure.
We did not think it was ethical to withdraw antihypertensive
therapy from treated patients for a placebo-controlled trial of
an unproven therapy for hypertension. Data from hyperten¬
sive populations do not show any "threshold" diastolic pres¬
sure below which decreases in pressure were not associated
with decreases in stroke and myocardial risk (32). Thus, we
believe including normotensive patients was valid.
The mechanism of the blood pressure increases in SAPIS is
not well understood; however, it has been postulated that the
sympathetic nervous system plays an integral part. Previous
studies have shown an increase in sympathetic nerve traffic in
SAHS which is reduced with treatment acutely (33); this is
borne out also in long-term use (34). The latter study did not
show a significant reduction in blood pressure or heart rate at
6 mo; however, their patient group included only 11 patients.
A further study looked at the acute effects of CPAP on blood
pressure in two groups: one group was treated with CPAP and
the other group had "sham" CPAP as a placebo. The two groups
showed significant reductions in blood pressure, and the au¬
thors suggested that the placebo effect was strong; however,
recordings were taken after only 1 wk of therapy (35).
This study is the first randomized controlled trial to show
that CPAP can reduce blood pressure in SAHS compared with
placebo. The previous trials of the effect of CPAP on blood
pressure have not only produced conflicting results (16-21.
35), but most have not been randomized (18-21, 36) and vari¬
ably controlled (18, 35). The only exception was our previous
but underpowered study (22).
Our current study found a fall in diastolic blood pressure
with CPAP over the time periods 2:00 to 9.59 a.m. Patients
were asleep for much of this time and this fall in blood pres¬
sure on CPAP during sleep is compatible with acute studies
showing that CPAP abolishes nocturnal blood pressure rises
by preventing apneas (18-22,33, 35-38). Our patients' median
reported waking time was 7:00 a.m. (95% CI 6:45 to 7:30 a.m.).
Thus, significant decreases in diastolic pressure were found at
times encompassing both sleep and the first few hours of
wakefulness. However, it must be stressed that the 4-hourly
analysis did not find any significant decrease in blood pressure
with CPAP during most of the waking day.
What is the clinical significance of the changes in blood
pressure found in this study? Investigations using conventional
antihypertensive agents in non-SAHS populations indicate
that a 5-mm Hg decrease in diastolic blood pressure is associ¬
ated with a 42% decrease in stroke and a 14% decrease in cor¬
onary heart disease within a 5-yr period (39). A similar de¬
crease in diastolic blood pressure results in a 31 % decrease in
stroke and 21 % decrease in coronary heart disease, a mean of
10 yr after starting therapy (32). Our hypoxemic patients had a
5-mm Hg decrease in diastolic pressure and thus CPAP ther¬
apy in SAHS patients with nocturnal hypoxemia would seem
justified on the grounds of pressure reduction alone. Whether
the reduction of 1.5 mm Hg in diastolic blood pressure seen in
the overall patient group is clinically useful is difficult to de¬
termine and might need further evaluation with longer term
trials. These could possibly be done in asymptomatic patients,
as there is overwhelming evidence of the efficacy of CPAP on
symptoms and daytime function (3-5) and long-term placebo-
controlled studies of symptomatic patients would not be ethical.
However, in clinical practice, the assessment of the value of
CPAP therapy in individual patients must include consider¬
ation of the symptomatic, cognitive, mood, quality of life (3)
and driving (2) benefits as well as any possible hypotensive effect.
This study also suggests that SAHS results in increased 24-h
blood pressure profiles, thus confirming the animal studies
(23, 24) and some (11-14), but not all (15, 1.6), of the epidemi¬
ological studies. This intervention study has the advantage
over epidemiological studies of not having confounders to
make interpretation of causality difficult. The study is also
compatible with the observation in animal models that noctur¬
nal hypoxemia predisposes to higher blood pressures and prob¬
ably ultimately hypertension (23, 24).
The significant improvements in ESS seenwith CPAP confirm
previous work (26). The FOSQ data extend the previous observa¬
tions (5, 40) of improved quality of life with CPAP as judged by
the general quality-of-life questionnaire, the medical outcomes
short form 36 (SF-36). This is the first randomized controlled trial
to report improvements in sleep-specific quality of life measures
with CPAP. These improvements with CPAP confirm the effi¬
cacy of CPAP both in this study and in general CPAP use.
Overall, the use of CPAP in this study, while disappointing,
was similar to that in our previous studies (3, 5, 22), in which
use has been prospectively documented in all patients present¬
ing with a wide range of SAHS severity. CPAP was used as
the best of the currently available patient acceptable interven¬
tions at abolishing nocturnal events. Although we did not per¬
form further sleep studies during the treatment limbs in these
patients, all patients had had CPAP titration studies in our
center after study enrolment, which showed a reduction in their
apneas and hypopneas to a mean of 6 (SE 1) per hour slept.
All studies of CPAP were carried out at that pressure and
were completed within 3 mo of the titration study.
The results from this study show that 24-h blood pressure
can be lowered by treatment. However, it is hoped that future
developments will make treatment of SAHS better used and.
thus, perhaps increase the blood pressure reduction obtained.
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INFLAMMATORY MARKERS IN BACTERIAL
EXACERBATIONS OF COPD
To the Editor:
Aaron and colleagues (1) recently showed convincingly that inflammatory
markers in the sputum of adults with COPD are elevated during exacerba¬
tion compared with clinically stable periods. However, their data do not sup¬
port their conclusion that the inflammatory response observed during ex¬
acerbation "appears to occur independently of a demonstrable viral or
bacterial infection." In then study, viral infection was established in just two
exacerbations and bacteria in a single sputum sample at the time of exacerba¬
tion. Based on these numbers, one cannot draw meaningful conclusions re¬
garding the role of viral or bacterial infection in the elevated inflammatory
markers seen during exacerbations.
The definition of an acute exacerbation due to bacteria as "demonstra¬
tion of a new pathogenic organism cultured from sputum on the day of exac¬
erbation, but not cultured at baseline" is problematic. Adults with COPD are
colonized by potential pulmonary bacterial pathogens during clinically stable
periods. Such a definition does not account for this observation, nor does the
definition take into account the dynamic turnover of bacterial strains ob¬
served in COPD (2). It would be important to know the results of sputum
cultures in the patients studied. The single patient whom the authors con¬
cluded experienced a bacterial exacerbation had Klebsiella pneumoniae in
the sputum, an organism that many authors would question being a cause of
exacerbation. Finally, the observation that only 14 exacerbations occurred in
50 patients over a 9 to 15 month period, differs substantially front other pro¬
spective studies that show a rate of 1 to 1.5 exacerbations per patient annu¬
ally (3). Do the authors have an explanation for this difference?
A recent study of 81 exacerbations of COPD showed that inflammatory
markers were significantly increased in sputum samples that contained Hae¬
mophilus influenzae and Moraxellu catarrhalix compared with sputum sam¬
ples that contained no bacterial pathogens at the time of exacerbation (4).
Another study involving 121 patients with COPD showed that bacterial
pathogens in sputum are associated with neutrophil influx (5). In addition,
Hill and colleagues (6) demonstrated that the degree of inflammation was de¬
pendent upon the number of bacteria in sputum. These pivotal studies with
larger numbers of samples show that increased airway inflammation is asso¬
ciated with isolation of bacteria from sputum in COPD. These observations
form the basis of ongoing work to elucidate the role of bacteria more precisely
in the course and pathogenesis of COPD.
Timothy F. Murphy
Sashay Sethi







1. Aaron SD. Angel .TB. Lunau M, Wright K, Fex C. Le Saux N, et al. Gran¬
ulocyte inflammatory markers and airway infection during acute exac¬
erbation of chronic obstructive pulmonary disease. Am .1 Respir Crit
Care Med 2001; 163:349-355.
2. Groeneveld K, van Alphen L. Eijk PP, Visschers G. Jansen HM. Zenen
HC. Endogenous and exogenous reinfections by Haemophilus influen¬
zae in patients with chronic obstructive pulmonary disease: die effect of
antibiotic treatment on persistence. J Infect Dis 1990;161:512-517.
3. Murphy TP. Sethi S. Bacterial infection in chronic obstructive pulmonary
disease. Am Rev Respir Dis 1992;146:1067-1083.
4. Sethi S, Muscarella K, Evans N, Klingman KL, Grant BJB, Murphy TF.
Airway inflammation and etiology of acute exacerbations of chronic
bronchitis. Chest 2000;118:1557-1565.
5. Stockley RA, O'Brien C. Pye A, Hill SL. Relationship of sputum color to
nature and outpatient management of acute exacerbations of COPD.
Chest 2000;!. 1,7:1638-1645.
6. Hill AT, Campbell El, Hill SL. Bayley DL, Stockley RA. Association be¬
tween airway bacterial load and markers of airway inflammation in pa¬
tients with stable chronic bronchitis. Am J Med 2000:109:288-295.
From the Authors:
We appreciate the comments of Dr. Murphy and his colleagues and we
would like to reply to the important issues that they mention in their letter.
Our study (1) included a thorough microbiologic assessment (including
quantitative bacterial cultures from induced sputum and PGR assays for re¬
spiratory viruses) of each patient with COPD at three time points: (/) at
baseline when they were well, (2) during the time of an actual COPD exacer¬
bation, and (3) one month post-exacerbation. Of the fourteen patients who
experienced an exacerbation, a potentially pathogenic bacteria was cultured
from the induced sputum sampled at the time of exacerbation from only one
of the patients. Cultures from the other 13 patients exhibited only Neisseria
species, non-pneumococcal alpha-hemolytic streptopcoccus, or Diptheroids at
the time of exacerbation. These bacteria are normal respiratory tract flora
and are not respiratory pathogens, therefore they were not judged to be re¬
sponsible for exacerbation in these patients.
Our study was able to demonstrate that sputum markers of granulocytic
inflammation increased, relative lo the stable state, in those patients in whom
no acute bacterial or viral infection could be demonstrated. However, as Dr.
Murphy correctly points out, the number of patients in our study in whom in¬
fection was definitively established was small. Therefore we were careful not
to make any conclusion about the magnitude of change seen in inflammatory
markers in infected patients. We simply concluded that patients with clinical
exacerbations of COPD, in whom airway infection cannot be demonstrated,
appear to have significantly increased sputum levels of granulocytic inflam¬
matorymarkers relative lo their stable state.
A recently published study by Sethi and colleagues (2) does suggest that
COPD exacerbations in which H. influenzae or M. catarrludis is cultured
from sputum are characterized by higher sputum levels of TNF-o and neu¬
trophil elastase than COPD exacerbations in which these bacteria are not
cultured. This study did not compare sputum markers within individual pa¬
tients at times of clinical stability relative to times of exacerbation. Therefore
the Sethi study presents complementary data that do not conflict with the re¬
sults of our study. We agree with Dr. Murphy's comments that further studies,
using longitudinal assessment of patients, at times of clinical stability and at
times of exacerbation, are necessary to elucidate the role of bacteria more
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THE SCIENCE OF DESIGNING ETHICAL CPAP TRIALS
To the Editor:
In their editorial. Karlawish and Pack (1) raised important and difficult is¬
sues. We agree that the problems are real but believe their analysis is one¬
sided, excessively favoring sham CPAP as the placebo of choice. We have
been wrestling with these issues for many years and indeed published in this
area (2) well before Wright and colleagues (3).
We do not believe there is a perfect placebo for CPAP since a perfect pla¬
cebo must be absolutely indistinguishable lo the patient. However, because of¬
fering treatment to patients with the obstructive sleep apnea/bypopnea syn¬
drome (OSAHS) produces such a large placebo effect—which is seen equally
with placebo tablets (4) or sham CPAP (5). both lowering Epworth Sleepiness
Score by 2 and significantly improving quality of life—it is vital that carefully
controlled trials are carried out and that patients believe theymay be receiving
active treatment. Indeed, it is uncontrolled trials that are arguably the least
ethical since patients are inconvenienced to produce no interpretable results.
We have adopted the placebo tablet approach, whereas Jenkinson and
colleagues (5) used "sham CPAP." which was specifically designed to be in-
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effective. One could argue that both research groups set out to specifically
deceive the treatment population, as we both knew that our "placebo" was
ineffective but could not tell the patients this. In this regard, there is no dif¬
ference between the deception with placebo tablets or sham CPAP. We have
been very careful not to mislead patients at any point and have had the full
support of our Ethical Advisory Committee. After our two most recent stud¬
ies (6, 7), we have written to all the patients to inform them that a placebo
was used as suggested (1) and noue have expressed concern.
Some of the reasons we originally adopted an oral placebo no longer per¬
tain. Specifically, there was an early report thai sub-therapeutic CPAP could
worsen hypoxemia (8), which has now proven to be unfounded. We thus be¬
lieve that there is a role for sham CPAP but are concerned that this approach,
like the use of placebo tablets, has limitations. Placebos should have no effect
on the variable under study, whereas sleeping with an ineffective CPAP ma¬
chine attached to your face is likely, particularly in mild patients, to perturb
sleep and could alter daytime function, artificially impairing the comparators
for active treatment below baseline values, thus biasing in favor of active
treatment. Our oral placebo will have no effect on the variables under study.
The nocturnal discomfort of the mask system presumably explains why Jett-
kinson and colleagues (5) had lower CPAP use (p = 0.035) in their sham
CPAP group than in the active CPAP group. This decreased use occurred de¬
spite these patients having very severe OSAHS with a median of thirty 4%
desalurations/hr in comparison to a median of seven 4% desaturations/hr in
our recent study that stimulated the Editorial (6), and four 4% desativrations/
hr our mild patients (9). We are concerned that less severe patients might
show even lower use of sham CPAP compared to active CPAP. indicating
that this would not be a true placebo. We designed our original studies to try
to determine the threshold of severity above which patients with OSAHS
benefit from therapy, and to achieve this it is the study of mild patients that is
most important. This was one of the reasons why we chose an oral placebo
and remain concerned that sham CPAP might not he ideal in less severe pa¬
tients. As a side issue, the editorial is surprising in its statement that "data are
not as convincing for mild disease"' in view of the three controlled trials show¬
ing benefit (4.9,10), two of which were published in this journal (4,10).
The ethical Issues are difficult and there is no perfect placebo to a CPAP ma¬
chine; but the important scientific message is that whatever control system is
used, all studies show clear benefits in favor of CPAP therapy for symptoms,
quality of life, mood, objective sleepiness, driving simulator performance, cogni¬
tive function, and nocturnal sleep (2,4,5.7,9-13). It is important that skeptics do
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From the Authors:
In response to our editorial (1) about the design of a CPAP clinical trial by
Faccenda and colleagues (2). Douglas and colleagues suggest that a discus¬
sion of the ethics of sham controls in CPAP research obscures the message
that all studies show clear benefits in favor of CPAP therapy for a variety of
clinical endpoinls. To the contrary, we believe that this discussion illuminates
important issues.
A major issue is what control should we test CPAP against: a placebo pill
or sham CPAP? Douglas and colleagues claim a placebo pill is best because
it has "no effect on the variable under study." But what are we really trying
to measure when we use a control? The absolute effect of treatment is equal
to the effect of active agent minus the effect of control. Arguably, a sham
CPAP informs us of the true absolute effect of treatment because both active
and control groups experience the same discomforts of the mask and its gad-
getry. Clearly, however, data are needed. We repeat our editorial's conclu¬
sion (1): the study that needs to be done is a comparison of CPAP, sham
CPAP, sham placebo pills, and other viable "controls." Even more useful
would be to randomize subjects to true versus false disclosure that they are
receiving active CPAP. Of course, after these studies, the investigators
should debrief subjects individually about the design and its results.
A secondmajor issue is whether the data for efficacy of treatment of mild
to moderate steep apnea are less well-established than for severe apnea. A
recent Pro-Con Editorial in the American Journal ofRespiratory and Critical
Care Medicine discussed this (3, 4). Dr. Douglas and colleagues cite studies
that raise an important question: what is the desired outcome of CPAP ther¬
apy? Their own studies (5, 6) show significant improvement using a cross¬
over design in self-reported sleepiness, a depression score, some aspects of
quality of life, but no difference in objectively measured sleepiness. It is un¬
like the results of sham CPAP-controlled trials in patients with more severe
disease where improvements in subjective sleepiness concur with improve¬
ments in objective sleepiness (3,4).
These results raise an important ethical and scientific question: what de¬
fines benefit of CPAP when one finds improvements in only subjective but
not objective assessment of sleepiness?
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